%PDF-1.3 % 39 0 obj <> endobj xref 39 43 0000000016 00000 n 0000001593 00000 n 0000001674 00000 n 0000001867 00000 n 0000002031 00000 n 0000002510 00000 n 0000002879 00000 n 0000003272 00000 n 0000003615 00000 n 0000004354 00000 n 0000004684 00000 n 0000005180 00000 n 0000005282 00000 n 0000006102 00000 n 0000006929 00000 n 0000007348 00000 n 0000007800 00000 n 0000008062 00000 n 0000008385 00000 n 0000008501 00000 n 0000009390 00000 n 0000009885 00000 n 0000010282 00000 n 0000011082 00000 n 0000011324 00000 n 0000011705 00000 n 0000011991 00000 n 0000012254 00000 n 0000013123 00000 n 0000013996 00000 n 0000014757 00000 n 0000015288 00000 n 0000017921 00000 n 0000024022 00000 n 0000029691 00000 n 0000033379 00000 n 0000034575 00000 n 0000037527 00000 n 0000037899 00000 n 0000039703 00000 n 0000039989 00000 n 0000042689 00000 n 0000001156 00000 n trailer <<32442962FA521E40AC408ECFB8AB8CCC>]>> startxref 0 %%EOF 81 0 obj <>stream xb```f``` Ȁ @Q)  fT>`FYƨ @! 5:# I+.;zæClZU yjb9$\Meflr "[#q5 SM\<:: ```RR 퀱cа +H!-@ b ?i ;܀C9ND`M˜D)>6 ; 3)\rX̡ێnE:>HkAy "y;n204>Qti%@a1C9xBl_X䶃T-1*C]0g endstream endobj 40 0 obj <> endobj 41 0 obj <> endobj 42 0 obj <>/ProcSet[/PDF/Text]/ExtGState<>>> endobj 43 0 obj <> endobj 44 0 obj <> endobj 45 0 obj <> endobj 46 0 obj <> endobj 47 0 obj <> endobj 48 0 obj <> endobj 49 0 obj <> endobj 50 0 obj <> endobj 51 0 obj <>stream Hn@y _.,޳7wDUQTUQ/g/!ݒ44;3矙Dftf (}5Io\kIE0'8mI9k ӄ3$]gm gkDS  @e[( ]BOЧM%MRVy[SCgXlV!lAkIoo@H4VD -a!Ъ}OT "Ab%'e1fHh(4'%@d>CCJeӹ1I(@_! AuquI)5}) NmG;vq5 N<N@;5{R03J(8>8 - x@%'"f"~F!1UX&tDUHNcy(\%δ_=,'< ?Gr5[0a PIzSRSh(Ty,o+?7k W׮˾A!ѣ4uB!BX~\q~[?.̮1uK؝> uԨ9- P]&PɦܕA̟L;E߶!]] EI>sK z1AD| endstream endobj 52 0 obj <>stream HlT0+rt* NMC`)6/F ̼"sYn2+sYqS]ei*Sעl#"^:W =m 9H"׹!z#0j%bo NUVy#h) \VmtЋ(bu(q1~^tDJ2iQeS3gfq .bRFkFMk֎hg6$6e]Q M ZU!&h<`ZN_ҋ b30! H ~-ч nG(FP;^63#AU`NjlAs䐼HUD";%U%{B.婙R@4h'"1! '|o6Top-ሷ mb՝!{3m 4 k/Fh[Weހ| ~eC_޵ď>PXQo D!>{[$2]kS6߇$QI7MӺRPyW|{> endstream endobj 53 0 obj <> endobj 54 0 obj <>stream hBɺa9gã^=QضA(gA_%;HtwJ9MU endstream endobj 55 0 obj <> endobj 56 0 obj <>stream hTPMO +B[c҃w Jb)/кd>ޛ7oh<6o~R-i X`%hž_v'؜_t[}.3Źo(@Z?K"Ghʜ]x8;K; J QZGKz",X%2Eq:8c|> ghFm2fdUȭ5}O]UҺ{# endstream endobj 57 0 obj <> endobj 58 0 obj <>stream HlTM0WIls[Bb9 vnYd-W=Ս㽙2ei<+33IZurβn$`t<,ngoޗbX_>&58vbDP&DVėIإ_RIZ㒫&_vSeͨO;5ѽm7i0#L endstream endobj 59 0 obj <> endobj 60 0 obj <> endobj 61 0 obj <>stream HTn0 )rZ,Ks6]s[{P9fKv2ҲX1`4I}$?n6mŚmiŘl7eU״%f(5m`ݣbP(ٛSA|}Q6$eCM~x(6‡A%&I% 8̌833tf"l^-d2\`SF5׋c6PUE0Z)>WP S)F7(c6XjcZk+ŕ5RC|BBvf^(FPECZZZ?Sm^2%ԫ)u[9kr%1_#B60G'Of D N ֤ɺtSSTi˜j2C0enT5zތ J=]Xsq7`]d> endobj 63 0 obj <> endobj 64 0 obj <> endobj 65 0 obj <> endobj 66 0 obj <>stream HtTˎ: +)cz[>Pn+PmąL=<EE(<<<$utRpYU8}8|auk1CWN7[s\9t,=l~Ɩ$Wu>e˱=FBqö,z&#Sx60?9<[p ȶ u% ns\' 7r}ӧ.R..UجیFrPhcxC+SyK]῰/x'O'z k>,vӰopIP7 cg*yQ8jUEnZ+) )Wi8}NMuKeL- Q{^Nr[F4Bio ᡌIK(qߩ *I _w.)DLZ 6Lfۇidr%K'(9AƦk#q!M&:$ 1 닕x D-` [^$yIAN2EYRs?gZo s@P/*˱>6QX miЕ|,؃ѨZy:}{>y"-wR4{gBJp*-M&q'i""Y+TwqAaw NP}V+bj߷@*V.酠"w d93AE]C΋_^^kw #e6ko!ڠύ}eLg*ֈ4ZD 0 endstream endobj 67 0 obj <>stream HlTMo0 W a}Y0 ==(k%OSx?+#tk"D>>>p9|<9q=m<]U b#ZMِΏw5-1 #v)HHٛt31Oۧ*dg1x ,)`"z5$1d-$9h)@j+rxEzY㺵W.`Fζx :n6ĤR)%oE)FC=f augt8E=[N)rUgF({>PK۪ P0Q+F PtѮH}JT@Մt :Xr20`$$GdhsEFf69y @r i8iУǢ/v^sD$bOLR1Qd٪)DJ8-eS״8wb{5Ooheəl:T s9k uLDf0a ʁ#>E5]nU%\Շ 7[ބlD1{-6q;5 4[sM1tdB:N͛$iYl3`qLzv qm UX(ꚩ,O߁oiI)k7CB|G/YE0? !-P5]tg2^W2yqX\<[<8c;aaT<Ѥ;&.*n9 'p/=q\~?-\; u70`A^.Mu-ng ?b* endstream endobj 68 0 obj <>stream HTN0)|t*_ؖPKVBְ$E}KUaf)?%iuX()jr C-((g",I\;LTW~pR'I{ F+ҹ>E /8Bk\`M i-D]VA<5My4f]a$\J̡PE2Ϣ %V$u<7[vYwY0wJȥ-!{[@J2c2I[׍fru?6O3ݐCY7CthfV9FDߵMJ0M=8 q/5G{Ll %, 'C jG'Kr|%OC3|W =sˎ6HYF1 o%ߧŽ5XVa`% 5L`8^D E#),ɱ5!^ظ W0rr9[GvcǨs-F +&qo|aۤAQ. ~ 7Y>8nt&9a_o6V x))7z/&XXp]\o /Vi}~f4x 9in I4KvؗDm߾| /^n>nq*_ B~Y7/Gtn endstream endobj 69 0 obj <>stream HTKn0:"aΰT- (PUQaK-EzCRnh33USuF~9\hlNF}Y~&LjI55^}7Jk)`L<6mvS3oOW`ydx~, >stream hdV TWm`(J; ݭA L1F>3H$FT,#QDcF7f5FSָs=o;ީVխh''3g4F OX=&rhSW=0V6=ԭij^SٮI\krbR<8~l4O>v`31YLyZZŚn d9| yB<ǜiS+VMrrlsɚ"[ސit>E6% Xdz73;.39!dM6g3Ɖ.øF0] 3҅e&ƅ0>a8ƃfZW'LfgyN{.] .Q.]|?>b1<A>{NEՑbMyӾK#Dc 1LDSD DY0Z=gQV0%a gth/t#00FB_22w {-E5YLt s^('>1 _p *?tqJ=vzs ++ c8uh+L!@5˅0OcE>Oi&ޘ.6t;`}/ 3~BSW 73e5B55oD2[HB64+,*¡|ڿ?Qe3x`'D=J%hf z(,Z諲N 'd6Hkb@k)u=(eRy|Cx|=`1ӷoY" Ţ.ַDA%x% ow%@"tu8-2(5w\JCKx7Y$hzЧTF}]! aͿC,:c0t!8P ;`#Cv8eq٧KOلTIGa4(̼e/@tf.ۖ{'H!-tJr{CCm[~VߑJFD>LTޠv:gT>Rml`[0JOWUo 7*|i~tj| {bLG篗z|X~8վaU C+꒼zO7H7j:ޙRt6-E;yu! z?w@E<ʴ^dց 9M] R㭙S"R!^\[נX(0:sa9~^;~H4xZ٦S] hā-(A@Ӆ]HEݚ=&4)<`Y):$nxpd8U؄NǼl4E}( `}p1cVI 9Jو rV ' eBgiA7 sm-oԙ?VōIL ^wF%]ob,VгW'fYn9hxp {¬blj MvCi "H+c} z fSZB(@U<`.a%*ҫ&yc3rsI$J_^ 7ISɖE%"~Ik\sɫGf?+eAVn|zŏX&]=cJ?2>stream h޴YtWG#6 ICf$ LSlܻe2.[,7bɖ-6! ]wmyawߙssF33[Woٺe{"[/X7n&KT]o3vῬG D悑bKJ X! `"`FpTld3KMffa~,F[DX% I@txo< ~JFF' +ˍ}0fܕ ǧ_7'HVIR鷲r)Y7q3"'ULjtg@/1<]GشzK}xo>#\kn?^z#ڴ >c+&i )0G &Y?W>_ 'ӖpP(Ё"0 ,V2`yL"04`p .62hw Zp%]NlVpIE`@GS Zy%PS*pU?9erWBS7뿔AӴ,*miD}uummpMBPuiM8 ]P" `.ز@O?T*t,Lgp`TZvt4f DaUb"jI:ȎAݚ.IUBf/ Ê+8w:/YSZm0jDT`p}~pꦭR.)."\V|ӷrr='"/;MiDIAwtf%q<K'N W :X͙AL,uߓ.?t2#3>wC7gH'7 6 Q E!Gc䱣,{ !w`( PkFzgWr"@`:*AZ nJ&\:)~=[;"#`pEV?C)y"×7өp  ()8~<7BNk (֢w(oJW EN˜ tG}N[zy^.2`C,UV%'˺˲Cx%> Vl_c m&8 @ 83'd6gџzl0z#{IOEl͟26nJ>@p10ˡ*t+ w cn=0'z$XpPf^0zjGȅJkՁUHdD(3TZ[Ce{Q.h@Mtfp9va7ıP]H,@JK]\ye>M*PJTIzez`T \s3B67l Sj(d?-jPƞo繝oVW2Di z2|:[T`"Uw.7}0Bdly;bMBG#XZ:SUtwt[t̺?{,*q_9oYE22x|'sJOS!|aIT` .9mݹ* .8554ue6myk{ "(H9H:!;{I݃(#› IQQ PwNVMftdzR~”mɢĨwKgT\SגKkLOZ5k$Bim\;f㙤ti?}+rg<_8F9UlSޯ=x/e\`Og~ٷyCYA=G Ps 2S):*D7lZJHLN`#0lؙb'9flc=T8p# 0@~UUh`32u1/ c=TT˟ X֟Y'Dra޴T$iL4RĦO,,V (*uR0bY+||+*Zm\,/$;~^nkɆz0ż ]%C[2okZJVJ 3hYjl@'3mR1`LU*1@Y9T,LZ*:}PF&ihYV*s d=-HjbH*Sʷ rؕ;Y|/Dx:L/-NmkBHCSFY-c%mw2mE a㚆2J4\ R}Jɀx-PΑ@` ޸v"/*O,¢<ș/`'5 ϣ!4ϴ(u (p!a N4L2\ :ms\#.5ќ*3=Wc2 .?OpQJ wrO4Yx'27C[/f技YS?HG'FFƊ}Cg ,ޕٔ1> u"(pL=w 3 e Р;%}!F,( e_Glƕ4'ңYgYw<ƲͿE h<ŁPg<_U>Hgab$&t(w.p%+i@7[ٔ{A,+찤XYPyTz"-xu0GͧB3Z^/,l$XJRuiAjBb^]o6J,yÓj4t  @e6@sZ|y.Cvl?sWz\P3ˆxa̜.ទj[_ #bLDRO̶HTip ^N΢|\_j>'BAA`4*+JçSAqd\"'zC:kh6C AAʐj5/88M 05X.X0&<@U6W3iǎILˈ},IG{N=:qpѸ͆^7w|ա^X锕g`܀] SmOz*S##(^6#`L;zWcAE ~60?1͞ gBt0679?!1k<8?~p'ٿ/ގb`~ v:`@xk(;5Q3oM-[1^ NͥJ_'_5bXnWb N9;N3T1+suw$I1bloT)[)E=po x |u79CO3a\s/tuw52a.e%GhP]wdC<L!NT̑Δ^fS = SXsn*͍\YTGΞ [[Qto UJT\"98l_[qjMc ؎[=VRKHU_M"0=JZɬ.*A%"[/"pUSŸMs;nRpˌ悪ẏQ2JCr2M֖4Uu?ogjY>H^v}Rh^ތs^h}#SfEeIX!E4i'B$(Uxb`uFmȢU<G`b O}GD3`"|u +>,\} ':]\]3HH:"b\{Xh)Ag!ѐd d`2rsBf+(jK6Au|B33Z,)9!5{B}r9 9y)RN_ƕ2#kb]NTf="99XI"pC~?#yr0[ `QޱY5Yni.c'Ⅱ]yr yZ= \M*yi}&'70"UR&'ZbpTe9yn>_s(RT+̿g3?&a",0,~ __Vk;ĵyJ!6 Nb/*6b[DRO䶨dBk7[eݬ OK,|DVPYXYR4g5&Nq1Xt3e'Gd]N'`ᝤEK~/}|W:TUՂdō&=? Br endstream endobj 72 0 obj <>stream hޔWy\Sg ڴ՞69gnVmkmVwEYTdIB,d%@X=l*" Vk[:ugԙvn0{6776a„緭ݺmkqA{3\=W S^0ϟ66/&P?F<i8 6{ hoiiu Z B Fh{h4>J>*h#i` iOpe5U~~w&z0Uƭɻa>1eS>?0ܙg>y/>}tɋ;赗^ˋ^.cMbղ`JG3j`ݎ.Z|S7t76%n i+{>~7 oh¥> a3K .<:q;'˹wn` #0 orWP0 ,~LdBZ/]p0g?fomYΏ ^pJ-"TN!c;}{i:ҟh"z2Vapr ]<{~`2D9o} ]wmW tyŸIXgo|v{=z-&$c48- ow5U*q\-D CCr(`Be66y8L@;,  }';|}pzܔp[i9__kAD䍹+ad./_) /V$?1Jg~q_ۺ,# [þZݵ2'Gsv-ϫB:[+C ߺ,GYQf)bTYkǹof5|Vb(1BYBq 9 n"E^8A|R]bGI2-[?r^"ueDIM!_TnA6&C? DOwwnȄ #O+! {e ؞Ai? >D9}pf6w$1Cvtx_Gʷ!dHR~CErF?o ~kky._l}6>+ lf9{ Ym37|Tqr.X'$ľ1 wW(eUOYCBCx U,˩wNN$΁w[ ._%p =k2Df bhn66@MI%WW>o-^=[xaW ~/7y9z!vk{j1&:xF[;{>O9ΫhlMRCqϴFoݼ30$jo J8V5Ynq L# ٰ\ӻ08 l}G ?|Cn o!UtI@!A, q|WAB14%czFd"ڬ}xbP'!6Z 3Q`J PMpCep-`Y x0 .̇oK>|D? xGw毱?ذTWOV_*ke` Lv(OanwSm&jLy%6Xu~wLľ]хxxA&NG/ׂ6Mǭ] O>G3@}w3@^mb06wݖyhu2T<Ӄ`#VSO>,=P;>}(^R+M1Hlak{nBr!pAȂ!L.`[G pG_:VE'DHaȠ40F9/m{0?g^86>d曕 SORRT<%ŠO>:A"U:V)BM:gD+f1m>HU"V. }^_5R݄ J5W?߃GW[ nR篋&cHb5٦ui쯾h.*i0'Sp.5#kHjX"[%pNT$NfE,ІW;>)2ᴧf'LBeqMDmH}AQ`B/V u mDU" bI {6$9gƿyz]EM2s/E](JDÖ5nwxCKKY#Gru37ۥ/jUQt(r1&Pz&B$YoĄ\tMDqE lYG䭑CG8rQ6"Jܑ uF#lQp[xK΍7ODhb`x//qa㾔F0 9Ԧ\EhZ u;UΎNj'gpbuWDycUezLs7֟᪮1NLIl Qg(VN~D0'bT(7S+GGtu'F]\"$s -8C [Ҵ!Ë9xܕZ0o,2Q²)aADfV4gY`Zzn2%J%Rļ\lv`TQj&kNu1ڇ`EC}; 8 7Cȟ1ΡL.PF+DPM t9Z]Xeb3|~ niaUF?0^Hd$̊jov2~J?DbUbv:ݦ0UIH]|wԸisQM+bH^|q4v.reE~l7'ojx$k"}l,!ʄ X``H9+E:y\lCŕLx d(! i+kk8D"2rpPL{jK}&>Nj>.:WyVVTYi؃d'Z.+Eoow{동t$8D)y\T˗~K3*+ [: Y6?(!Η2^ftʈ!Pkgq!N@umF*|]-OAssڼƣVN .X ^`ʗ|n'&ӂ_ 0J endstream endobj 73 0 obj <>stream hެW{PTWo۷& }==Qg41>#_QE%jZh7}/6  -$,Sj*OS$ \~Q'~꧳<:Ok㆙q.>IbQW]] 1~/*ʜVNd?ӕoU[ڱUv!04L 1^D(Qm=jx] qVBG%Fx2Y$6*et!{H8y_~}pP!;r|Wٸu>kᚭ";dιXe /x(3JXizkM z ~Wwqf l"M[?p,iAooD@,!߹ݲ$n(||NivDvp |{Ba.Z㛮9LmY d' 2XdPz{\ݪnюNs!oAQHC\>e>d]*Pce ÖF<n;?R?_o#CgP?B:jBR2ٮrςv+.-/lDV6B@`09 8AH\ o bmtyM!1f=2Yk+!y=DjdYn@V) j2+ V%̾дt 7"u*P jUmVGsE=ܜ~8:M^~_s{~Ia|0Pp܍p ,Sk^)UL'>_Cgsxy^LNlf"Ǥ](Aːp UW&VHʆN *3B&rZ[omÖS8%[8\h/P jGA>*JQ8~mfF`9} ]Ah~/bbȢ: F`&U:8';7o5"\s âQL` vw* ~ k R#0J|NXTdOQaxѵ)݇M`dY!=Y0"]^bTq:>3:'x2 [5 w+xŸ)ٌ1taN+\ڽh J/2Iln/e!^q-w7 B"E@/ qep!#+{L/D! rRG֍ذ˟9^R4icg\&{ݓwFA @#u#{-OiɻӆzZ֡ޣ}XL? tZ[ ײЍD(W-@J;|+0g2 Dg` )-)G%|W0z- cfaB=W>B!Ю]{9+oR1ܝ%m6vcJ GzC}MSnuɿJxQ#Wּggd2{(8&-g<ߒTs6I-.x wv-y,uDXrE;Tn%Aej4Z_f(2Gkkv<ŸwGrhs % 3=;ؚ}6XUEKMRAX]hW|CQNQ  PgaQâ'F^t#bc!ߴ 2`~*&y $7di</3\;s[Z v6{s8C.bNܧJ/$Es7V~_ 'd!T}gq>q"8)$m )ӂp2XVgٯ"#y!X w5t_aȨ<(5g=DXl-/!rͬ]z+(vrs^($,qo+'?rXϞ(D^%Y;!1#ҟO+9J\9^\uP]<"c3sMiy鹇!q"3q%cnMk-SE{(`{`endīG3vwVD=4Tt ]èJ|Vn:lt sQ'QrW9\xՃz%bcX~@Nbn&&!1şLE:/ށ?~+٨ djR'^o?jF,׏w`Lgc{qn:~R endstream endobj 74 0 obj <>stream hތ[LWYؙ,BvwAiKr wE. r] B!f.\E ]`\XlAy>Xۚ6&6IWbԾ4}'$ H$G'ON ήHsӽ]̆ЫZ{o~Ez%?0ga-^V d#71nHsJ9"h;BA%hàlo/I-, 0dJYYEwfij"Rp/ =:Je?p#9v5'i-^K!l%;.3d^ m=n<4Lu-(03Z*>>~V~'~Ѧ3l=o10 voa( #;d4ơP$.a5-tGh`8rs2cLɹ􃨹ÙEJ-ח[#1yI\Qmi͝]b1hx* z,xdg>OȊTm|a#\ɘL(ami[c G)Dը^Ukwt; -nB?seAW+rwqqnZ8y|TI(ֱz] gcV1 7J5FUmNbOß41pL|6fm0Ȟ *c2fIw'>q@yW2J((95yA_S!dJݐŠp >stream htV TgG$ch{( (ATVA"xa@g`T<@#!^$1" {QTGfWTb!xjRmowvꮚUچQToFGLv JH:*/ *=0]Xޛ_v`lTqK3,މjjX>dj^bKO,MS ŋ R sْN͋ͩFCbhHKEyɉIɩK͆ cR{ŐHuSL) FK9eb`TǼ0W dƓe|&XÄ(adI` ƟIg*/,7FB6ml۞}hR-ǫ7տt I'EqA3Q_sMӪyct=ح;bWS3Wf2^u$6s1KJtMN 0.:Åq`!8Z(~-:,`-:-5)d=QjpCߡwP~A-0@"|'GԮAWyЂNIgosL:]QKlso &>NյW봰1DmpRp| WRnhn)qZ9SߍxB?Î̾*-'n>U{c^nK?TOA5ͻP||MeiM~R+i{uI11a5_S)7ſu+<Ʉ >n4I K6XpSB۹wCidz'nE_C3IĢ ]L `f7U6tUV ]x!7O<\qd2xN?}ҝSP/UҮ!y̙NzWpQa9X%7~ Qd㧀བྷ@we*:앴uPN  ⑃8E C~Ma>xf^ 5fe,mVJ_DkIp7+2S7JهWzaZe]]&~Xg!2vQ1L˅Zh:,h`,FTXp xQ UpE=Vn^ CuPp&h_(2dGvk>@}Db61#]s43 T[,rV[DV)XPu܈bW@ܰehxQaءwHSv`w6JYs'h[PFh-hHߊs"|# l P3n%E${ ?={W%$茽{Q)w\QzP'|<>8`4JEN>'-8$ف@xأztbm4oH|=HNn?pm.g媜U׬҈qו-tVMXMWHuvIsӸ<Ԣk'M{ ́z 0t!1sf,%Ym' .Ji Pwx:Y3KݩF׭7ٚsDsugvƌq_1sįW,&E$(e{?93" E*O{b=Dl"h? @GC@tDAl.4tdqX:zf׿9'Q-PK\T_|u\QUZI9BX)b}uQg8e Ɲw#C|fa>ܷҨoe2:q4WDyv.s\NvBҭ'59jpDk}-_m=(^]e,p\_9eN.\¡h;uξf:<{{2ֽo\*"BN%eRJ6Rڧ~ԩ e[ R'qTi"CSޙ]PVkۤDM:θvUicen*ݒ+x/AUjy:X3ou0@- endstream endobj 76 0 obj <> endobj 77 0 obj <>stream hތTkTT>3=w@¹^~T H,)(ZF+DMۤ**&4$*&#JTV;jخꏮ}ܵ9|FfMɶfmXy)l#Fb7aWpw 32'2?Bu$H axBR IdbՒ '"B|DGxC2Fh24M5TZ;i-]n"s"+ 7{ؠf~R=RIWlܸI*?P{{^݀s,[w[#/5bҗ6[+gyiQPzl& ɷ%[E3R}l9?qs)ƶ"O4_4r{.Qg)'gˊR YkcľXH:TPr2$TJ! I*,c UuE!LeT̲B1_yS!xB`<}Ve$|oZq=cCХ'M? R%ّ{ho߶t5!EmVQ7v/ՇDT&2< /_oxd6)Yc"bbKJdtQx>gP1{Yf˘)-O12+>_ Gt dIٗ~ GR3!8fUAǠ3SS9I:pæ#7@ng 3ߜq(]9 ( Q0 @ IXX mpix5l;0m= pXx}l>Wc} MA~dΙA`|!i<:-2uutdeL,l2o=!ztp24U~NJ3?-8$++mL{^Fh>,1OKe wΔJV0ljS[~,vfc(0!|`(`=v7h:|D8ع Rd|ːOUbV}"Z+ezL]%%Яsp!$0B0H4xɰ S!@:N=xd0؈sAA|Gc^ҥqae]%> endobj 79 0 obj <>stream h|VkP[eRuvgCjgU]mhzr'r#!! H$rm @)txuuL/3uvǝ}{CĬ?7@ګ[3v&?s5d"{|߭5()By<' Y JR,5 u e %} %+D(q*=qƬLfNY9 J|T >9m+ͽvښ="W < Z)IBk*!zx%r>/ FfSg]%xy嗠0 k+ N g FSehlbX Sac6zj|gt͵zcKtQDfj鸁a.gɴ[3 vhCFGJ"U+ 0xdrLL%MQ6ā 0i'wi'Ah) 4WIQkWl}{`525vzDq" ?LINy+9LtBfC Lgp|iI+2gA'af?I3b,ch$ԫ$F;4yb,ڜϢ[S8_ !cV}]}F٩ Kg=*CnL8 w/ nGlwZ'ۓ;!`t u^uO:]=n{@µ,el::H&+PrY;-IPzLx]+ X#nX<]*; u1I3˵xdHӉyKK7aA x Io|a\[Vm~&^X[~ͮ=8G8{ E*b\s8\!I=$[ 1U<~4柛kcl]@%Ӹ`֙,}> ywoհku .rd}5LxɅ'#LWɃ/.ǻhJcE/M͗Dh2R?3 /fל V>M?w!@?_4XҋX6ӉXtjtN13Mi-$hEB-+܌o@=?O ueO/=5&!e ll-]]Lg35PTo*x @ v/[::-K* ).ވjM6j5pYhClYu<+ iiC BV$MW&w9{:q>uӡpmjTbV׈*Hfj+70E@ u H^K*\#Úir8DQFլ||rR>^ {'.=sɡ*[X9dfw:8Z `P:J#4Br^WkrʅubsIc/*V;!H_Ilxkd蒼7qdf9Zuu[Q*h?`q׼Dty1J1UoZNl`s'yJÅ螨u8y]͵M,boMՕJv9"r߁xQHQWvLgER'ѩІ~Ab](W+4bdk 6sO%R[r4{!^tH-U#G-B-Mmn4|MGo4@)əd,Ё/v >+SL&RaY4`w'Ys!@~: R#Fřro /= endstream endobj 80 0 obj <> endobj 1 0 obj <> endobj 2 0 obj <>/ProcSet[/PDF/Text]/ExtGState<>>> endobj 3 0 obj <>stream /GS1 gs BT /F5 1 Tf 8.9663 0 0 8.9663 59.7543 725.7825 Tm 0 0 0 1 k .0134 Tc 0 Tw [(no)4.3(n)3.7(h)-2.6(o)4.3(r).1(m)3.2(o)4.3(nal)-704.6(a)1.2(l)3.5(t).3(er)6.4(nat)13.4(i)-9.6(v)6.3(e).9(s.)-704(Severa)13.4(l)-716.8(t).3(r)6.4(e).9(atm)3.2(e).9(n)3.7(t)-707.9(m)3.2(o)-2(d)4.1(a)1.2(l)3.6(i)3.5(ti)3.5(es)]TJ 0 -1.2203 TD .0112 Tc [(i)-5(n)1.5(cludin)-4.8(g)-612.9(c)-.7(lon)-4.8(i)1.3(di)-5(ne,)-611.4(s)-2.8(elective)-614.7(seroto)-4.2(nin)-618.2(r)4.2(eupt)11.2(a)-7.7(k).5(e)-614.7(i)-5(nhi)-5(bi-)]TJ 0 -1.2266 TD .0124 Tc [(tor)5.4(s)-1.6(,)-382.5(s)-1.6(elective)-379.5(norep)4.7(i)-3.8(nep)4.7(h)-3.6(r)5.4(i)-3.8(ne)-385.8(re)12.4(u)-7.8(p)-1.6(ta)12.4(ke)-385.8(inhibitors)4.8(,)-388.9(a)12.4(n)-9.5(d)-382.6(ga-)]TJ 0 -1.2203 TD [(bapentin,)-458.4(c).5(an)-465.2(be)-461.7(pr)5.4(escr)5.4(ibed)-458.5(to)-464.6(meet)-462.3(this)-463.1(aim.)]TJ 6.7246 0 0 5.9768 251.7165 696.8691 Tm 0 Tc (6)Tj 8.9663 0 0 8.9663 259.3133 692.9006 Tm .0124 Tc [(However)5.4(,)]TJ -22.2566 -1.2203 TD .0126 Tc [(many)-522.9(patients)-526.2(are)-524.7(n)2.9(oncomp)4.9(li)]TJ 13.8851 0 TD .0109 Tc [(ant)-527(w)-3.4(ith)-529.9(t)-2.2(hese)-532.8(medications)]TJ -13.8851 -1.2266 TD .0124 Tc [(becaus)4.8(e)-354.2(o)3.3(f)-354.8(a).2(dvers)4.8(e)-354.2(eff)12.4(e)-6.9(cts.)-350.9(A)-349.4(subs)4.8(t)-.7(antial)-351.5(proport)12.4(i)-10.6(on)-351.4(of)-348.5(pa-)]TJ 0 -1.2203 TD .0122 Tc [(tient)12.2(s)-261.5(with)-250.4(bre)12.2(a)-6.2(st)-253.8(ca)12.2(n)-9.7(c).3(er)-247.7(have)-253.3(been)-250.4(interested)-250(in)-256.7(and)-250(t)-.9(ur)5.2(n)-250.4(t)-.9(o)]TJ T* [(complementar)5.1(y)-574(a)-.1(nd)-572.6(alter)5.1(n)-3.9(at)12.1(i)-10.9(v)5(e)-575.8(m)1.9(edicines)-577.2(for)-576.6(m)1.9(anaging)]TJ 0 -1.2266 TD .0144 Tc [(ho)5.3(t)-757.5()-1.2(a)14.4(s)-5.4(h)4.7(e)1.9(s)-758.3(a)2.2(nd)-753.7(ot)14.4(h)-8.4(e)1.9(r)-757.7(m)4.2(en)4.7(o)5.3(p).4(aus)6.8(a)2.2(l)-760.5(s)6.8(y)3.7(m)4.2(pto)5.3(m)4.2(s.)]TJ 6.7246 0 0 5.9768 263.9621 642.1038 Tm .0227 Tc [(7,)11.4(8)]TJ 8.9663 0 0 8.9663 279.5527 638.0786 Tm .0098 Tc [(Acu)-4.2(-)]TJ -24.5139 -1.2203 TD .0124 Tc [(punctu)4.7(r)-.9(e)-354.2(i)2.5(s)-355.6(o)-3(ne)-354.2(of)-354.8(the)-354.2(m)2.2(os)4.8(t)-354.8(p)-1.6(opular)-355(forms)-355.6(o)3.3(f)-354.8(c).5(omp)4.7(l)-3.8(e)12.4(m)-10.4(e)12.4(n)-9.9(-)]TJ T* .0131 Tc [(tary)-326.4(me)13.1(d)-8.8(i)3.2(cines.)]TJ 6.7246 0 0 5.9768 121.6629 620.1636 Tm .0143 Tc [(8)-8.4(10)]TJ 8.9663 0 0 8.9663 69.7323 605.2534 Tm 0 Tc [(Recent)-399.2(studies)-396.6(have)-395.6(suggested)-401.8(that)-395.9(acupuncture)-400(is)-390.5(effec-)]TJ -1.1128 -1.2266 TD [(tive)-440.9(in)-436.9(reducing)-439.2(vasomotor)-438.6(symptoms)-443.1(among)-437.6(menopausal)]TJ 0 -1.2203 TD (women)Tj 6.7246 0 0 5.9768 89.2913 587.2817 Tm (1113)Tj 8.9663 0 0 8.9663 109.3039 583.3132 Tm [(as)-361.2(well)-356.3(as)-354.9(patients)-364(with)-356.8(breast)-360.4(cancer)-362.5(receiving)]TJ -5.5262 -1.2203 TD [(tamoxifen)-344.9(\(Table)-333.3(1\).)]TJ 6.7246 0 0 5.9768 139.2944 576.34 Tm (1423)Tj 8.9663 0 0 8.9663 159.137 572.3715 Tm [(A)-336.5(randomized)-341.7(controlled)-341.8(trial)]TJ 6.7246 0 0 5.9768 278.5889 576.34 Tm (17)Tj 8.9663 0 0 8.9663 288.3401 572.3715 Tm (re-)Tj -25.494 -1.2266 TD [(ported)-254.8(favorable)-251.8(effects)-248.4(of)-249.8(acupuncture)-254.6(compared)-250.7(with)-249.3(sham)]TJ 0 -1.2203 TD [(acupuncture)-444.2(for)-433.9(hot)-430.3(ashes)-438.4(in)-430.6(patients)-439.9(with)-432.6(breast)-436.3(cancer,)]TJ 28.0042 19.5568 TD [(although)-625.8(another)-629.8(randomized)-632.5(controlled)-626.3(trial)]TJ 6.7246 0 0 5.9768 502.1857 729.751 Tm (18)Tj 8.9663 0 0 8.9663 514.5447 725.7825 Tm [(failed)-629.6(to)]TJ -22.7182 -1.2203 TD [(show)-249.4(any)-247.6(such)-251.9(effects.)-251.3(Walker)-247.4(et)-253.3(al.)]TJ 6.7246 0 0 5.9768 449.9715 718.8093 Tm (19)Tj 8.9663 0 0 8.9663 458.929 714.8408 Tm [(compared)-250.7(acupuncture)]TJ -16.5154 -1.2266 TD [(with)-280.9(venlafaxine)-287.9(and)-284.1(demonstrated)-283.9(that)-288.4(acupuncture)-286.2(was)-280.7(as)]TJ 0 -1.2203 TD [(effective)-295.5(as)-298(venlafaxine.)-297.2(Frisk)-298.9(et)-291.2(al.)]TJ 6.7246 0 0 5.9768 448.4408 696.8691 Tm (20)Tj 8.9663 0 0 8.9663 457.7951 692.9006 Tm [(compared)-294.9(the)-300.9(effects)-299(of)]TJ -16.389 -1.2203 TD [(electroacupuncture)-552(with)-546.5(those)-545.3(of)-547(HRT)-544.7(and)-543.3(reported)-552.6(that)]TJ 0 -1.2266 TD [(electroacupuncture)-501.4(relieved)-491.7(vasomotor)-495.5(symptoms)-493.6(in)-487.5(most)]TJ 0 -1.2203 TD [(women)-277.1(with)-274.6(breast)-271.9(cancer,)-276.9(but)-278.1(that)-275.7(HRT)-272.8(was)-274.3(more)-279.1(effective.)]TJ 1.1128 -1.2203 TD [(Acupuncture)-452.5(is)-447.4(increasingly)-456.9(being)-451.9(introduced)-453.7(into)-452.8(stan-)]TJ -1.1128 -1.2266 TD [(dard)-398.2(care,)-394.3(and)-397.9(is)-396.9(also)-399.2(being)-395(included)-396.4(in)-398.9(oncology)-402.7(clinics.)]TJ 6.7246 0 0 5.9768 543.1747 642.1038 Tm (24)Tj 8.9663 0 0 8.9663 310.8472 627.1368 Tm [(Considering)-734.3(the)-737.2(increasing)-739.8(prevalence)-735.3(of)-736.7(breast)-733.5(cancer)]TJ 0 -1.2203 TD [(among)-557.7(Korean)-559.2(women,)]TJ 6.7246 0 0 5.9768 408.4156 620.1636 Tm (1)Tj 8.9663 0 0 8.9663 416.7495 616.1951 Tm [(information)-561.9(on)-556.3(the)-560.2(role)-557(of)-559.7(acu-)]TJ -11.8112 -1.2203 TD [(puncture)-387.2(in)-392.6(Korean)-388.5(women,)-387.5(especially)-389.3(patients)-389.3(with)-388.4(breast)]TJ 0 -1.2266 TD [(cancer,)-485.5(is)-491.7(necessary)-490.3(for)-484.5(treating)-492.9(patients)-490.5(with)-483.2(hot)-493.5(ashes.)]TJ 0 -1.2203 TD [(However,)-324.7(there)-326.8(are)-328.9(no)-328.6(available)-324(data)-325(on)-328.6(the)-326.2(effectiveness)-333(of)]TJ T* [(acupuncture)-513.8(for)-509.8(treatment)-508.2(of)-509.1(hot)-506.1(ashes)-514.3(in)-506.4(patients)-509.5(with)]TJ 0 -1.2266 TD [(breast)-259.2(cancer)-255(in)-259.8(Korea.)-255.2(This)-257.8(study)-257.2(was)-255.4(designed)-258.7(to)-256.2(assess)-263.9(the)]TJ 0 -1.2203 TD [(feasibility)-498.8(and)-505.4(safety)-499.3(of)-502.8(acupuncture)-501.1(for)-503.4(treatment)-501.9(of)-502.7(hot)]TJ ET 59.754 514.545 490.167 .22675 re f 59.754 78.293 490.167 .22678 re f 59.754 485.575 490.167 .28345 re f BT /F9 1 Tf 8.9663 0 0 8.9663 86.2299 520.214 Tm (Table)Tj /F5 1 Tf 3.0666 0 TD (1.)Tj /F9 1 Tf 1.2456 0 TD [(Overview)-336.6(of)-336.4(Clinical)-333.9(Trials)-335.4(for)-334.5(the)-332(Treatment)-330.9(of)-336.4(Hot)-335.6(Flashes)-333.3(in)-335.1(Breast)-332.8(Cancer)-334.5(Patients)]TJ /F7 1 Tf -7.265 -3.1551 TD [(Author\(s\))-6192.6(Study)-337.1(design)]TJ 17.6852 1.1128 TD (Participants)Tj 1.84 -1.1128 TD (\()Tj /F5 1 Tf .3225 0 TD (n)Tj /F7 1 Tf .5691 0 TD (\))Tj 4.4513 1.1128 TD [(Intervention)-339.9(type)]TJ 1.5934 -1.1128 TD (\(protocol\))Tj 7.7266 1.1128 TD [(Type)-337.8(of)-330(control)]TJ 1.9032 -1.1128 TD [(group)-5377.9(Main)-333.2(outcomes/results)]TJ /F5 1 Tf -36.0912 -2.0929 TD (Tukmachi)Tj 6.7246 0 0 5.9768 99.3826 477.1274 Tm (14)Tj 8.9663 0 0 8.9663 147.6283 473.1589 Tm (Uncontrolled,)Tj .999 -1.1128 TD (single-arm)Tj 8.8331 1.1128 TD [(22)-3805.4(AT)-333.2(\(traditional)]TJ 5.8044 -1.1128 TD (acupuncture\))Tj 8.7509 1.1128 TD [(None)-5633.4(Reduced)-333.1(HF)-339.5(frequency)]TJ 9.0354 -1.1128 TD (\()Tj /F7 1 Tf .4869 0 TD (p)Tj /F6 1 Tf .6702 0 TD (<)Tj /F5 1 Tf .7208 0 TD (0.001\))Tj -45.1013 -1.1128 TD [(Porzio)-339.4(et)-335.5(al.)]TJ 6.7246 0 0 5.9768 107.6031 457.2282 Tm (15)Tj 8.9663 0 0 8.9663 147.6283 453.203 Tm (Uncontrolled,)Tj .999 -1.1065 TD (single-arm)Tj 8.8331 1.1065 TD [(15)-3805.4(AT)-333.2(\(TCM\))-5149.8(None)-5633.4(Improved)-336.9(vasomotor)]TJ 23.5908 -1.1065 TD (symptoms)Tj -43.2234 -1.1128 TD [(De)-336.4(Valois)-335.9(et)-335.5(al.)]TJ 6.7246 0 0 5.9768 120.7559 437.2723 Tm (16)Tj 8.9663 0 0 8.9663 147.6283 433.3038 Tm (Uncontrolled,)Tj .999 -1.1128 TD (single-arm)Tj 8.8331 1.1128 TD [(50)-3805.4(AT)-333.2(\(traditional)]TJ 5.8044 -1.1128 TD (acupuncture\))Tj 8.7509 1.1128 TD [(None)-5633.4(Reduced)-333.1(HF)-339.5(frequency)]TJ 9.0354 -1.1128 TD (\()Tj /F7 1 Tf .4869 0 TD (p)Tj /F6 1 Tf .6702 0 TD (<)Tj /F5 1 Tf .7208 0 TD (0.0001\))Tj -45.1013 -1.1128 TD [(Hervik)-338.1(et)-335.5(al.)]TJ 6.7246 0 0 5.9768 109.644 417.3731 Tm (17)Tj 8.9663 0 0 8.9663 147.6283 413.3479 Tm [(RCT)-7854.1(59)-3805.4(AT)-333.2(\(TCM\))-5149.8(Sham)-334.1(AT)-3861.4(Intergroup:)-336.2(signicant)]TJ 33.4229 -1.1065 TD [(difference)-339.3(\()]TJ /F7 1 Tf 5.1532 0 TD (p)Tj /F6 1 Tf .6702 0 TD (<)Tj /F5 1 Tf .7145 0 TD (0.001\))Tj -7.5369 -1.1128 TD [(Intergroup:)-336.2(Reduced)-339.5(HF)]TJ .999 -1.1128 TD [(frequency)-336.3(in)-335.7(AT)-333.2(group,)]TJ T* [(both)-333.5(during)-338.9(and)-334.7(after)]TJ 0 -1.1065 TD [(treatment)-337.5(\()]TJ /F7 1 Tf 5.0647 0 TD (p)Tj /F6 1 Tf .6639 0 TD (<)Tj /F5 1 Tf .7208 0 TD (0.001\);)Tj -6.4494 -1.1128 TD [(reduced)-335.9(HF)-333.2(frequency)]TJ T* [(in)-335.7(sham)-330.6(AT)-339.5(during)]TJ 0 -1.1065 TD [(treatment)-337.5(\()]TJ /F7 1 Tf 5.0647 0 TD (p)Tj /F6 1 Tf .6639 0 TD (=)Tj /F5 1 Tf .7208 0 TD [(0.01\),)-333.6(not)]TJ -6.4494 -1.1128 TD [(signicant)-338(after)-336.2(treatment)]TJ T* (\()Tj /F7 1 Tf .4869 0 TD (p)Tj /F6 1 Tf .6702 0 TD (=)Tj /F5 1 Tf .7208 0 TD (0.22\))Tj -45.1013 -1.1128 TD [(Deng)-337.9(et)-335.5(al.)]TJ 6.7246 0 0 5.9768 103.2944 307.7857 Tm (18)Tj 8.9663 0 0 8.9663 147.6283 303.7606 Tm [(RCT)-7854.1(72)-3805.4(AT)-333.2(\(traditional)]TJ 15.6366 -1.1065 TD (acupuncture\))Tj 8.7509 1.1065 TD [(Sham)-334.1(AT)-3861.4(Intergroup:)-336.2(not)-335.4(signicant)]TJ 8.0364 -1.1065 TD [(Within-group:)-337.2(Reduced)-339.5(HF)]TJ .999 -1.1128 TD [(frequency)-336.3(in)-335.7(both)-333.5(groups)]TJ T* (\()Tj /F7 1 Tf .4869 0 TD (p)Tj /F6 1 Tf .6702 0 TD (<)Tj /F5 1 Tf .7208 0 TD (0.01\))Tj -45.1013 -1.1128 TD [(Walker)-335.9(et)-335.5(al.)]TJ 6.7246 0 0 5.9768 110.6645 267.9307 Tm (19)Tj 8.9663 0 0 8.9663 147.6283 263.9055 Tm [(RCT)-7854.1(50)-3805.4(AT)-333.2(\(not)-335.9(reported\))-1861.9(Venlafaxine)-2844.4(Intergroup:)-336.2(not)-335.4(signicant)]TJ 32.4239 -1.1065 TD [(Within-group:)-337.2(Reduced)-339.5(HF)]TJ .999 -1.1128 TD [(frequency)-336.3(in)-335.7(both)-333.5(groups)]TJ T* (\()Tj /F7 1 Tf .4869 0 TD (p)Tj /F6 1 Tf .6702 0 TD (<)Tj /F5 1 Tf .7208 0 TD (0.036\))Tj -45.1013 -1.1065 TD [(Frisk)-336.9(et)-335.5(al.)]TJ 6.7246 0 0 5.9768 101.707 228.0755 Tm (20)Tj 8.9663 0 0 8.9663 147.6283 224.107 Tm [(RCT)-7854.1(45)-3805.4(EA)-333.2(\(traditional)]TJ 15.6366 -1.1128 TD (acupuncture\))Tj 8.7509 1.1128 TD [(HRT)-5944.4(Intergroup:)-336.2(HRT)-336(is)-333.6(more)]TJ 9.0354 -1.1128 TD [(effective)-339.8(than)-335.6(EA)]TJ -.999 -1.1128 TD [(Within-group:)-337.2(Reduced)-339.5(HF)]TJ .999 -1.1128 TD [(frequency)-336.3(in)-335.7(both)-333.5(groups)]TJ 0 -1.1065 TD (\()Tj /F7 1 Tf .4869 0 TD (p)Tj /F6 1 Tf .6702 0 TD (<)Tj /F5 1 Tf .7208 0 TD (0.05\))Tj -45.1013 -1.1128 TD [(Davies)-335.2(et)-335.5(al.)]TJ 6.7246 0 0 5.9768 108.9637 178.2425 Tm (21)Tj 8.9663 0 0 8.9663 147.6283 174.274 Tm [(RCT)-7854.1(20)-3805.4(AT)-333.2(\(traditional)]TJ 15.6366 -1.1128 TD (acupuncture\))Tj 8.7509 1.1128 TD [(Sham)-334.1(AT)-3861.4(Intergroup:)-336.2(not)-335.4(signicant)]TJ 8.0364 -1.1128 TD [(Within-group:)-337.2(not)-335.4(reported)]TJ -42.2244 -1.1128 TD [(Nedstrand)-340.1(et)-335.5(al.)]TJ 6.7246 0 0 5.9768 124.2141 158.3433 Tm (22)Tj 8.9663 0 0 8.9663 147.6283 154.3181 Tm [(RCT)-7854.1(38)-3805.4(EA)-333.2(\(classic)]TJ 15.6366 -1.1065 TD (acupuncture\))Tj 8.7509 1.1065 TD (Applied)Tj .999 -1.1065 TD (relaxation)Tj 7.0374 1.1065 TD [(Intergroup:)-336.2(not)-335.4(reported)]TJ 0 -1.1065 TD [(Within-group:)-337.2(Reduced)-339.5(HF)]TJ .999 -1.1128 TD [(frequency)-336.3(in)-335.7(both)-333.5(groups)]TJ T* (\()Tj /F7 1 Tf .4869 0 TD (p)Tj /F6 1 Tf .6702 0 TD (<)Tj /F5 1 Tf .7208 0 TD (0.001\))Tj -45.1013 -1.1065 TD [(Liljegren)-339.5(et)-335.5(al.)]TJ 6.7246 0 0 5.9768 116.5606 118.4882 Tm (23)Tj 8.9663 0 0 8.9663 147.6283 114.5197 Tm [(RCT)-7854.1(74)-3805.4(AT)-333.2(\(traditional)]TJ 15.6366 -1.1128 TD (acupuncture\))Tj 8.7509 1.1128 TD [(Sham)-334.1(AT)-3861.4(Intergroup:)-336.2(not)-335.4(signicant)]TJ 8.0364 -1.1128 TD [(Within-group:)-337.2(Reduced)-339.5(HF)]TJ .999 -1.1128 TD [(frequency)-336.3(in)-335.7(both)-333.5(groups)]TJ T* (\()Tj /F7 1 Tf .4869 0 TD (p)Tj /F6 1 Tf .6702 0 TD (<)Tj /F5 1 Tf .7208 0 TD (0.001\))Tj 7.9702 0 0 7.9702 67.748 66.4441 Tm [(AT,)-531.3(acupunctu)9.3(re;)-533(TCM,)-531.2(traditiona)11.6(l)-537(Chinese)-526.8(medicine;)-529.8(RCT,)-524.8(randomized)-524.1(controlled)-525.9(trial;)-534.6(HRT,)-531.7(hormo)11.8(ne)-539.1(replaceme)15(nt)-535.7(therapy;)-526.3(EA,)]TJ -1.003 -1.1239 TD [(electroacupun)8.7(cture;)-333.4(HF,)-325(hot)-336.2(ash.)]TJ /F3 1 Tf 8.9663 0 0 8.9663 59.7543 749.7069 Tm [(ACUPUNCTURE)-340.1(AND)-337.2(HOT)-334(FLASHES)-339.4(IN)-328.8(BREAST)-338.7(CANCER)-340.8(PATIENTS)-19735.3(691)]TJ ET endstream endobj 4 0 obj <> endobj 5 0 obj <>/Font<>/ProcSet[/PDF/Text/ImageB]/ExtGState<>>> endobj 6 0 obj <>stream /GS1 gs BT /F5 1 Tf 8.9663 0 0 8.9663 62.022 725.7825 Tm 0 0 0 1 k 0 Tc 0 Tw [(ashes)-514.3(in)-512.8(Korean)-514.9(patients)-522.1(with)-514.8(breast)-512.1(cancer)-514.2(undergoing)]TJ 0 -1.2203 TD [(antiestrogen)-342.2(therapy.)]TJ /F3 1 Tf 0 -2.447 TD [(Materials)-332.7(and)-338.2(Methods)]TJ /F10 1 Tf 0 -1.8336 TD [(Study)-332.3(design)]TJ /F5 1 Tf 1.1128 -1.8336 TD [(The)-531.1(institutional)-545.7(review)-531.2(board)-535.2(at)-537.4(Daegu)-537.7(Catholic)-537.5(Uni-)]TJ -1.1128 -1.2203 TD [(versity)-245(Hospital)-252.7(approved)-243.3(this)-249(study.)-247.4(There)-247.2(were)-242.4(no)-246.4(conicts)]TJ 0 -1.2266 TD [(of)-268.8(interest)-268.9(for)-263.2(the)-269.3(investigators)-268.7(or)-262.7(the)-269.3(research)-263.9(staff.)-270.7(This)-264.2(was)]TJ 0 -1.2203 TD [(a)-416.8(prospective,)-418.9(single-arm,)-415.6(observational)-414.6(study.)-418.1(Participants)]TJ T* [(received)-550.7(12)-542.8(sessions)-552.3(of)-540.7(acupuncture,)-554.6(delivered)-545.3(3)-543.3(times)-552.9(a)]TJ T* [(week)-378.9(for)-377(4)-378.9(weeks.)-376.8(The)-379.3(severity)-377.7(of)-376.3(hot)-379.7(ashes)-381.5(was)-375.5(assessed)]TJ 0 -1.2266 TD [(via)-376.8(a)-372.6(visual)-376.7(analogue)-374.8(scale)-376.6(\(VAS\))-383(and)-372.6(total)-373.5(hot)-379.7(ash)-373.9(score.)]TJ 0 -1.2203 TD [(Patients)-243.9(were)-236.1(evaluated)-235.5(1)-239.8(week)-233.5(before)-242.1(treatment)-242.6(commenced)]TJ T* [(\(baseline\),)-335.5(once)-340.5(a)-328.3(week)-334.6(during)-338.9(treatment,)-334.1(and)-334.7(4)-334.6(weeks)-329.6(after)]TJ 0 -1.2266 TD [(the)-566.5(nal)-565.8(acupuncture)-570.7(session.)-566.5(Figure)-570.7(1)-562.2(shows)-566.8(the)-566.5(study)]TJ 0 -1.2203 TD (design.)Tj /F10 1 Tf 0 -2.447 TD [(Study)-332.3(participants)]TJ /F5 1 Tf 1.1128 -1.8336 TD [(Informed)-357.7(consent)-364.6(was)-356.5(obtained)-358.4(before)-362.2(participant)-360.9(enroll-)]TJ -1.1128 -1.2203 TD [(ment)-361.7(according)-363.7(to)-357.3(a)-359.9(clinical)-357(trial)-361.8(protocol.)-364.3(Recruitment)-364.9(was)]TJ T* [(performed)-505.9(from)-507.3(September)-508.5(2011)-503.9(through)-509.7(December)-508.9(2012,)]TJ T* [(and)-505.4(10)-504.9(Korean)-508.6(women)-511.1(with)-508.5(breast)-505.8(cancer)-507.9(were)-508(enrolled.)]TJ 0 -1.2266 TD [(Inclusion)-254.6(criteria)-247.9(were)-248.7(as)-247.4(follows:)-246.6(\(1\))-253.4(pre-)-249(or)-243.7(postmenopausal)]TJ 0 -1.2203 TD [(status)-390.1(and)-385.3(presence)-391.4(of)-382.6(breast)-385.7(cancer)-387.8(treated)-389.6(with)-388.4(antiestro-)]TJ 27.9978 29.9453 TD [(gen)-304.9(therapy)-306.9(using)-304.9(tamoxifen)-306.9(or)-307(anastrozole;)-307.2(\(2\))-304(moderate)-301(or)]TJ 0 -1.2203 TD [(severe)-432.4(vasomotor)-425.9(symptoms)-424.1(according)-426.9(to)-426.9(the)-421.1(denition)-427.7(of)]TJ 0 -1.2266 TD [(the)-345.2(Food)-341.8(and)-341(Drug)-343(Administration)]TJ 6.7246 0 0 5.9768 453.5999 707.8676 Tm (25)Tj 8.9663 0 0 8.9663 460.3463 703.8423 Tm [(;)-344.4(\(3\))-341.9(an)-338(average)-346.1(of)-338.4(3)-340.9(o)0(r)]TJ -16.4269 -1.2203 TD [(more)-348.7(hot)-348.1(ashes)-343.5(per)-349.7(week)-341(during)-351.5(the)-345.2(1-week)-347.3(period)-346.4(before)]TJ T* [(the)-585.5(trial;)-586.1(\(4\))-582.2(Karnofsky)-588.9(performance)-587.3(score)-585.7(of)]TJ /F6 1 Tf 21.422 0 TD (>)Tj /F5 1 Tf .7208 0 TD [(60,)-577.3(which)]TJ -22.1428 -1.2266 TD [(means)-431.6(ability)-430.4(to)-426.9(participate)-426.9(in)-430.6(the)-427.4(trial)-431.4(for)-427.6(oneself)-428.6(or)-427.1(with)]TJ 0 -1.2203 TD [(occasional)-337.4(assistance;)-334.9(\(5\))-335.6(voluntary)-333(participation;)-332.2(\(6\))-335.6(follow-)]TJ T* [(up)-236.7(for)-237.9(the)-237.7(duration)-236(of)-237.2(the)-237.7(study;)-241.1(\(7\))-234.4(cessation)-239.1(of)-237.2(HRT)-234.8(or)-237.4(other)]TJ 0 -1.2266 TD [(pharmacologic)-498.2(or)-490.3(alternative)-492.2(treatments)-496.9(for)-490.8(hot)-493.5(ashes)-495.3(at)]TJ 0 -1.2203 TD [(least)-403.1(4)-397.9(weeks)-392.9(before)-400.2(the)-402.1(trial,)-396.4(if)-396(such)-397.4(treatment)-400.7(were)-400.5(used.)]TJ T* [(Exclusion)-254.3(criteria)-247.9(were)-248.7(as)-241.1(follows:)-252.9(\(1\))-247(pharmacologic)-245.3(or)-250.1(other)]TJ T* [(alternative)-384.7(treatment)-375.4(for)-377(hot)-379.7(ashes)-375.2(during)-376.8(the)-376.8(trial;)-377.4(\(2\))-373.5(se-)]TJ 0 -1.2266 TD [(rious)-300.5(medical)-297.2(or)-300.6(psychiatric)-295(conditions)-301.7(making)-297.4(participation)]TJ 0 -1.2203 TD [(in)-373.7(the)-370.5(trial)-374.5(unsuitable;)-375.8(and)-372.6(\(3\))-367.2(hot)-373.4(ashes)-375.2(caused)-371.1(by)-369.2(meno-)]TJ T* [(pause)-338.6(without)-336.1(antiestrogen)-342.2(therapy.)]TJ /F10 1 Tf 0 -2.447 TD (Interventions)Tj /F5 1 Tf 1.1128 -1.8336 TD [(The)-341.4(study)-339.3(protocol)-342.5(involved)-346.4(4)-334.6(weeks)-342.3(of)-338.4(treatment)-343.8(with)-344.1(3)]TJ -1.1128 -1.2203 TD [(acupuncture)-400(sessions)-387.9(per)-394(week.)-388.1(For)-393.6(all)-385.9(sessions,)-390.8(vital)-393.5(signs)]TJ 0 -1.2266 TD [(including)-347.9(blood)-345.3(pressure,)-350.9(pulse)-342.6(rate,)-344.9(and)-341(body)-343.4(temperature)]TJ 0 -1.2203 TD [(were)-368.9(measured)-363.7(before)-368.6(treatment.)-365.7(All)-362.5(sessions)-368.9(were)-362.5(40)-359.4(min-)]TJ T* [(utes)-268.6(long,)-263.6(and)-265.1(the)-263(acupuncture)-273.5(portion)-267.9(was)-261.7(20)]TJ /F6 1 Tf 20.5431 0 TD ()Tj /F5 1 Tf .7145 0 TD [(5)-265.1(minutes)-266.8(in)]TJ -21.2576 -1.2203 TD [(duration.)-713.2(Acupuncture)-718(was)-710.6(performed)-714.5(by)-704.4(a)-714(traditional)]TJ 0 -1.2266 TD [(Korean)-729.9(medicine)-718.3(\(TKM\))-726.4(physician)-727.9(who)-722.3(was)-716.9(registered)]TJ 0 -1.2203 TD [(with)-508.5(the)-509.6(government)-506.4(and)-505.4(had)-505.4(at)-505.8(least)-510.6(3)-499(years)-511.7(of)-502.8(clinical)]TJ T* [(experience)-541.1(in)-538(acupuncture)-539.1(treatment.)-536.4(Acupuncture)-541(points)]TJ 0 -1.2266 TD [(were)-508(selected)-506.8(according)-502.8(to)-502.7(the)-503.3(recommendations)-508.2(of)-509.1(TKM)]TJ 0 -1.2203 TD [(clinical)-300.1(experts)]TJ 6.7246 0 0 5.9768 371.6786 428.3716 Tm (26,27)Tj 8.9663 0 0 8.9663 389.5369 424.403 Tm [(and)-296.8(standard)-301.8(acupuncture)-298.8(textbooks.)]TJ 6.7246 0 0 5.9768 537.0518 428.3716 Tm (28,29)Tj 8.9663 0 0 8.9663 313.0582 413.4613 Tm [(Acupuncture)-281.7(was)-268(applied)-271.4(at)-271.9(ve)-275.5(acupuncture)-273.5(points:)-275(GV)-267.1(20;)]TJ 0 -1.2266 TD [(M-HN-3;)-387.8(and)-378.9(bilaterally)-389.8(at)-379.4(three)-383.7(points)-385.9(including)-385.8(HT)-382.4(8,)-381.8(KI)]TJ 0 -1.2203 TD [(10,)-431.9(and)-429.5(LV)-429.4(2.)]TJ 6.7246 0 0 5.9768 369.4109 395.4897 Tm (29)Tj 8.9663 0 0 8.9663 380.0125 391.5212 Tm [(Table)-427.7(2)-429.5(shows)-434.1(the)-427.4(acupuncture)-437.9(point)-428.8(pre-)]TJ -7.4674 -1.2203 TD [(scriptions)-498.2(and)-492.8(their)-494.9(anatomical)-495.9(position.)-496.3(The)-493.1(acupuncture)]TJ T* [(needles)-390.3(used)-391.3(were)-387.8(sterile,)-391.6(disposable)-387.4(stainless)-387.3(steel)-390.8(needles)]TJ 0 -1.2266 TD (\(30)Tj /F6 1 Tf 1.4922 0 TD ()Tj /F5 1 Tf .7208 0 TD [(0.25)-165.8(mm;)-459.6(Dongbang)-466.3(Acupuncture)-465.1(Inc.,)-465.9(Chungcheong-)]TJ -2.213 -1.2203 TD [(nam-do,)-325.8(Korea\),)-318.9(and)-322(a)-322(total)-316.6(of)-325.7(eight)-321.5(needles)-320.8(were)-318.3(used.)-324.6(The)]TJ T* [(skin)-518.5(was)-508.3(swabbed)-513.7(with)-514.9(an)-508.7(alcohol)-514.3(prep)-509.1(pad)-516(before)-514(acu-)]TJ 0 -1.2266 TD [(puncture)-810.8(was)-805.5(administered.)-809.1(Depending)-810.6(on)-802.8(the)-806.8(points)]TJ ET q 1 i 62.589 425.083 m 300.529 425.083 l 300.529 74.041 l 62.589 74.041 l W n q 238.023 0 0 351.042 62.589 74.041 cm /Im1 Do Q Q BT /F8 1 Tf 8.9663 0 0 8.9663 108.5102 57.3165 Tm [(FIG.)-336.8(1.)]TJ /F5 1 Tf 4.0909 0 TD [(Flow)-334.8(diagram)-337(of)-332(the)-338.9(study.)]TJ ET 313.058 272.466 239.131 .22684 re f 313.058 57.317 239.131 .28348 re f 313.058 253.19 109.134 .22682 re f 313.058 235.502 239.131 .22676 re f BT /F9 1 Tf 8.9663 0 0 8.9663 337.6062 288.1133 Tm (Table)Tj /F5 1 Tf 3.0603 0 TD (2.)Tj /F9 1 Tf 1.2519 0 TD [(Acupuncture)-333.2(Points)-338.9(Prescriptions)]TJ -5.9182 -1.1128 TD [(and)-331.7(Their)-338.4(Therapeutic)-333.7(Effects)-337.3(with)-331.4(Acupuncture)]TJ /F7 1 Tf -1.1318 -2.0423 TD (Prescription)Tj 0 -2.0044 TD [(Point)-4296(Meridian)-7898.2(Location)]TJ /F5 1 Tf 0 -2.0992 TD [(GV)-336.7(20)-1712.5(Governing)-340.1(vessel)-803.4(Midway)-333.4(on)-334.9(a)-334.6(line)-332.8(connecting)]TJ 13.9736 -1.1065 TD [(the)-332.5(apex)-338(of)-332(both)-339.8(ears)-330.2(in)-335.7(a)]TJ 0 -1.1128 TD [(depression)-339.6(slightly)-334.4(anterior)]TJ T* [(to)-332(a)-334.6(larger)-337.6(depression)]TJ -13.9736 -1.1128 TD [(M-HN-3)-802.2(Extra)-334.6(points)-3066.8(Midway)-333.4(between)-338.4(the)-332.5(medial)]TJ 13.9736 -1.1065 TD [(ends)-336.4(of)-332(the)-338.9(eyebrows)]TJ -13.9736 -1.1128 TD [(HT)-338.1(8)-2263.1(Heart)-335.7(meridian)-1648.8(Between)-337(the)-332.6(4th)-338.5(and)-334.7(5th)]TJ 13.9736 -1.1128 TD [(metacarpal)-336.5(bones)]TJ -13.9736 -1.1065 TD [(KI)-340(10)-2136.2(Kidney)-339.5(meridian)-946.9(On)-335.2(the)-332.6(medial)-335.8(side)-330.2(of)-338.4(the)]TJ 13.9736 -1.1128 TD [(knee)-336.4(joint)-331.3(between)-338.4(the)]TJ T* [(tendons)-336.7(of)-332(semitendinosis)]TJ T* [(and)-334.7(semimembranosus)]TJ -13.9736 -1.1065 TD [(LV)-334.6(2)-2370.6(Liver)-336.7(meridian)-1844.8(On)-335.2(the)-332.6(dorsum)-335.5(of)-332(the)-338.9(foot)]TJ 13.9736 -1.1128 TD [(between)-338.4(the)-332.5(1st)-336.4(and)-334.7(2nd)]TJ T* [(toes,)-336.2(proximal)-333.6(to)-332(the)-338.9(margin)]TJ T* [(of)-332(the)-338.9(web)-334.7(at)-328.8(the)-338.9(junction)]TJ 0 -1.1065 TD [(of)-332(the)-338.9(red)-332.4(and)-334.7(white)-337.7(skin)]TJ /F3 1 Tf -41.9715 76.5072 TD (692)Tj 47.6052 0 TD [(JEONG)-333.7(ET)-338.7(AL.)]TJ ET endstream endobj 7 0 obj <>stream AdobedC        s!1AQa"q2B#R3b$r%C4Scs5D'6Tdt& EFVU(eufv7GWgw8HXhx)9IYiy*:JZjz?Nlٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛1 IIuʯ*}GwzP*uEL2^d?W*#ee (߯2)]r]kG&dK:Mo`{ߐw뿚e m.'/W+7uqSq*2OBsG$S[q ɶw{_[A29'n(Wl^"} SX5q~^IE*rysrDaM'q&.u#!ߞ?~Z7&$6̛YOrUʏ3A4V~FfdzgKHE6WSPAAyf͛6lٳf͛6lٳf$(,ƀnIqMGrL^}~UoJ:G) #cqj?6?S+o-.Iq{rC\cRH;l2'^-.%)$H Tɾnu}GUm5aݔHPOP1?<1//0z֪.4v?Zu pWu4m_X sk c$^G?AzTzw]j}Υ;fZ#(!RLMxXkҵT}J?5],f휄VX u nYeuT,}m#Q bO-o2RkΩϜ$ӵΫ Q#TeV:R~rs>S)G2DP׮מ@ @yY=._; -jKm[>bk}x3݉uy0>سf͜wD|%c..q7v+k\!)"ȷ?%>''쮋[Rya >ݗX_kj^J7w<{~1O"Z uy-{B5iho/$Kl OrXs' >9S oSAo&k.$5fVBΪ閭W^zO EYsqs#/y:73+c块h\ C̢YԴF[9!"]*W٨9f͜r#vhzZյ-*6 Qz0?&ƉJGz@#"c-rc6lٳf͛6lٳfȯK/5&L6~D9!}CZ,)턇FUy*sy:?-ySIyCIUVrکC'yqR:O~`k7qZOwQdӇ<~8x_(d5_kP;ꀚ,\󮋮~_ivo͏C- R2FFAZxm#K󭗞}a4'YXZ]iĪԝBD<$|JOm7S4*=nu]oF%;{/ QRi#G`׍1j_Yk:5~rG41,lO0 2*ɪ\:O{N]СM Ʀg$pm摠i:6;L[YutJ+`ޤWP}^OsQU,C~䲓 8Rfei qM. 2ƴ买uO*Ƌ3 &dTrZ4"ycyЪױ e&unޡ)Y#,Q.4KqCҕķm#iXHq0 ehZVv}҇3PAp|AŸ7jO}Nogg<ҁJH Wj~Jx#,RT{ea^tε6lٳf͛6lٳf{y:m~uU)$VĜ~_t;,uOA!r_ W[W_{C=GGpo/svq7Au[n?W_{C=GGs~k#S[˧wsmI'(\mt76:?W_{C=GGs~k#Ohq\ߧ?o\mt76:?W_{C=GGsIyV 7ֺiaȲLIy#߶t#Ll/#1]iDhJ*lF677qmnxg!E*s~Rkw~w<4Z:3ܖ z= 9槐&<֞ zZ~6-܄WGD/l_26j#GH4KaCFV˟2hֆH:pd4ɮY+SŇӿ-4t-NG~!:6q'^csaQʡuo(O6!dUѥ lj0VU>sM685/nH&L0\$r)fK aC~T_WZMΟvl!Z$Ki\L6-w]L+%֌Yh}(GoAB nNq/%a_1MiڥY}Y?tG8C^?F.c*_=ZKZ?1ޑ?UK_\>i){L/*FmO[]$0Va-9TL?6]_tkU{Lv7e۫/Sv:. [ۧ~()Sz0͛6lٳf͛6lٳf}?ʏ4j= ImÑN)o\(Y ]TB#VgG-Iw_S7 X[o%L+??aoKV$uU3ЬHՅ.fY ]TB#Vʟھ mژ= q:#|.즪Ƕ\8Pk>Ah-oqu/nWF=GB#VgG-Iw_S7 X[o%L+??aoKV$uU3ЬHՅ.fY ]TB#VgG-Iw_S OZ=[IУ[y%kfpP:ltUL70~̇^=_ߘw y-s7[/2#So@&:=KCQUfÏ}f͛6lٳf̀sG,$5{l,4K/[V'?(m^ޖ ) Q0Sֆ`:Gп.F&W>?{q'ST;6lٳf͛6lٳf͛6lٳf͛6lٳZb/ ZkrWd UI+ CWƺm;Goa D!Km4՛6lٳf͛6lٳ`}COl岿u)57Sٕ884J]o^Rԟ6J%ĩ5 iOϏ"~PXDΌj[.T_I9=ES}o)דQJ7utNLX$ˊiYf̀5-C%[YC!ʑQ49ט&'`U5ҷRinFQ["~q~sЛ%I9d5 n%ք|GWvkd5QL8^;q4HѴONlⱱR+hFUf͛6lٳf͛6lٰ6Yzm֥{ 'ScK1y˾dڸ^Ωo&Cꇏ2ʌ;V#k9 J/CU7]oVtd9ZCҋk9 J/CU7]oVtd9ZCыk9 J/CU7]&<&H?2ӯ0@l@:7QU o kxφ8 E(K 1OVtd9ZCыk9 J/CU7]oVtbd9ZCыk9 J/CU7](oVtbd9ZCы{_=kg-,p߼q% 枢szg5MOMԬߝ1[V9T:6lٲ;˿"Z ee ? > ?S:|7<~t?}OQ i&Ik̭ns6s=K*:o櫺RX?S;*r._ _S@_@`Pg`o88GLkO1fkWڭL٪#pNQxn51M~v1ڢparOa{ei"''XU+ZR'mNIf͛6lٳf͛6lٳf͛"ߚ,l0W qNLFi 5I;w''ˋ-y$X`KI,F[3ooO+gf=rIÌ[Ѭbk{hui&QޜBGii,,fD<='6lMmuiP\:HKeV/REqLRӬ"cq ֑c$oȎL{cccw зёd_Ğ,;+[HEe8Vgb-m.m 4Yd9XG* !X|=:,f;ېU@Q {`ٳ@g8q?ʲtlٳf͛6lٳf͛6lٳf͛6lٳf͛6lٲ+_ɼ ߑ?'l迎N-寚Jp:e*鳀z^bt=x H|[ēQOMnn(>٩ɿ't=KQӼէZˣXG"i8sǂSE+~b.BI_3h?o"9Fңw^h?1onrUUؤ=̍yHU?d:޿ k 7OipZxI/9d+,V[ߘiе-BNմmHY9%Z!,rN(F-OI4O5lhb򭿛otWNl-&լ7@^%m'toOx /N6v8CH)_嗪~aqI?6j}䋹c[?RK1/O{k?3O龍I"בaFrژ;GZ/̞bK˸b5TRM*:W 73<šIƋ+ Iu N->]ZUEI#KXJ nNd^j g5>-B$ \G sR9|6}RL4c]k|Cd(b++^rӼ}3[,dZ~(pRx hߘ/Xh=#IK.-d{4x *WQ:?$-VCSGM5=N^t{]t':TX.V(EFG3%>nw7ivX(PEa$A8T+5l9/䵦'U5mOYӅ,l"x̱~*&J%wZ^oз(n#aȜ/4;Xv牤PoT~j_Ze_kZX[hVb Ð5q-V^ucA th5'`?(IWnl|pο^fմnSе1}SNdYL]dY0_KtKKkSѵd>s0iPP23ʿtS[֬naOpyKjDr/~0}'CU]O7 WwU ?oޫH\5_W$j+z Is~W_@}'CU]O덓r$/(VkI9k9[VTeaUac!\ޫH\5_W$j+z Is~W_@}'CU]O7 WwU ?oޫH\5_W$?F ^iŹ{oPzWm[m[?Cy{L=O[u8cXSzW͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6QU=@?<ޜ>ޜ>ޜ>ޜ>ޜ>ޜ>ޜ>ޜ>ޜ>ޜ>f?:ח俷\mfOf 3O3gU4;Pt*jаwJ}U"}8}ٽ8}ٽ8}ٽ8}ٽ8}ٽ8}ٽ8}ٽ8}ٽ8}ٽ8}قe͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lFSo4+|*`oW+_՛AG5fh?rY\|VoW+_՛AG5fh?rY\|VoW+_՛AG5g#~}c՘"Z֤$U/,/mZE<Ct(>uΛ k#4Z V>?7Aj k#4Z V>?7Aj k#4Zk{gvgh\U'͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6l/oh:r A[Ku* >m=~`~cKk}3#B'*+Q^-hHߖW?$*f\gㆻif^hUԡichOא4نYy_8i^i2is=սqJQjZ,p75LЮ~HՀUT֍֑}]Ni忎4ie-'$8P8O+Sut6-E7/վN{+c'eV2QnsB#VIW_S ǯǍJVtӭ3wt4Τ-q7ZZNfQ^vOڴBOЮ~HՀUTB#VIW_S7 X%]L+?`?uU3Ю~HՀUT™? ,^[moҳ[I~cf QKW W?$*f\sGoJW?$*g?[_^Ckc:>K)KWq˵xU o]i(è[Eu7Uirٳf͛6lٳf͛6lٳf͛6lٰFO5:V攼^=/V&t6gZt6G-ͻEd: qm:'4M+:b ` a6i'V j^GmU$]!4{^'7*>ٰմZMWK%@KQTkWo?awOI):/㓼Ƽiߖߛm9M-[rXԱ5C.?~X򖼷ߝ|kk gez~TVOwSƶTt."7'~]8Isi6xzͦYQ*|8|m$j#]zy.tb,( 0;yk:j.H+I4Wu>6o׎ 'Qk/n+_TKru "b_4yq9?.GL/bB$_k ysX5Su WЊ{_q_Z1Fo?#Xm~ *p2(O[W`DWPōjԷZ~ 4eLr (G/םaK㘊 :˂+IcRB|M2/i䋏'hwzl|:PAu'…",l0]{_΋6lٳf7Ijy*yrNѭlaI6I<2ɷ5 (y>KvQ,hJM-G"XحKa-?<ê_隍1Ɨ FFז njPѵM i4- wx7 N݃~[t-Vu["/1Ȥ$y^p~[7sE7!#'Sk8f#&o懛_;꺕[XN H\!Uj}*|˟O&k[~h8^#>GΟSaVi,57<8*GdU,O&'Qe XK&7mn|//g@m%Ydf,iM3vbԺx"[/4GDWdx(LU]i^>L֭G˪QoSbG3f͛6l˿%?KףzKƖv9<:$VI4/f~\dhLI#pUw?͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6l:㡃~h}w-ւIYc.z5ʞ˵}HQL8__S7WT*{.!EU3ʞ˵}HQL8__S7WT*{.!EU3ʞ˵}HQL8__S"_~Y/3bb/VUzSza/8|M#^?wTR'nFD}pV_/Z'oYk#9eB嬏p9 ?ÛV_/Z'oYk#9eB嬏p9 ?ÛV_/Z'oYk#8r'' ?2qkKXmUFy㸩V4у#U #/"_lֻ euel~idalkY9Ѵ*k]A}}{~ic5Eˎ,zS_˖:amNs $r(Y9:/ʁ)uS+KQROxu|u;/rM9`ɩx]U-O'[Õi\=&O׻"/%= 3&rȗP4p~D*~3jzBڋhDpDm xU]hA#|sU5u/OEu,TjHdrMr/tvll ~kR 3ʐ#vp^4].=NyŤv!xIXa}\>`ҙ$kKId%Ԑ79owϨi\\ Hթ߯l|\ys_h`l4lF|.C8oI*?<9q-VvZ(Z|Bf͛6lٳf͛6lwO_41G]*) 7B0qI'<շ=KK3v'Ώ6lٳf͛6lٳf͛6lٳFXY~LQ,W[9~ıȼ\{%eP,$akDtOgɕq/nӧ?f59*ґ 7>QѮI_j:sXjPY%ٔr+8.M"Hӯķ[Fe;wtq+ ~Fեm4î^֪Z>+$,Jr7&/4o*KFsCNCsNOeq<[ZCMv `ks?sXUX[HZݭ JDpeJmS]a5?36lٳf͛6lٳd#ϟSUzv,-\H(䧫g>֍y VvY :/˧?R&P?=WsȟRt_'yͿ=<Ǥfz ou+HY;AnTZs p?uK\󇑼BkX]ZFmBQgpd{ߜVM-b\5(-auuutyGiΊ,5}/Y// ZYu,ߒ~qν?;[yha$'K`,sD<|r7~bzG7eRT򮇦~$~+*;eֳIg覸>S)86/< \*I*&H|6e_6{Euu+?JG7w:q?ª/8yu9g>3?5'$|GDӥueÜlªYlp/y!?Z/喹ZhݭqszP)Y7i砼(l_2 Ϋ5l^nqT{: /zGMW5zvŌڧ 4S 4Ѓ֚!(&Ֆ˞t&MݶwBh=6*~yBMQmt#P%uywK}?I±}"N' Ώ$iUg{֥k՞).<ؐ>4lz"YUךam K",(\HROG)~oy2˚6>jʼ9,@Fw/ȉfdʼONpPTqXS\[,FVC΃z;Լ3VM#P-m71k$831r^ge\o_D5h5Xݢ{S*"ty*V-?3/,om)mt,(œc[C$4+[wКӈf%cDX OLf͛6lٳf͛6lփTÿ_^jMl-=/gErw=:RӮ-o"x'CME*z9%* B Ҵi!<.ב#XGɯ;iAՆ%h7CO kElN#vTt忶7V>g^ͦKkKD+JZ}o!yG~].._>g2<[Y]Q=7BCjJɟvtԼui:2i{utaiS("HJ+0ou}g)t^MnuǏw:/_?U+?;^M- *@ K}+Zt*Y Ϫdx"X`ND5˭6M=-?^>fUY$Xy 2cʿ=yI2O,47jx)MkK/"y?2Q[vΓqefAUqJޙ_4IyM!=ϘtKYO]JJC~LylJ惨0Amih9WkȮƒ$d6z,ޣ04#r0ϔ-OkSx-MygB/A 0|kaFizV@8JV-͜r$ϛ?.?_ygV_"g9'O&NGD}\S|hwڕHk:u'cg{BZW^͎^$ <%rKs7ywߗb5/ib.֖@(䈘OJ0? gB%4^]S^E-īVHP~ciڇ7s/u3Sd0˂? >s%e΋iyZl]Z߭[ʕ$ILgoS,^\4GKs4ir!WN?GL~akZǛ|}ZZcJΊcO bڟrK3 fi[RJ{ktHy4@NrVN󍏙t="Om$kWosi>s*YzjiZih,o3\\?)"l7^z򟚛Wǔ{M^,a}Y.mO)?lBdb0|Q|&ͩR<) [r%!2O(QaF}12DYCa.xƥa.<y̷j;ͧ^m4vv5\yTj:<ǧSjEL˓q,_ IUu'ⵡlg։͛6lٳf͛6lٳ I^jH%y}ۡ4I"eQ_rs;~iya/|jN77R, *=Bwu?ǒ`27_0iכq4Lk8WLo&A5y+ 7 <SIyJM?%d^oǒ`27_0iכq4Lk8WLo&A5y+ 7 <SIyJM?%d^oǒ`27_0iכq4Lk8WLo&A5y+ 7 <SIy?"3*Z^okUϫ ϧmƀΫ:Mv^'wg (UTusrO$ ?M|(l_2o͏:~Ojm2^ل.#Qu(Ayb˖Bw6/ysm;I$HefoAm*}:xZIlmffc{~<o6<2}:{Adw1ݫ_G E|NU^՝ƣ}#":ܚ rAqk,v96C| b2_->~iҵYl4ᵸHd[xƈfjzaFIԶǸJ]=-'k=I!xR#XݥvVkID^W+:RD> LDL%N+YnE/)ltOsZKi0waǟUOLt?~QQ~Mq-2=KE_XG ea;O[[ Aootc>?$\}Hs2_YIm)HᕡyEt5W{9#kT [fV*$ ehdnRrn4q1,?&sf͛6r*i -ּu{jg!I4l%-.nkW~jy~kƺ疓Eo>5-F_/i~>ܴdעᰱgpbG&k-_5oiLSTHMm"QS~ C%.m5mOm&i©<*zv'l"'_f>`ݞYdHXc&3:]jw,EoM3F7qU6֚Ζ.eoeqiѹ),ƽd ^?:sփTΉ2MXSmS[K6`9zl \%?UL.*o?OmdS7 J2S[o?TB)RfsVFOU3йJԫm#'\%?UL.*s-TkƇAe[FRga0U楨ynNvyy0rrMB)RfsVFOU3йJԫm#'\%?UL.*o?OmdS7 J2S[o?TB)RfsVFOU0_ZS|ki~w֩>|q9kqs/id!U<#䪤>l˿/jvR@jƁ[w %9 F?*âؼ<46~ې07/o'-eiSLI,#dfS"ȷ)Qj6M˨^jO]u2$Cr8/Sž5al"5q {InmdFLJ e3m;T{xC~6d־er }X+^e|ův,W:5K,.$cEd<]7Nգ OqӵRyXkT-5-$#VwG?-^7S+`Y$yWSA"^5gWwnl5mZ̷RqE +è5è*n4ku^I4pdI=,r ϛV=7_Wk.frޕv~Em߮_+0|t.Gxt7N\^:f~kŧW[^^H{*Ua__ڦY^~zv|zĄ12x(;:vlxm'捶@X~dZi#(r,6MNX'cI]wDׯu[+hL4WKy㑛Д4s,jޙo3k>]|ogLY.Y,#HC J9'u?~gc$0-4ܰJUZS|m{zn6ė$۔ph讄20Xn;"OϏ?%a($|+-i?9A@D͛6lٳf͛6ysz]zek$!xKV',y'U|\M}GZ+[_AyT݈՛6lٳf͛6lؕխݴQ,ӣG4.+2=A84?̿D,k^ iAU`5p7J^?o+{OSԯJf?9MR*O7J^?o+{OSԯJf?9MR*O7J^?o+{OSԯJf?9MR*O7J^?o+{OSԯJf?9MR*O WrK{m@撊pdh܅we;{a>>`Ԏ=\^8K\MNՠ 鹳f͔QI @%z7!`AeHfdGe <eUU)b+kր (zeSe@€թ^sփT嵕RifI>g1~u~q^\jRWGl9]\v=*ZT]GN~n??T]CN~n??T]C?(?6cB~n_.iLOl?n_.TZȿ)5%n1~o E'NE.zHxS)?(6+'+G7z%qr7OkIĦP? jT xcN~n??T]CT>+rԧ.TZz1?7jT*sw.֡HqL?7jT*sw.֡HqL?7jT*sw.֡HqL?7?j?Tέο˻}SZ~pMwtPհWYI= eym{g嬂[kh%]$X|ųf͛6lٳf͛6lٳf͛6lٳf͛6lٳfvr*P8u_ɼ ?ߓT[x%%py gcjsf͛6y˶^d֧ޭm+y-aFǛ?!bRO!0Mu?TO.u/1yMށg5ߔ)Oǔq2p?X9u.I(l~Ea$7vwLTWqo!X:FOAk?iRlj8r}jw_[Slln=V[|5vk_Eiuo$`\C) /Ț|iq-d5cY%~{d F^EunH&dBAN# -ir GZ6O-{Dž5PFL}2!%@΃eRyOsz"FD#*8+ywAl1j'B; e~_꺓izol/5ZJEo#|y7̖ZgjF{C9'f ^R_/ti U; 4ռ=JV5{K-2կ&)9KTo!q{} ~mv=(5:z!J'l'8eg:fihYc)h+Fw8B<"^AhޱIcԚWC VwZ5]3BX@r񲿧Ŀ-EXVx%wI4/kvk-]J&C$̡hjxuٳg>3?5ˏYUCHf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͑_o^jMl'}H$X $LQ gB͛6q[+ؿ:5X+*IH E|^okԱMOϩG]g ڼEj4(Y^kǘt_ziiv34VrHWg瑽^ߖCϝ2AMYhheL߽~.l7[]H+oeAHpeo;B^ox( e҆AHzOfMԇAoHzOfMԇAoHzOfMԇAoHzOfMԇAoHzOfMԇAsz νy'K-8 [PQ/ŽXL0^9iZm*[RC|r/%%Y7a97Rq!?_a97Rq!?_a97Rq!?_a97Rq!?_a97Rq!?_:;4;{?Gg&ZMƛc([O.ZF[ H(8bf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lo.@"Fx،y^Mi\ՙ,$I0Q1ϵ+dϞp򏖮5thള游q1v^NT25#[YkV^InhႩ+49?#*0r3h [pcK@ P;_%Zrl60ًy fmd:b oZ|[O ؖBUlp.-m.O4u[+{)bkxFlCTխRII[21V>=pc\ѮI5̈́M]A:Ywp7:TWν9I6#˫_#yv\7鶑@ ee-PA_/M@ayT:hAu 9; Uw:'l)KoCqm}ba3Y̳I(Hȶ/=ٵ>C,/E?XfmJ@ѪEwj.?/2uXK;*C򾣢,[YZk5FTqp>[ė"jz\R%ֳY-#v0Ew#迖{A兌zWu!*/F:I#Oƌ 1A}_@Թ1zav59䏜)tRzz[܈W9mTDWm ?ɞxF>qwg{ FU,T4BHu7wS0kz$HӑP>JӉ#Bsɍ*ǹf͜rW$M(0ep6lٳf͛6lٳg#ϏMS 40/%Y>`ʯm#ZӭKxKt欰++H "OyK;={A4[km0" Vۥk?~znu<ۘo4[ Vu .8RFKxBR̮|k)HH2|' 2yK'r2/46^6FqƼ~E~Yy{KwӶs)VIH+ !jG\)^\T=ΌD-ͬr¡CYۉf-7PG<mcJMA;eR=A[DxdUSǨK?0CX†B:-67,*=h]]rbJt,y|ku.c4[}RP mb5?g_=O{߬6 fKKm5(LH'-X{+5#y']:imefoﮄs+$F>NM/gX4Mjet lW[J|5?}/'5&M:}>pE"\ēFT`Q۸<unTԭJI6f o4'ӭkǷck 4E9(,N'9I6yS>_W:uUGY$?D~Oԥȯ垇MSI啖mF(]CEF^oqfIǺoFY5}^&@ImwctT:C$#rƥKԬƭge|!Ĝdqĭo&κݹ򞍢Guj,"-qP:3v[XH/UM[LtSEoN'PU>-S~ghvν5 amix aT'hߞ1+Iֵnbytr9;RA\Z~gh7cBo+x=KhZ/Z#E_o)i@ ͝ޯ\閺[dXY *E T#ql!nHFW :+嶺P:^qqiy bh "Vy]M.u+(#Ӓ `/wC:l } >+yw6cY$jrO$d#pAg4%Dœ('\6͛6lٳf͛6lZ_S3AK4]``ㆻߓ^ 9,SP zΙ6lٳf͛6lٳf͛6lٳHטܢ&mm^YxA9+GO yiJvA"6 9I?3&<;Qepvjzm֛x[KȞ RE*z9 < x5 NMn=K" c~Sd}gy{Zd}~AipPC q&G%ѧUд%Y5/Ao)TA~fο+p#ѵtcP]5vU5m^ R+wyix/"hF_^u.'ֵ=ONmLS-vT9L+ۦJ<}Kdƫ Vhmx0i ի[tZ5O4]yb@uZ][iwi.-F0A~" ֽ,eeӋjE=(F ʲ046]ߔڝ< 'O(G $fiu I埘<ͮeU[M]c-V!K2$8I!pq+|7yCQi!"U%ryx5u noTHIcy7Hxq2~L_yVm}oEso<-G+>,EoG ,h8UG`)rW$M(0ep6lٳy?vTG5cOK-GwNL/%s4qNN׵~-@.זauVrԚ|ߙoyyγYytGV0Ik(V,RiާoO ШO޸]b;_ykX,iev5zp:^ZrImHxgcB1ᇿqSmE#E AS!zwo.t͵s-pa+,7 w˭yD.>5`כTOy^oQ>w˭yD.>5`כTOy^oQ>w˭y|/]Gʱ;ry+~b򆍮˩trTiP1PKԁ\:`כTOy^oQ>w˭yD.>5`כTOy^oQ>w˭yD.>5`כTOy^2q_ռSͩaFjD[7!Nt1!k^\I=)u rIJI悾˿(=/Dɟ7˾is%#!QĤqNEFt/]ߔ_77/IOWwM_$+/SES~I)sKw~QߥJ\(o%?o]ߔ_77/IOWwM_$+/SES~I)sKw~QߥJ\(o%?r̨4/ˆ+&*6F?`0۰9-&t.OW2-۬PTz`ٳf1k%Ι0d+.qnV,|&ǷV>U\Q$~f~ne~> h 7 /?:eouhSkp}j׍JoD/[E<ߥM<-,(u'M&e$:}hJ́&B}6#umOW/H䳳д6HKDyW h:V[.HG{Yj7VkU|^]?Y)LƈVv M| 3p-#GʖqI$M:\Z9JQO;fsփTΉ6lٳf͛6l.?ːk$RCWmsѰtq&YyzHD84 X+PQw[؜9f͛6lٳf͛#y73G>Yjs -ʧ4 N~Tԥ$?NoS?)i?ӛTOJZO"C49SRH9N~Tԥ$?NoS?)i?ӛTOJZO"C49SRH9N~Tԥ$?NoS?)i?ӛTOJZO"C49SRH9N~Tԥ$?NoS?)i?ӛTOJZO"C49SRH8wyS>^Ht-*LV*‘=*x^k6lٰށjV݅/^Iٽ7#wwe#cw$j ?Uyk~]5Aiڕu$ͧyw@4uCc Hn ywhFn>rZtV(/. =y&a۫r/UAk]DѺ}TR5*l':e廉 te`li/u I8I* ,zI9ewkKZOA7u-I_p>xo;rXSGW*7ycEO4f9]Wo,ȩߣ+?ћww]"3~?TFovh;rXSGW* /?6z@>zeQTWFPp^oH4CXXBR1~vh;rXSGW*7ycEO4f9]Wo,ȩߣ+?ћww]"3~?TFovh;rXSPAm5{W5 otHf4RVh Q3"IG 9yf͛6lٳf͛6lٳf͛6lٳf͛6lٳg;Oh9O."XEFmO܂X!A&$omg3~X-jK6"hj)Ps'R~r]Rg "P;JU4f1 ~n_ٖ9q˒OI$Yf͛6lٳf͛6lٳf͛6lٳf͛6lٳg;Oh9O:edɆȟRt_'yf͛94_~n_!ruxZ15Ɣ+?,|'|]6]7q5 `\DuV]#g7k]ҠQqRngIA.Ý Κ&mRo058줻y i4m"ג+E:Gy=V]5aүebXd? ZH>e)h ZԒEDv S][,BV&2O0F|kؚkj iyv]RGYVD9 #ʿǙVB@%#PGψJwDFw!QA,`ܓr Fx..oGA}M$P_L>4Ϋ6l?&|0G&q?ʲtlٳf͛6lٳf͛6lٳf͛6lٳf͛6lٲ+_ɼ wT "<͛6qo?7s=|Yi󏺷td5kꚋ/ӚVEy҃p/ŬZhf_S4 JQu3?XR4m^iu-=v06kBA2]C;ԣogt/|p7 R7пQ7i;F~`Qodt'e &M]Ҧǥ"ޯn'|~s~Yh)p/嶳-ڄ[m8*cl2&lἴu bWIYX XDg/,$wbb' ' "bB:Gc:>]L/5Hf⵹ҡ[XlVmWFnxͺH e ƿC /ϐ.5)|=ݹm)L[rOro" }&ik|*o鿛z^ڶglX4QW_; 3?oC;ԣoG'|z-uy"K͊xei旨7ӯŠr%PZb Pʢaq!aB~]?MX[ۨ zC*p8>~{Ze+IUO\z5hzt;o0,Mo a3HΨ%&Ey&+ZKLǤOiQt-9PHH݈JT9mkJ<*X:m~Z˗p9z)nΗk }ek-P0MV3)eC⻵8I0b;n7b@:5G=Unve@Uc8b jxHK+'ƿmbT)8SǗLhLBTYR/>_S$Pqt RSѬ-d{#秫?G%79I6\2ErO$ ?M|(l_2o6A:4=_W;Ǥ+-@Y!K;H2x<{6.wWwVٿydC``HY8#|jmR&j,1y%qPԇjW0w4YG<}{%ƛ&a<5RHb i"dkԛB]QզOMnX$x \hFc_ѡz_e}A5a%/uSxkxt/yOp_ZQhRw\^^"[\,F}ezw;Dd5Ig?HkWjZtZr%-DJx_Ι~g=eiڳotU\bz D% J GZ*i;6l_$oDO+ٳf͛6lٳf͛9G2/&Νe:/BZKo*UʞQYZ׶z;k'ǘ`dխ#d4EZk\^S6)#Cj׋Ts98U5rr{=6v}z%@d@ވ\Ui%_~aOl/[Qz7+.甁~-둟2_&o:kLaNsiKC5G2OCMS,lRK!B xi??[8l[γN78"7P߼wۧȼ΋oJ݆.IJYEfD'겂SX[\f4k*[;KW aor.# "K)>Nר=?^:^Zwyi@Kx J ][8m?/$KX#55Y.%qZ"yʾIP^o'K2IUeL빳@gߔQ.4uk;{ ia)<*PlaOZO=ߖZ楨cjzՕqˈb@b^>NGD}\:=f[?AmtaeS w#Uf-Ww|4q^߫mkn@v"8Ŵo'^ywFֵ BG7lv֗FrV+2ʱk)IZ&!UKŝy"j˸>P] MR[WHh+izsýC~SӵHbRKIfD 5<f3#Uƿh.u#k[[˻]~k]=%e!FpdZQHQLaHcRkVWl#ӹI}>[*V፥>G-o)xE)Wee"v vVVv6ABA E _P׾BzBkÝ9qj深i-K.4Tim4Mlkk<nY@&Ygm"IbH33$IŮ4=fOgOIٌt]>eUKl;y(hЊCJbcGE[1{DIFnJ1>'Ge%z}YLk5۲F,nA;Zfme1(R)gi&Sei ac@~xcd/ 跋=#s}S5Μ׵q|?!$?ɟ5sp"XȴH.?^gV_"g9'O&NGD}\wi?-jz Gԭs);kmE]/dFIa&.\ +#WмiZ&+Z\}&)mZDz geSCVac{?+6we隌R'[ Ggw ~YcykCek$Ԋn1uBky>q5;2^]6?>_u[o^xZ[UsdWGM?1p]eY鯨>9dSQO'j|95/˯qH.~'46'OV{F ˉɓҎbrYa+F?Mp7\Z5Ǧ!51iVu[_(yԵ 4\{2~HP ~+yyXyxI}*"3{ޣd7pyC =wRpIj7yd[st%٧~*þB|,VR=-k ,A`9[~h7fdatl!qhf{g#|jVP}^ ~Lތi)*YsrW$M(0ep6lٳf͛6lٳg;Oh9O^gwksE<.*8AV~x~^鿗Zƛ{9ݧF*z`yPW xZ7~-?ʿun?_7OsyWr\9iUsqo*9Z7~-?ʿu_KߘYīn!FU|S؟, =J;unUJh|pǏyWr\9iUsqo*9Z7~-?ʿun?_7OsyWr\V[uka:e tGY \mPd*wk;;k+H,cXmmX#@T-/}R?)<˧izג[ #ua +}rKʗԦԤUlm՚Idv 8*w4!ZW懞t6y{B·ew}ēn~*0_:sփTΉ6lٳf͛6l瞵 /Ytv[̲IBo>j>i5 [[߼%WÛ6lٳf͛6lوPA6zo2K*:tiO9 OP6ĿA.?oݛTyFٿA.?oݛTyFٿA.?oݛTyFٿA.?oݛTyFٿA.?oݛTyFٿA.?oݛTyFٿA.?oݛTyFٿA.?oݛTyFg?-ygRyR7 R;EQJ9JL9f͛<Λ$).q%fX9+1%#Q~_7XRh3t .( mgX&n*9[FWN{cx5K= MКB V"xܬy"U2)*Og,kEq']+Y'Zi7^5"+Wr+8岴4="A<*.;;}4yԼKa\JM%eTQA<{1\]Z@sV&3jw^XV?0-W]E'_o)Iacꞙ(#vr*P93yr')^V֕%ble^_~QC7ԙf<p7 ޏRg?7LG3z?IhߛoG3&y~o4?oC7ԙf<p!/toc6KOs,C1m8g /˖>KGa ?y%?9'f<p7 ޏRg?7LG3z?IhߛoG3&y~o4?oC7ԙf<p7 ޏRg?7᷑"/<٬=΍1aF ymf^UkC6lٳf͛6lٳf͛6lٳf͛6luzuco>c_I4ٽ7#hEuea'w5Y$f'r7<=e%Yi:ߛ8-PĨە+ۮjߛuP݌k ![VKarz3P]էt*yImdne1, kyAP:vl濙^U4L羹X[+h.Xb |;ojVj7ZȖޚ|eMz Ηy6#H`4n @ ;{)NRI p6lٳf͛6lٳf͛6lٳf͛6lٳf͛6li/u,l0[{_΋6lٳ~w=ϗ0 >]OWo= <HY8M?iz}:ik\p.#}HrJoOOK_"ޢ>mHO/lT3Gy,e xz9;S G̐Y̗c.Wb'zg`wv <թhGO joZ9 {m򧒵Q{7j/YߋMX}Ar^Uiwu=>;X$u&FHQ`{;*NR3?5ˏYUCHf͛6lٳf͛6lٳf͛6lٳf͛6lٳfOB~]G]pG:ܙRNS~a~cy>a,MInɣ4, ^,=/gErw6u'H{V (ss"4P]hZ;VO}NC)PGBl؍L3[:HnC48l%(I\$h ;@I鍶Ueѐ¡p򞣨ɦXk67z%pE$PѪŅ]6[ʗ:͔ڴEM=."kd@G}6lϿ L`Mp%eP,ٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳdW[%y& "OyḰ?Pk[h-\N,d#c3~YNmX,kX&HJZSL(|7{b>Ec+ 1) '01FXEdpΐ<6p&(X4Ew¯/~i[Ky< h|'TZzc/Q>"/%M)N_}OELi/:mGWӴs/՘B =%Evw*90 syS(m4(kMM,〘/۲!q[r{l?!ֵI&h~a SiR0xܜ~O5-UymuH{gh#o{6lϿ L`Mp%eP,ٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳaOtF|'ڕ-+@i\__|{$o #% />^TW:ʯtKj++J*mҿ."#^e_yoKsQ}0(FzZl6D6hpd]%@qªiI+h5_:u=Z)Dv҂$X=5 ܾE%_\~i\_]&U:x=z7&&kiQXj 6^%*JKU˪a_OM.?1 Fbҿ 6>|ˆozͶo%2qdn_g+ugyi~Kƶ#֤.58e2xPjqE\2"5/3b]ZShpD[VUܟyW?Z{=[LX~WFpT@Li'MqKM3% V c(V>rcL*mҿ.'RzWB*E4#qPHwfw,i7:e3I4%؝ǾJH~Pԣ:L?(Q?oR?(7tGOTJ:_#*C/f!CRH3ʐGKtH~Pԣ:L?(Q?ysIϠhvzdӀm 0{lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6ys P>q}O[MKVj#(H~o˹(Huyb x?:v͛6lٳf͛6l؝HA 4Ɗ96)yZ'zS$ vhƘkZs3z_*Lޗʿ7?79i Zs3z_*Lޗʿ7?79i Zs3z_*Lޗʿ7?79i Zs3z_*Lޗʿ7?79i ]󿗼aͽ 4Y=-;] ٻW8^*n;lٳf͛6lٳf͛kj]>K!v<'{Oou?,,izY)! ^L~%g yGٿ_C̿;nBoevo3/п.wݛt<#/fˡ_7f7]27 yGٿ_C̿;n/uB{̟0ܡYCe&Z?1ƟdT@M@|Y/fˡ_7f7]27 yGٿ_C̿;nBoevo3/п.wݛt<#/fˡ_7f7]2"mѿ7(󅇚y"][JԹ<!Kn~ҝ랂u[}_Gm-o*dg7[A#D4,IG]2$?_yMӅV0?jʂGf,I>l$8I$h ;BRI=zfAj6*zh^i$8i$`, I$4R,i,NE"GR PAF;6lٳf͛9?c{3Oq9N%$|U·7wŝm3L*I$lٳf͛6lٳf͑_o^jMl.=/gEpX1^u"߻cKɐN* 7UC;]2\ˣ}OP*N1J*\ٱ M>{V KXkh93`u;]Ѭ2C.k)R}j\,MwTY$@YD٤).DNu7b]]%XI;D#__663-ŝk5jJr 9g͟k/|l/Lg3'DǓ_'#>L͜r -nD맽j \)"bRFդ 踬# 0OG =WRחLy/T5h*XG$r1R;FKI>k/C6(u&i3!YfoI@"=15SPV;xbS1Hg+3U_cڜX|娡׼{KZݩ_O| ̿5Euiu`ymJO=܋?y0B6|i~j -_W?GgsI;yQ%mzd;k(<}uNR+UAu 0`TN;Ah#u$Tm͛9I/3(?&,CQ=`-lٳf͛6lٳfc2~f|y4)0zh|"wп S^a\>I\յ1sEq%kCL~D8WJޚ*\ŭiG&-jܥln:NȖ[~`y]!}#X pʩJV:"7A6+޾Zk'N^!:IL4-NIe1^KF%BxHmzq@|kus5u_JyDXeF]jQރ&;KZjQK4IDj4k)ysAƓb:s 4JVh:ɤZkys5e%ʋZ%L_IKY'$9s,yOr#;bv6aP?^sU-7|\kW:M.{kky.bC"Fő]F!9)Bylk,eKu!uI)r6^A*4ifOUs }/iallC"a_M\,ÏП1sy ҿ %>]hk] v_Y8fE|?k&W׼ˡy~ f;.g eZJiʝǢZVz&ZZQpohw:=JWܸEN8F/nEXj1]\ۛ9#3[̉&kw䘒_XhEb(?ZYIBx.$ s:^m5ŬVSMRĊǗ-u]/Ma 2Im$y)o _ jKwKjv` H7oncZy;Q4SFO6-2TZKNQ1U#6I} H㵐DZ$5C~0/4JUNaa,1]Veiy4SSnE|͛6s/_^gPLY7z'Zɕlٳf͛6lٳf͜?U?p[%y& "OyKM S$2xR!U@WKtVZLF>\ʼ\~%7^zK)dM>#f"FmO\2O&F"G/*٘=M7q]>UhtVW,|40$ Xn-VMOMIc$nYB ::ukSڬY]yF TiqF;]{H5kqu^'s-kJt:L6v6HTAE5; go/`HM#r*D(x v)=cCI,dWRR}`-~V~^fy4= kZ?uoȏ+knͬw,:~ (AF?S/u _ԥc%fY9lQzakB]eAj,~F71ZS0Oʟ˹|ЭCcs U&bItjRjzU~^G+dѾ)˛08gs,_OM`6o3j䖋8ټ-SMm3 #Lm,W`7X`HԴNfZWӧ$ONB4mi#|j g0b Jj h#a H*@ L`Mp%eP,$akDtOgɕ*5yVcn焽$q" Z4mOI5Xmy\WW +k6Ԕ\UgXy8^lo/\2:ƣkrıCw,>Ĕ6Zt ?OhKI(EyM>>3jd^ciQo-TO,FJ9G6rtu,ajZQѡL76RnN6}^z6JFא>{5 Csߨc#} j{Vw>ڠtO,%Յp^F= 7 XPT"KQlt=5uW KD/@qdb-u]f7NϯK4^31JE/)YJ_LW79(o3ȭR>Y;#pl+d)~#Pw+rW$M(0ep6lٳf͛6lٳg;Oh9OyE4GFfK}F[Y]>Y#W80;Imn ܅ο!?&| M4dໞL9bNUOߗ; C/ $nƴeeV4Glj6|rʩ 鶗V76N!7.q-EӴ}H pZeR% 'rh: Rh*E o o;ݎ(@$t40iXT (༆+i@8)4Q3dR NoJ>~tAZ|}癢fEbd ,vrOMkNl$ެ@7y%$@kʱKxC[$Œ( Ѓf͛6lٳf͛9A@D͛6lٳf͛6pRc}I3MnB "p^s?Ze[xWkLMʧr.ɾcMֵMUgK ~EnM+z^Vo٦SS&_1qn$2M%x #UA$^hG{{x\$0EU2  ^nѼXEgfRHvH ՝OJ4>c\uwz-&b*I%c'= ?U?pW%y& "OyKך|]^dTW! XhX%|͠r-K\ÈUA|ggx0vickU % 1IфrmCk>gE QQS?˿mZeޡZk;HV&ⲕBxoO,~eAM(5َᯯ?[aV?TK~ʧ]#;t#N#_՗@.a񌊞|5 k{I.VI)+Wssuyzg/gMcXIeHd%Zq]Z[&+pE F$Zh֌-kF" hX)j6]6HylF!qr/,?H\]3?5ˏYUCHf͛6lٳf͛6lٳf͛6lٳg#֩?]6wq[h sچdᬦ3۵W?1;kӴҫB"\["Ѹ+˗ |ao*ڬisi=c"2j#^em-N[ KDN}JK:JK*I8?_֓]CҬl`Hk4h3R=Ň䧛,RHϞZyg I&s5W%vΣ$yk:T:o9[$UYUJ4f2i:_o,f:e^_q%]]^UTUtǜKߛ?=jnD,ZqO7^b,M qtOJ"OyK?ڶSdVgM)Ns '?3&ⴋH:&2w fs*gQttml|dZexP85E+BN5 m[Tɡ`mImPHb{S&ZM6okZk7m;q;TҥT mGZwj(jƝND06jtAkH( {@Ҥ$^=Es,*ƫ, 3SOSLjZe112R,,er[i۩泴bPS| ml`DE@(exDj ސgi:Ghlꪠ0o[n1a!Q_2[#ȑ"I'uPduK 3' QdJaPj T2pD<\cCO?i2ȱ"]P+Ԝ\2E6lٳf͛6lٳf͛6lٳf͛6lٳf͛6sփT΁smouo-k-# 2{7NFyomH`m,bHm[>4Qռp#r{>]u_2h[vEVU q8gr/,K7H,ߠ?)g"T~'Rr/,K7H,ߠ?)g"T~'Rr/,K7H,,&6imIj4^F.6rT;;r5XQETc'x$wF4UU$3MZ~Rh.c/'5V^4z ֔fL:A3yx,3{dY@SEf9OS?O?L^Y?o3{dY@SEf9OS?O?L^Y?o3{dY@SEf9OS?O?L^Y?o3{dY@SEf9OS?O?L^Y?o3{dY@SEf9OS?O?L^Y?#wWEm$y*-)s >w?:oǢyu_ѷ^RՔ3Jϛ6lٳf͜?U?sf͛6lٳf͛<9MwJm5El P'JYZcr,9#*O.۝{gyu֍e#ۗR #o̎8\q ҧ]]gH!ԛ'vƋk$ܢ^KǘuWYwg=sZZYk, .y(ĸIw7I.k#A9c[E @~w,i[cE\ax'Tr d%(J2=]} NѮNMR3-Ky<78A~`fHam΂.=N,Dx`]30Z5$o1 C Jv#Tʧl6;KXs{sYj%uYOInhH{4}^-}?\MX#x hiVg~Tm,|M}۶ҠM][mg!GRh6?mwˢɡG~Ey qu!5 VMBy^\IoXmIG J8lG_0t=:[AR1+u?pc u&tK+Fknl \•8EmF?9mc ~[[*ūZƛv;vivٳf͛6li/u8?&|iI<#Q]4w'KHTM@؟ 6a^goC ?#fomo-3klHٛF0[/37fy7 6a^goo#yz_O2s't4?怚nUῒ6]3˺叙Ŷ껻wrX 6a^goC ?#fomo-3klHٛF0[/37fy7 6a^go<91k20/eKcGG(H+QBE7Û9I?3&<;Qer+sgZ#iZdkB[e0M=in0q&n,et.H|:l.An_x!"/;kk[MۏR+C$]<k˟7kV^c>jXcb( nzڒ 3HMp6)r4 u ?$oHd-ۦyGD>] QkE}p7%Ri_2D9qhzm9-qxZw]]U8i*NYt]v[>#vCGX8l`#"~Y_-k8\jz~ uK.jd#uZMR^NԴCuX ܦmIs4ܢ)yW 9BL:E<-Gt%H ;X[Eg-圖sIp&Q?PһgY͛6qڇ᝗6lٳf͛8瞼gh5^m*++gQ:^Y[J&֧0]6(Q/PsU U&,=/gEp_.jR9nyC+.5"x \~ }ʌ53|ws_yN&<䘡Y4 β=I$ ud֪w/PYI**qkg˂k'GD{g*z$'_͑@#׎erL~_-뚾~4Ѯ+F39&l ߞ~V[4]?בK!-xv~~/!ۅ ;3 *0r/ɷ7Zo7:<O~wJڀO/0?9u|:N[*7^O _FcC^cO]OR[hڴ^W򭍉J ..ݲM^īVmG>lյ_z[Ԣ]G p[ZI=@gO_o->^\G{HUuFGH_K ߝߟ>e״MZΧykmpΎ~'T|*zNGD}\7͛#_?кɕ On&һԪnG6GK8 :Vo[7~l挰(XZT5OF:nZz^щFS4I6F^mTj.~Y^]M*{E,{{vg;ܷo?->sFXפ_Qx}f&5})i]Z֪CwM^,8DsX R_ɍY5MSQf72C')X@yI >9$o=g_YoomtQ-U Txjk{.k7OR{ӭ/eM(rGmQGbpM-얷w`.5k ӵF!-X&HbOC˾-~Ry_KN9.eٮ%Ғ .{P iokV5'4%LD* dA]&;8ڂAJ FbYg-]sf͛6lٳd[W%y& "OyK4yN^ZͳG"Մ|D^TMz鿗swI++yq}n$j8[VA~]y.Fy -{JՒMbYRƍN$ڽ0MO;y'S$]F];~s]cB*X +JFg1iGMZH#֊eGW'FW<ޏ8ח޴s{F[(i3h 6~H\K] _K; GuM2(Y'$T? ʕ 6]x1*3y;Qep6l/;j:b-/ExvHߙ4S邵2iii[kz g;GSG2߱Huw4 ;`[Z^LD-[-zXL#/CL(7|ףiiK=6D3WL..[PH=%)^L~ZsImy$a-fDqtq_yE-Ԓ\p*|ִ ̛S-eiXO鼭 YJ IT;eiƮ]ֺ3E4m*U/:M֤b N:; ϭ]G# \T܍?~扒Kլ{Im%RnG B̾(9pخnmͷ:tڵ\ƚ{D[ JpR+?4s˝FAm5K:jjHr~(r;~lcVK${m.kn!f WsMc\|:V)R=KFY3Y*р`A[ܗf#7%/|FnK3r_ܗf#7%/|FnK3r_ܗf#7%/|Frɏ4WNNQKK %e3HH> Ux2w;K?#z6Mx\QVRvpx]/|FnK3r_Zw4 ;\;qqɏ R$A=R~_GQOcp˪[J\VA?o._绒]8^ē}bqo^)IXq-GwQ/99EH ݞ4Q4P"r|c:aSe &WKL-?^D7Is)RQ2SLcz<Tj^_}/~Iy_PkOK6\to)G^jW˭ۑ*ZC<;|6lٳf͛6l8akkRZ׷#'t$bI.Ȣ:o 7 7 7 7 7 7 7 7 7  Lo宫TBfy$mU/|AouS{[ܔu_RH7§$*ߖӬ{L*ߖӬ{L*ߖӬ{L*ߖӬ{L*ߖӬ{L*ߖӬ{L*ߖӬ{L*ߖӬ{L*ߖӬ{L*ߖӬ{L1w~Σ{mCmFvHX296uٳy#zڥjkyd (9jxҾVcfVcfVcfVcfVcfVcfVcfVcfVcfVcfVcfVcfVcfVcfVcfVcfVcfVcfVcfVcfVcfV;b&@?.i=ԸHPd6lٳf͛6lٳf͛6lٳg18C}WNn?w,,a A5)QVO+iq@XqqoyphteoUFUn3͛6lٳf͛6lr4vo.SG~l.ЌFUY*Ae{ʥ_#yq~p奿o\_io6?WZ[Mcyq~p奿o\_io6?WZ[Mcyq~p奿o\_io6?WZ[Mcyq~p奿o\_io6?WZ[Mcyq~p奿o\_io6?WZ[Mcx_խ~Sj(G4L$Ǟ= _2ڨk}9zgF͛6lٳf͈^YO{w"kmMK U?0wy+O򾭭?L7+kʞz(ݣ$Y֠w_(޳XCZ4\35~J^?3<.i&IEEV$$K#(ȋ j ,9_˩OXϨ%K*—- q=OrLdIck6s-ͼD1$k#|W~Ҹb?5/̀M=9ct=b/*͏aӦmf7MZ).4F9ib+*[O]7o-.MZT?Q*()DE)CTZ̈́B3vLr!!i!_MWm4};JңKo2zەSq?JBTTƣ:懜o2X.tMy=/ܳv Wia(&9L!wj+5l1yki,n+EW!ljt򆕨&v671\\EHG`w=0ND[gQӭ]$R(X [ϟ_Ɲ85+BֆqLvJƽ`^iE3s1א_zdcϿh_дy\2-HmieRo/5SFgX5KTO1_ dW[%y& Ưb8QJ݉ld32EA*YaQTc>gxBsZzbؚ\8rۄ0<[M:SG &6*JEFmԏ1TrJhaNsHNNB'#)Eu$l{?~5{bٳf͛6lh3Ju-H?.?^gV_"g9'O&NGD}\7[kdyZVZkkze-Zx.#uni^R}NӭKiG JHBZKgo҆Y5ΈgqN$?JZO=ǜ:68^М+I9Q_nXLR8z>JA0''<7" .%w>O/,k SÊ5cpoˍT-bVdեԾ]F~%GN<^0x^.ߔRNp8Q9ƽuAkgw6NmzT^|\֕j0(W}o0QLAyvN]yaqsCeII_r!䁠 bGMǾ~\=P-$7(&7.}cDv; BB˓ MRȑyupࠪ;5/0z$hf/~p&EpeWjg|ãVMdhjvxE$oXrO6h_ڮ,^͇s(8ӑۜn~g 'u)?8K̶ pl-[«Zoճy%W #\:O߯,_'嵲~ 7ļkFԮY'l.KW'Q YgJE1Km3˾p40CPD׬ྐ%ޜiy^4:s!Pw^YԵ̿͋1nXű_On7r$,T2Ο2ZyZm&ۺH=^*YH_^WI@ūk9Hn!8~Ahqy:#Կ0|e5̰q1'MVr7_=[44[{KE es||6ɏ|[vy隖,E"uhIY:Nl?&|0G&7祷K{!we Z~=X '*zacpLrR,ѣ3GԾވ!QV>'?k&W f_<߬~$p-yײ૙D2ER7Eu͏5n4{[[_ZO/y6V_\)s$\U#e~l}csUW^ W֮oK}9:4FC ME•o0˩]隦$SkSNZ"nAŸ3~d?44/jZhsw-䬂xdUUX-=)^V췻PO^H{mY=J;%0n #HM_Mh9B:=6w+M;:i^rt:tiU{f^|Mrpߚ[M~X/aVm$ +!<F5Ϋy/2nFK>ݖqދtSzS$W5MwutQSԎmumV+˻x/I}bKs1ǨH9v_ːi隽W"f q-+9U nqGeɨ3iK(gIPO ʄco*j Wqqg\ZW֊99qjU@44lٳ[?.O Wy_˺5敧euH&%4 ўOqg4-.Pbdj3ƴyP@g=ȩs^Jk^(M <;(lu&Q`Ckys:כxw p@@cT{n?&<{ C6:]ܐ>B9HB #jW:GmWWƛ'LnYnl13~Og-]sf͛6lٳaGI5*,rdԬIXT+M@{W8G7v/'2E΋h[BA8PdzAyvGOHHLIZ4'KKJ]R L?J3yQWjw8my]5_6]փk(X}kO7f O'i:\5R- oZVՊf`lԕ j:WYl.uFOOz1Fi$baZVUV5ڸ$!yK >m}rY)AW]~جFy5u-F G$+c"0Uq _v/ϨXivZ+&xcH [CXu"Qề̈WPU:I8Suo<]gw-S:A$RJuj$.VwІ1v&(B|5͛6p^+~C0y,92_93f͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛1 zwx͟45P_?MrG}O_rY/_-Y/_-Y/_-Y/_-Y/_-Y/_-Y/_-Y/_-Y/_-Y/_-Y/_-Y/_-Y/_-Y/_-Y/_-Y/_-Y/_-Y/_-Y/_-Y/_-Y/_-Y/_-Ï_w[OVӕOOVzW endstream endobj 8 0 obj <> endobj 9 0 obj <>/ProcSet[/PDF/Text]/ExtGState<>>> endobj 10 0 obj <>stream /GS1 gs BT /F5 1 Tf 8.9663 0 0 8.9663 59.7543 725.7825 Tm 0 0 0 1 k 0 Tc 0 Tw [(selected,)-326.4(needles)-320.8(were)-318.3(inserted)-315.7(1020)-168.3(mm)-317.6(deep)-320.3(into)-320(the)-319.9(skin)]TJ 0 -1.2203 TD [(and)-568.6(were)-564.9(gently)-566.2(manipulated)-563.2(manually)-562.9(to)-566(obtain)]TJ /F7 1 Tf 23.9069 0 TD [(De)-564.8(Qi)]TJ /F5 1 Tf -23.9069 -1.2266 TD [(\(needle)-452.7(sensation)-451.9(referring)-450(to)-445.8(pain,)-447(numbness,)-451.8(and)-442.2(disten-)]TJ 0 -1.2203 TD [(sion)-441(felt)-434.3(around)-434.4(the)-440(point)-435.2(after)-437.3(the)-433.7(needle)-439.6(is)-434.8(inserted)-435.8(to)-439.5(a)]TJ T* [(certain)-398.8(depth)-393.8(as)-386.5(well)-394.3(as)-392.8(the)-389.5(operators)-397.1(sensation)-395(of)-395.3(tension)]TJ 0 -1.2266 TD [(around)-339.5(the)-332.5(needle\).)]TJ 6.7246 0 0 5.9768 137.4803 674.9856 Tm (30)Tj 8.9663 0 0 8.9663 147.2315 670.9604 Tm [(After)-331.7(10)-334.1(minutes,)-339.2(the)-338.9(needle)-332.1(positions)]TJ -9.7563 -1.2203 TD [(were)-432.1(controlled)-424(by)-426.1(gentle)-428.9(rotation)-430.9(without)-424.6(evoking)-430.2(needle)]TJ T* [(sensation.)-524.3(No)-521.2(electrical)-528.1(stimulation)-523.3(or)-521.9(other)-519.4(interventions)]TJ 0 -1.2266 TD [(were)-337.2(used.)]TJ /F10 1 Tf 0 -2.4406 TD [(Study)-338.6(outcomes)]TJ /F5 1 Tf 1.1128 -1.8336 TD [(The)-373(outcome)-377.2(measure)-379.6(was)-375.5(severity)-371.4(of)-376.3(hot)-379.7(ashes,)-371.8(which)]TJ -1.1128 -1.2203 TD [(was)-274.3(assessed)-279.4(via)-275.7(a)-271.4(VAS)-280.9(and)-271.5(total)-278.6(hot)-278.5(ash)-272.8(score.)-278.8(Hot)-275.1(ashes)]TJ 0 -1.2266 TD [(were)-242.4(evaluated)-248.2(at)-240.3(baseline,)-239.7(once)-245.6(a)-239.8(week)-239.8(during)-244(treatment,)-245.6(on)]TJ 0 -1.2203 TD [(the)-515.9(nal)-508.9(treatment)-520.8(day,)-509.4(and)-511.7(4)-511.7(weeks)-513(after)-513.2(the)-509.6(nal)-515.3(acu-)]TJ T* [(puncture)-355.6(session.)-351.6(A)-349.2(self-report)-359.3(diary)-346.3(was)-350.2(used)-353.3(for)-351.7(data)-350.3(col-)]TJ 0 -1.2266 TD [(lection;)-540.6(this)-533.5(is)-529.6(a)-530.6(valid)-535.1(and)-530.7(reliable)-533.5(method)-538.2(for)-528.7(collecting)]TJ 0 -1.2203 TD [(subjective)-679.8(data)-679(such)-675.6(as)-671.1(patient-reported)-688.1(symptoms)-677(and)]TJ T* (perceptions.)Tj 6.7246 0 0 5.9768 107.6031 527.0172 Tm (31)Tj 8.9663 0 0 8.9663 117.6944 523.0487 Tm [(Participants)-387.5(were)-381.5(asked)-374.9(to)-382.6(document)-380.8(the)-383.1(av-)]TJ -6.462 -1.2266 TD [(erage)-295.3(severity)-295.5(of)-294.1(hot)-291.2(ashes)-293(during)-294.6(the)-294.6(previous)-289.9(week)-296.7(using)]TJ 0 -1.2203 TD [(a)-328.3(VAS.)-328.1(The)-328.8(VAS)-331.5(assessment)-328.5(was)-331.2(then)-329.6(converted)-332.6(into)-326.3(scores)]TJ T* [(ranging)-499.9(from)-494.7(0)-499(t)0(o)-496.4(100)-498(\(0,)-496.1(no)-493(hot)-499.8(ashes;)-498.2(100,)-494.6(severe)-502(hot)]TJ T* [(ashes\).)-239.4(Participants)-235.7(were)-236.1(also)-234.8(asked)-235.8(to)-237.2(record)-234(the)-231.4(severity)-238.6(of)]TJ 0 -1.2266 TD [(hot)-278.5(ashes)-280.3(on)-278(a)-271.4(scale)-281.7(ranging)-278.6(from)-273.4(0)-277.7(t)0(o)-275.1(4)-277.7(\(0,)-274.8(none;)-277.9(1,)-274.3(mild;)-276.1(2,)]TJ 0 -1.2203 TD [(moderate;)-335.5(3,)-331.2(severe;)-334.2(4,)-331.2(very)-328.2(severe\))-338(as)-329.6(well)-331.1(the)-332.5(frequency)-336.3(of)]TJ T* [(hot)-335.4(ashes)-337.2(per)-337.1(day.)-332.3(The)-335.1(total)-329.2(hot)-335.4(ash)-336(score)-339.1(was)-331.2(calculated)]TJ 0 -1.2266 TD [(by)-388.2(multiplying)-387.5(the)-383.1(frequency)-386.9(by)-381.9(the)-389.5(severity)-384(of)-388.9(hot)-386(ashes)]TJ 0 -1.2203 TD [(recorded)-338(in)-335.7(the)-332.5(daily)-336.5(diary.)]TJ /F10 1 Tf 0 -2.447 TD [(Statistical)-336.1(analysis)]TJ /F5 1 Tf 1.1128 -1.8336 TD [(Statistical)-338.9(analyses)-335.4(were)-337.2(performed)-341.5(using)-336.5(the)-338.9(SPSS)-331.9(statis-)]TJ -1.1128 -1.2203 TD [(tical)-265.6(package,)-257.9(version)-265.3(14.0)-260.7(\(SPSS)-262.8(Inc.,)-263.5(Chicago,)-256.3(IL\).)-261.4(A)]TJ /F7 1 Tf 23.439 0 TD (p)Tj /F5 1 Tf .4995 0 TD (-value)Tj -23.9385 -1.2203 TD (of)Tj /F6 1 Tf 1.6187 0 TD (<)Tj /F5 1 Tf .7145 0 TD [(0.05)-753.9(was)-748.6(considered)-756.6(statistically)-754.4(signicant.)-758.2(Using)]TJ -2.3332 -1.2203 TD [(quantitative)-365.1(data)-356.6(recorded)-363.3(over)-358.2(14)-359.4(visiting)-362.4(days)-356(in)-361(the)-364.2(case)]TJ 0 -1.2266 TD [(report)-303.1(form,)-301.6(the)-300.9(mean)-303.9(VAS)-299.9(value)-302.2(and)-303.1(number)-298.2(of)-300.4(hot)-303.8(ashes)]TJ 0 -1.2203 TD [(per)-349.7(day)-348.4(were)-349.9(calculated)-344.5(for)-351.7(each)-349.8(participant,)-351.1(and)-347.3(these)-346.4(val-)]TJ T* [(ues)-451.5(were)-451(summed)-449.6(for)-452.9(all)-449.2(participants.)-453.6(For)-450.5(individual)-448.8(par-)]TJ 0 -1.2266 TD [(ticipants,)-458.4(changes)-453.8(in)-449.5(mean)-449.3(VAS)-451.6(and)-448.5(total)-455.7(hot)-449.2(ash)-449.8(scores)]TJ 0 -1.2203 TD [(from)-330.3(baseline)-338(to)-325.7(4)-334.6(weeks)-329.6(after)-329.8(the)-332.5(nal)-331.9(acupuncture)-330.4(session)]TJ T* [(were)-248.7(tested)-245.3(using)-241.6(paired)]TJ /F7 1 Tf 10.9829 0 TD (t)Tj /F5 1 Tf .3225 0 TD [(-tests.)-247.1(To)-239.7(investigate)-251.1(changes)-245.1(in)-240.9(the)]TJ -11.3054 -1.2266 TD [(severity)-352.4(of)-344.7(hot)-348.1(ashes,)-352.8(a)-340.9(repeated-measures)-354.5(analysis)-345.3(of)-351(var-)]TJ 0 -1.2203 TD [(iance)-258.5(\(ANOVA\))-256.2(using)-254.3(the)-250.3(VAS)-255.6(and)-252.5(total)-253.4(hot)-253.2(ash)-253.8(scores)-251.9(was)]TJ T* (performed.)Tj /F3 1 Tf 0 -3.054 TD (Results)Tj /F10 1 Tf 0 -1.8336 TD [(Participant)-340.7(ow)]TJ /F5 1 Tf 1.1128 -1.8336 TD [(Thirty)-470.8(\(30\))-467.9(women)-473.1(were)-470(screened)-475.3(for)-465.5(eligibility,)-474(and)-467.5(of)]TJ -1.1128 -1.2266 TD [(these,)-475.8(10)-466.9(were)-470(included)-472.2(in)-468.5(the)-471.6(trial.)-465.9(All)-470(participants)-476(com-)]TJ 0 -1.2203 TD [(pleted)-444.4(the)-446.4(full)-438.8(course)-447.9(of)-439.5(12)-441.6(acupuncture)-444.2(treatments.)-449.2(Com-)]TJ T* [(pliance)-674.4(with)-672.9(follow-up)-675.5(was)-672.7(good,)-667.1(with)-672.9(all)-670.5(participants)]TJ 0 -1.2266 TD [(providing)-510.3(data)-508.3(for)-503.5(the)-509.6(primary)-507.3(endpoint.)-507.6(The)-505.8(participant)]TJ 0 -1.2203 TD [(ow)-336.2(through)-339(the)-332.5(trial)-336.5(is)-333.6(shown)-335(in)-335.7(Figure)-330.5(1.)]TJ /F10 1 Tf 0 -2.4406 TD [(Baseline)-337.8(characteristics)]TJ /F5 1 Tf 1.1128 -1.8336 TD [(The)-354(baseline)-356.9(characteristics)-360(of)-357.3(the)-357.8(participants)-355.9(are)-354.2(shown)]TJ -1.1128 -1.2266 TD [(in)-247.2(Table)-238(3.)-242.7(The)-246.6(mean)-240.6(age)-244.1(at)-240.2(baseline)-249.4(was)-242.7(46.6)-241.7(years)-239.8(\(standard)]TJ 0 -1.2203 TD [(deviation)-402.5([SD])]TJ /F6 1 Tf 6.6391 0 TD (=)Tj /F5 1 Tf .7208 0 TD [(4.93;)-396.4(range,)-402.9(3853\).)-399.3(Nine)-398.8(\(9\))-398.8(of)-401.6(the)-402.1(10)-397.4(par-)]TJ -7.3599 -1.2203 TD [(ticipants)-493.4(were)-489(receiving)-489.6(tamoxifen,)-493.2(and)-486.4(1)-486.4(participant)-493.7(was)]TJ 0 -1.2267 TD [(receiving)-375.8(anastrozole.)-376.7(The)-373(mean)-373.4(time)-374.5(since)-374.1(initiation)-378.2(of)-370(an-)]TJ 28.0042 41.5668 TD [(tiestrogen)-269.8(therapy)-262.7(was)-261.7(19.1)-267(months)-261.8(\(SD)]TJ /F6 1 Tf 17.622 0 TD (=)Tj /F5 1 Tf .7208 0 TD [(17.25;)-256.8(range,)-263.8(253\).)]TJ -18.3428 -1.2266 TD [(No)-394.8(participant)-392.5(reported)-400.8(the)-395.8(use)-394.6(of)-388.9(dietary)-397.2(supplements)-397.1(re-)]TJ 0 -1.2203 TD [(lieving)-373.1(hot)-379.7(ashes)-375.2(at)-373(baseline)-375.9(or)-370.2(during)-376.8(the)-376.8(entire)-374.6(observa-)]TJ T* [(tion)-332.6(period.)]TJ /F10 1 Tf 0 -2.447 TD [(Effects)-334.4(of)-330.4(acupuncture)-332.8(on)-337.6(severity)-332.5(of)-330.4(hot)-334.8(ashes)]TJ 0 -1.2203 TD [(assessed)-331.9(using)-332.2(a)-333.2(VAS)]TJ /F5 1 Tf 1.1128 -1.8336 TD [(Changes)-246(in)-247.2(mean)-247(VAS)-249.3(score)-250.6(from)-248.1(baseline)-249.4(to)-249.8(4)-246.1(weeks)-247.4(after)]TJ -1.1128 -1.2203 TD [(the)-408.4(nal)-401.5(acupuncture)-412.6(session)-405.6(are)-404.8(presented)-414.6(in)-405.3(Table)-402.4(4)-404.2(and)]TJ 0 -1.2266 TD [(Figure)-368.4(2.)-369.2(Repeated-measures)-370.7(ANOVA)-369(showed)-372.4(a)-366.2(signicant)]TJ 0 -1.2203 TD [(reduction)-349.5(in)-348.4(the)-351.5(average)-352.4(VAS)-350.5(score)-351.7(for)-351.7(hot)-348.1(ash)-348.7(severity)-352.4(at)]TJ T* [(the)-332.5(end)-335.1(of)-332(treatment)-343.8(\()]TJ /F7 1 Tf 9.7689 0 TD (F)Tj /F6 1 Tf .7145 0 TD (=)Tj /F5 1 Tf .7208 0 TD (30.261,)Tj /F7 1 Tf 3.3322 0 TD (p)Tj /F6 1 Tf .6639 0 TD (<)Tj /F5 1 Tf .7208 0 TD (0.001\).)Tj /F10 1 Tf -15.9211 -2.447 TD [(Effects)-277.5(of)-279.8(acupuncture)-282.2(on)-274.4(24-hour)-279.2(hot)-277.9(ash)-279.7(frequency,)]TJ 0 -1.2203 TD [(severity,)-336(and)-329.4(total)-335.3(score)]TJ /F5 1 Tf 1.1128 -1.8336 TD [(At)-488.7(baseline,)-486.3(the)-490.6(mean)]TJ /F6 1 Tf 10.2937 0 TD ()Tj /F5 1 Tf .7145 0 TD [(SD)-493.1(24-hour)-488.3(hot)-493.5(ash)-487.8(frequency)]TJ -12.121 -1.2266 TD [(was)-293.3(9.30)]TJ /F6 1 Tf 3.9645 0 TD ()Tj /F5 1 Tf .7145 0 TD [(9.72,)-295.2(and)-303.1(the)-294.6(mean)-297.5(24-hour)-304.9(hot)-297.5(ash)-298.1(severity)-301.8(was)]TJ -4.679 -1.2203 TD (2.80)Tj /F6 1 Tf 1.9158 0 TD ()Tj /F5 1 Tf .7208 0 TD [(0.79)-305(\(Table)-308(4\).)-306.4(Repeated-measures)-313.8(ANOVA)-305.8(revealed)-310.7(a)]TJ -2.6367 -1.2203 TD [(signicant)-325.3(reduction)-330.5(in)-329.4(the)-326.2(average)-327.2(frequency,)-326.6(severity,)-330(and)]TJ T* [(total)-639(hot)-638.9(ash)-633.2(score)-642.6(at)-632.3(the)-642.4(end)-632.3(of)-641.9(treatment)-641(\()]TJ /F7 1 Tf 22.7309 0 TD (F)Tj /F6 1 Tf .7145 0 TD (=)Tj /F5 1 Tf .7208 0 TD (3.719,)Tj /F7 1 Tf -24.1662 -1.2266 TD (p)Tj /F6 1 Tf .6639 0 TD (=)Tj /F5 1 Tf .7208 0 TD (0.007;)Tj /F7 1 Tf 2.8832 0 TD (F)Tj /F6 1 Tf .7145 0 TD (=)Tj /F5 1 Tf .7208 0 TD (21.698,)Tj /F7 1 Tf 3.3828 0 TD (p)Tj /F6 1 Tf .6639 0 TD (<)Tj /F5 1 Tf .7208 0 TD (0.001;)Tj /F7 1 Tf 2.8832 0 TD (F)Tj /F6 1 Tf .7145 0 TD (=)Tj /F5 1 Tf .7208 0 TD (3.825,)Tj /F7 1 Tf 2.8832 0 TD (p)Tj /F6 1 Tf .6639 0 TD (=)Tj /F5 1 Tf .7208 0 TD [(0.006,)-376.9(respective-)]TJ -19.0573 -1.2203 TD [(ly\))-330.9(\(Fig.)-338.2(3\).)]TJ /F10 1 Tf 0 -2.447 TD (Safety)Tj /F5 1 Tf 1.1128 -1.8336 TD [(Acupuncture)-313.3(was)-312.3(well)-312.1(tolerated)-313.8(with)-312.5(few)-311.8(adverse)-314.9(events.)]TJ -1.1128 -1.2203 TD [(During)-318.3(treatment,)-327.8(1)-315.7(participant)-329.3(experienced)-322.8(a)-322(skin)-316.2(rash)-327.4(that)]TJ T* [(was)-388.1(deemed)-395.3(unrelated)-397.5(to)-395.3(acupuncture.)-396.6(No)-394.8(serious)-396.6(adverse)]TJ 0 -1.2266 TD [(events)-334.5(were)-337.2(reported.)]TJ /F3 1 Tf 0 -2.4406 TD (Discussion)Tj /F5 1 Tf 1.1128 -1.8336 TD [(This)-264.2(study)-269.8(demonstrated)-271.2(that)-269.4(among)-266.9(Korean)-268.3(women)-264.5(with)]TJ -1.1128 -1.2203 TD [(breast)-316.1(cancer,)-314.8(who)-311.3(are)-316.3(undergoing)-317.7(tamoxifen)-319.6(or)-313.3(anastrozole)]TJ 0 -1.2266 TD [(therapy,)-246.6(acupuncture)-254.6(reduced)-253.7(the)-244(mean)-253.3(VAS)-249.3(score)-244.2(as)-247.4(well)-248.9(as)]TJ ET 310.847 710.135 239.074 .22681 re f 310.847 473.102 239.074 .28345 re f 310.847 691.143 239.074 .28351 re f BT /F9 1 Tf 8.9663 0 0 8.9663 351.8361 725.7825 Tm (Table)Tj /F5 1 Tf 3.0666 0 TD (3.)Tj /F9 1 Tf 1.2456 0 TD [(Demographic)-337.9(and)-331.7(Clinical)]TJ -2.4659 -1.1128 TD [(Characteristics)-337.2(at)-334(Baseline)]TJ /F7 1 Tf -6.4178 -2.0423 TD (Variable)Tj /F5 1 Tf 18.1341 0 TD (N)Tj /F7 1 Tf 1.1571 0 TD [(\(%\))-336.3(or)-335.1(mean)]TJ /F6 1 Tf 5.3302 0 TD ()Tj /F7 1 Tf .7208 0 TD (SD)Tj /F5 1 Tf -25.3422 -2.0929 TD [(Age)-334.5(\(years\))-14872(46.60)]TJ /F6 1 Tf 22.3768 0 TD ()Tj /F5 1 Tf .7145 0 TD (4.93)Tj -23.0913 -1.1128 TD [(Height)-334.2(\(cm\))-14148.5(159.80)]TJ /F6 1 Tf 22.3768 0 TD ()Tj /F5 1 Tf .7145 0 TD (4.78)Tj -23.0913 -1.1128 TD [(Weight)-333.2(\(kg\))-14685.3(66.50)]TJ /F6 1 Tf 22.3768 0 TD ()Tj /F5 1 Tf .7145 0 TD (11.23)Tj -23.0913 -1.1128 TD [(Menopausal)-333.9(status)]TJ .999 -1.1065 TD [(Premenopause)-14071.2(8)-334.6(\(80\))]TJ 0 -1.1128 TD [(Postmenopause)-13645.2(2)-334.6(\(20\))]TJ -.999 -1.1128 TD [(Cancer)-331.7(treatment)-337.5(history)]TJ .999 -1.1128 TD [(Breast)-333.7(surgery)-13664(10)-334.1(\(100\))]TJ 0 -1.1065 TD [(Radiotherapy)-14559.2(6)-334.6(\(60\))]TJ 0 -1.1128 TD [(Chemotherapy)-13987.2(6)-334.6(\(60\))]TJ -.999 -1.1128 TD [(Time)-332.8(taking)-331.9(tamoxifen)-338.6(or)-338.6(anastrozole)]TJ /F6 1 Tf 1.1634 -1.1065 TD (<)Tj /F5 1 Tf .7208 0 TD [(12)-334.1(months)-15025.8(4)-334.6(\(40\))]TJ -.8852 -1.1128 TD [(12)-333.7(years)-16388.5(4)-334.6(\(40\))]TJ T* [(34)-333.7(years)-16388.5(1)-334.6(\(10\))]TJ /F6 1 Tf .1644 -1.1128 TD (>)Tj /F5 1 Tf .7208 0 TD [(4)-334.6(years)-16502.3(1)-334.6(\(10\))]TJ -1.8842 -1.1065 TD [(Concurrent)-334.6(use)-337.7(of)-332(goserelin)]TJ .999 -1.1128 TD [(Yes)-18993.1(4)-334.6(\(40\))]TJ T* [(No)-19180.1(6)-334.6(\(60\))]TJ -.999 -1.1128 TD [(Previous)-334.1(use)-337.7(of)-332(HRT)]TJ .999 -1.1065 TD [(Yes)-18993.1(0)-334.6(\(0\))]TJ 0 -1.1128 TD [(No)-18680.6(10)-334.1(\(100\))]TJ 7.9702 0 0 7.9702 318.7841 461.3101 Tm [(SD,)-330.8(standard)-329.3(deviation)12.5(;)-333.3(HRT,)-332.6(hormone)-321(replacement)-328.7(therapy.)]TJ /F3 1 Tf 8.9663 0 0 8.9663 59.7543 749.7069 Tm [(ACUPUNCTURE)-340.1(AND)-337.2(HOT)-334(FLASHES)-339.4(IN)-328.8(BREAST)-338.7(CANCER)-340.8(PATIENTS)-19735.3(693)]TJ ET endstream endobj 11 0 obj <> endobj 12 0 obj <>/Font<>/ProcSet[/PDF/Text/ImageB]/ExtGState<>>> endobj 13 0 obj <>stream /GS1 gs BT /F5 1 Tf 8.9663 0 0 8.9663 62.022 590.3431 Tm 0 0 0 1 k 0 Tc 0 Tw [(the)-452.7(total)-455.7(hot)-455.6(ash)-449.8(score)-452.9(for)-452.9(severity)-459.9(and)-448.5(frequency)-456.4(of)-452.2(hot)]TJ 0 -1.2203 TD [(ashes.)-283.2(The)-290.8(reduction)-286.3(in)-285.1(symptoms)-285(was)-280.7(maintained)-285.7(at)-284.5(week)]TJ 0 -1.2266 TD [(8.)-426.1(These)-424.8(results)-425.9(suggest)-424.2(that)-427.5(acupuncture)-425.3(is)-428.5(a)-423.1(useful)-425.2(alter-)]TJ 0 -1.2203 TD [(native)-399.6(treatment)-400.7(for)-396(alleviating)-401.4(hot)-398.6(ashes)-400.4(in)-398.9(patients)-402(who)]TJ T* [(have)-680.1(breast)-676.5(cancer)-672.3(and)-676.1(who)-678(are)-676.7(receiving)-679.3(antiestrogen)]TJ 0 -1.2266 TD [(therapy,)-588(and)-581.3(are)-588.1(consistent)-591.2(with)-584.4(the)-585.5(results)-590.3(of)-585(previous)]TJ 0 -1.2203 TD (studies.)Tj 6.7246 0 0 5.9768 92.0693 528.5479 Tm [(14)-9.1(23)]TJ 8.9663 0 0 8.9663 72 513.6377 Tm [(Recent)-298(studies)-301.7(have)-294.4(reported)-299.6(that)-301(acupuncture)-298.8(is)-295.7(effective)]TJ -1.1128 -1.2203 TD [(in)-607.6(reducing)-609.9(vasomotor)-615.6(symptoms)-607.5(in)-607.6(patients)-616.9(who)-608.5(have)]TJ 0 -1.2266 TD [(breast)-252.9(cancer)-255(and)-258.8(who)-254.4(are)-253(receiving)-255.7(tamoxifen,)]TJ 6.7246 0 0 5.9768 246.6708 495.7227 Tm [(16)-9.1(22)]TJ 8.9663 0 0 8.9663 265.833 491.6975 Tm [(but)-252.8(there)]TJ -22.7309 -1.2203 TD [(is)-333.6(no)-328.6(consensus)-336.5(on)-334.9(the)-332.5(optimum)-333.4(treatment)-331.2(frequency)-336.3(or)-332.3(the)]TJ T* [(duration)-425.7(of)-420.6(acupuncture)-425.3(in)-417.9(these)-428.6(patients.)-423.8(The)-417.3(duration)-425.7(of)]TJ 0 -1.2266 TD [(acupuncture)-292.5(treatment)-293.2(in)-285.1(this)-286.9(study)-288.8(was)-287(4)-284(weeks,)-288.3(which)-289.4(is)-289.4(a)]TJ 0 -1.2203 TD [(relatively)-338.7(short)-331.1(period)-340(compared)-332.9(to)-332(that)-339(in)-329.4(previous)-340.5(studies)]TJ T* [(\(range,)-359.1(412)-358.5(weeks\).)]TJ 6.7246 0 0 5.9768 143.433 440.9007 Tm (1622)Tj 8.9663 0 0 8.9663 163.5023 436.9322 Tm [(The)-360.4(earlier)-355.5(benecial)-364.2(effects)-362.2(in)-361(the)]TJ -11.318 -1.2266 TD [(current)-277.7(study)-276.1(may)-267.1(be)-276.2(due)-276.1(to)-268.8(the)-275.6(cumulative)-279.1(effects)-273.7(that)-275.7(arise)]TJ 0 -1.2203 TD [(from)-374.6(multiple)-371.6(acupuncture)-374.7(sessions)-375.3(within)-370(a)-372.6(short)-369.1(period)]TJ 6.7246 0 0 5.9768 294.4062 418.9605 Tm (32)Tj 8.9663 0 0 8.9663 62.022 404.0503 Tm [(or)-439.8(from)-437.8(placebo)-440.7(effects)-444.4(generated)-441.1(by)-438.8(frequent)-440.6(exposure)-445.7(to)]TJ T* [(treatment)-413.4(administration.)]TJ 6.7246 0 0 5.9768 163.7858 397.0771 Tm (33)Tj 8.9663 0 0 8.9663 174.1606 393.1086 Tm [(These)-412.2(ndings)-401.4(suggest)-411.5(that)-408.5(the)]TJ -12.5067 -1.2266 TD [(effects)-254.7(of)-256.2(acupuncture)-254.6(are)-253(not)-253.2(inuenced)-250.7(by)-255.4(longer)-248.7(treatment)]TJ 0 -1.2203 TD [(duration.)-460.3(Further)-466.2(study)-459.5(is)-460.1(required)-462.4(to)-458.5(determine)-463.6(the)-459(opti-)]TJ T* [(mum)-401.2(frequency)-399.5(and)-404.2(duration)-400.4(of)-401.6(acupuncture)-406.3(for)-396(the)-402.1(treat-)]TJ 0 -1.2266 TD [(ment)-336.4(of)-332(hot)-335.4(ashes)-337.2(in)-335.7(patients)-338.7(with)-331.5(breast)-335.1(cancer.)]TJ 1.1128 -1.2203 TD [(Various)-353.4(acupoints)-360.7(were)-356.2(used)-353.3(in)-354.7(previous)-359.4(studies,)-355.2(includ-)]TJ -1.1128 -1.2203 TD [(ing)-782.7(both)-788.8(standardized)-788.2(and)-783.6(individualized)-789.8(acupuncture)]TJ 0 -1.2266 TD (therapy.)Tj 6.7246 0 0 5.9768 94.7338 320.3716 Tm (1622)Tj 8.9663 0 0 8.9663 114.5763 316.3464 Tm [(In)-334.3(this)-337.5(study,)-335.9(ve)-338.8(acupuncture)-336.8(points)-341.6(were)-337.2(se-)]TJ -5.8613 -1.2203 TD [(lected)-328.6(with)-318.8(the)-326.2(functions)-325.8(of)-325.7(nourishing)-331.3(the)-319.9(Kidneys,)-324.8(cooling)]TJ T* [(Heat,)-483.3(and)-486.4(calming)-479.1(the)-490.6(mind)-481.7(because)-486.2(patients)-484.2(with)-483.2(breast)]TJ 0 -1.2266 TD [(cancer)-514.2(generally)-506.2(tend)-512.6(to)-509.1(display)-509.9(disease)-514.3(patterns)-512.9(such)-511.2(as)]TJ 0 -1.2203 TD (Liver)Tj /F7 1 Tf 2.605 0 TD (Qi)Tj /F5 1 Tf 1.3405 0 TD [(Stagnation)-306.8(and)-303.1(Blood)-299.6(Heat)-309.7(due)-301.4(to)]TJ /F7 1 Tf 15.39 0 TD (Yin)Tj /F5 1 Tf 1.7894 0 TD (insufciency)Tj -21.1248 -1.2203 TD [(\(Table)-327(1\).)]TJ 6.7246 0 0 5.9768 99.0425 265.5495 Tm (27,28)Tj 8.9663 0 0 8.9663 117.1275 261.581 Tm [(Acupuncture)-332.3(consists)-329.5(of)-325.7(inserting)-330.5(needles)-333.4(into)]TJ ET 62.022 710.135 490.167 .22681 re f 62.022 642.501 490.167 .22681 re f 62.022 691.143 490.167 .28351 re f BT /F9 1 Tf 8.9663 0 0 8.9663 136.0063 725.7825 Tm (Table)Tj /F5 1 Tf 3.0603 0 TD (4.)Tj /F9 1 Tf 1.2519 0 TD [(Mean)-333.3(Values)-337.5(of)]TJ /F5 1 Tf 8.1818 0 TD (VAS,)Tj /F9 1 Tf 2.5924 0 TD [(Frequency,)-333.7(Severity)-336.3(and)-338(Scores)-330.6(of)-336.4(Hot)-335.6(Flashes)]TJ -6.7655 -1.1128 TD [(from)-337.5(Baseline)-334.3(to)-333.9(Each)-336.1(Measurement)-334.2(Point)]TJ /F5 1 Tf 6.7246 0 0 5.9768 400.1952 719.7731 Tm (a)Tj /F7 1 Tf 8.9663 0 0 8.9663 62.022 697.4927 Tm [(Variables)-3437.8(Visit)-336.5(2)-3938.7(Visit)-336.5(5)-3932.4(Visit)-336.5(8)-3692.1(Visit)-336.6(11)-3432.4(Visit)-336.5(13)-3438.7(Visit)-336.6(14)]TJ /F5 1 Tf 46.2774 0 TD (F-)Tj /F7 1 Tf .8726 0 TD (value)Tj /F5 1 Tf 6.7246 0 0 5.9768 504.0565 701.4612 Tm (b)Tj 8.9663 0 0 8.9663 519.0802 697.4927 Tm (p-)Tj /F7 1 Tf .9105 0 TD (Value)Tj /F5 1 Tf 6.7246 0 0 5.9768 548.4471 701.4612 Tm (b)Tj 8.9663 0 0 8.9663 62.022 678.7274 Tm [(VAS)-3834.4(71.50)-336.1(\(11.32\))-1260.2(51.00)-329.8(\(16.80\))-1266.5(39.00)-329.8(\(11.74\))-1266.5(34.00)-329.8(\(18.38\))-1260.2(23.00)-336.1(\(15.13\))-1260.2(19.50)-336.1(\(13.23\))-1601.6(30.261)]TJ /F6 1 Tf 51.4179 0 TD (<)Tj /F5 1 Tf .7208 0 TD (0.001)Tj -52.1387 -1.1128 TD [(Frequency)-1762.9(9.30)-336.6(\(9.72\))-2259.7(3.50)-330.2(\(4.60\))-2266(5.00)-330.2(\(6.13\))-2266(5.10)-330.2(\(9.28\))-2259.7(1.60)-336.6(\(2.41\))-2259.7(1.50)-336.6(\(1.72\))-2601.1(3.719)-2770.4(0.007)]TJ T* [(Severity)-2783.9(2.80)-336.6(\(0.79\))-2259.7(1.70)-330.2(\(0.48\))-2266(1.80)-330.2(\(0.63\))-2266(1.60)-330.2(\(0.70\))-2259.7(1.00)-336.6(\(0.47\))-2259.7(1.10)-336.6(\(0.74\))-2101.6(21.698)]TJ /F6 1 Tf 51.4179 0 TD (<)Tj /F5 1 Tf .7208 0 TD (0.001)Tj -52.1387 -1.1128 TD [(Score)-3491.4(31.10)-336.1(\(36.62\))-1759.7(7.20)-330.2(\(9.09\))-1766.5(11.60)-329.8(\(18.22\))-1266.5(12.90)-329.8(\(27.81\))-1759.7(1.90)-336.6(\(2.47\))-2259.7(2.20)-336.6(\(2.53\))-2601.1(3.825)-2770.4(0.006)]TJ 5.9774 0 0 5.3127 70.0157 634.2234 Tm (a)Tj 7.9702 0 0 7.9702 72.9637 630.7085 Tm [(Data)-333.6(are)-325.7(presented)-327.6(as)-335.9(mean)-323.6(\(standard)-327.4(deviation\).)]TJ 5.9774 0 0 5.3127 70.0157 625.266 Tm (b)Tj 7.9702 0 0 7.9702 73.3039 621.6943 Tm [(Repeated-me)13.7(asures)-330.5(analysis)-323.1(of)-332(variance)-328.2(at)-330.3(visit)-336(2,)-331.2(5,)-331.2(8,)-331.2(11,)-329.1(13,)-329.1(14.)]TJ ET q 237.657 0 0 154.602 62.759 83.962 cm /Im2 Do Q BT /F8 1 Tf 8.9663 0 0 8.9663 62.022 67.2378 Tm [(FIG.)-634(2.)]TJ /F5 1 Tf 4.3944 0 TD [(Changes)-638.1(in)-632.9(mean)-639(visual)-636(analogue)-640.4(scale)-635.8(\(VAS\))]TJ -4.3944 -1.1128 TD [(scores)-334.1(for)-339.1(hot)-335.4(ashes)-337.2(over)-332.9(time.)]TJ ET q 1 i 313.795 580.082 m 551.452 580.082 l 551.452 93.657 l 313.795 93.657 l W n q 237.657 0 0 486.425 313.795 93.657 cm /Im3 Do Q Q BT /F8 1 Tf 8.9663 0 0 8.9663 313.0582 76.9323 Tm [(FIG.)-260.9(3.)]TJ /F5 1 Tf 4.0214 0 TD [(Changes)-258.7(in)-259.8(mean)-259.6(hot)-259.5(ash)-260.1(values)-259.3(per)-261.2(24)-258.3(hours)-256.1(over)]TJ -4.0214 -1.1128 TD (time.)Tj /F8 1 Tf 2.7189 0 TD (\(A\))Tj /F5 1 Tf 1.9348 0 TD (Frequency,)Tj /F8 1 Tf 5.3492 0 TD (\(B\))Tj /F5 1 Tf 1.8273 0 TD [(severity,)-526(and)]TJ /F8 1 Tf 6.4241 0 TD (\(C\))Tj /F5 1 Tf 1.8779 0 TD [(total)-525.2(hot)-518.8(ash)]TJ -20.1322 -1.1065 TD (score.)Tj /F3 1 Tf -27.9978 77.247 TD (694)Tj 47.6052 0 TD [(JEONG)-333.7(ET)-338.7(AL.)]TJ ET endstream endobj 14 0 obj <>stream AdobedC       B s!1AQa"q2B#R3b$r%C4Scs5D'6Tdt& EFVU(eufv7GWgw8HXhx)9IYiy*:JZjz?Nl;qOFyrJPn"i aZW─tl~wIzŭ]]zl6q 3ޤ@$y٣ipN6~k%Ċ[3z>1MV X 嵵|~R~ߝ <+t@uNM%pзW֓i:MWWҹq$mĕj2f͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6s>Oo8okI6(. .< bM.<874RSbDvjO$1|)Jh?#je*`..enyW|8\W 858yѤ˧l~KGu/!jz`%ܖ-Mw6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6ly}* S/Y@}_X QO"/{[nZR0]\ו d ڣ:lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛9΃M_Z6ז:r%ܖE,N. ? IG&u4s:<זtiu4 ť5)Px5jhN&tD'P:7.lƜΓƽofD@5nkۍ㑏ɷҽ)o|V4S74WiN3f͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6l?%}yNW 76}f&ͤ$(FvIM3nS>[]2/'iiqM Mp$nwY2eSiG_41>ע}_X+J-(}FZA!Heto:v?_2FM!}Fgfwx~7f^Of͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳfͅCrzt5rɥ_&ȷ%.Ÿ"/郿 Nsf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lIڞs՝ޯi6̏2p4z5N6(yC-5+6ҬI=*)\'2h|JSyӅk^:|<K]q[I4}c WſZާG>/ȴO[KeԄA}7':lĀ*MPe; ͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳagN sgkwr9% @X# vKv)ܚ I N`oBu:M7VKH2@J@#|/S 䑢T ;6ʱҳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳfEApǹ<͚t.hZΧa~́ߜh*_nS/+bm~z4KqKuR-atp¸H|{m|"g$7F0zz$2Vy˂_5I.Ac%#6gTW' #O[ Kꖎ7/M6Cqٳy#YƁ&geejIx\ M~Ӽ)Ѯ4+݌2-[y)V+(6pE ~D%Jj:9+oKr~d6lٳf͛ |zlfac/ڂu SO;>N ||b{Y+qRWIly3[f}041Qwj+] mZTd6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf̈́|Եm;ɺŵ{kI$ )̾ 5_;l?YKK^X`DDYVE{oْcp$+;}QG>͛6l vB'™UH-MAH)u?#y dSl5  MOf͛6lٳf眿/| U[Yf{[艊)ҎbQ/xlrJ@{Qi)ͮtxG;M ЃJae^iwoON8㙒(d5n2Jre;E4$YU"'f͛6lٳf͛6lٳf͛6lٳf͛6lٳf5255kg mJs4Ƶ:IY-<-L;+HR)KQdtTVO` -Eh~B*{S78|[ m!k$g+}Z08g<ˤ ćP-[~\=ks rڣ^@>r_)H5Сeޜ|v듬+ͭmɭd 8Z`?n4#?y){Cz5X mu6lٳf͛6l 7|x&]̱}LoBOa!_UWl! (ͺDEUU W $SR˧^Er_jSF3$KTu;?͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6q_=Bu.NM2=BsSa<&^o|jZm@×+yUĠ]Ff͛6lٳf͛6lٳf͛6lٳf͛6lٳd?vz?m|U5E2Y[|34!UO䧖?8h]ޭapf Xn-*B~Ѩ3^G&|"$Q STvV_EZ\͛6lٳf͛6lٳf͛6lوEAA-wѦhBjKԐ¯'?/y2!,4z?N~*(yNr~oiZechorY]mF7/Ⱥl>gaoմr#`+!SΏeiXCw3"%If͛6l_+jzխrO~!(^^EOZ5)o=W;le;:͛6lٳf͛6sO},#Фռo$Ƴ-̯"Y!oK<3zvJ_/yR{2DZ 汽haI9tkk]"\AoS5KU0^%K_}oя~#ˇ:rz`+?,ynN,;Qt-ϣo~ߊL'=|鶣Weڈ?iΔۮё+GN POՒW{L"kV%կ#\"鸼܀nd}:lٳf͛6lٳf͛6lٳf͛6lBep1=A^/凗ԴK-V&-XIٳfv}~00+>5<9zm#o|NHoTM178S75F498͛6lٳf͛6lٳf͛6lٳfͅ>fՇӧ_Ku7'Ķ„gwɾDмfZ3] 2c8+Eefg$9f͔ʬXSppU򗕵{ckiw<Ȼ{2j"?mbd'oup%nhimZjR<[tnurݽ>g8je`c넾vo{(u$t۵i-ݵOE!!kE׾{B8\yGRx"~sR55 Bq5ڙҢ)Ybu7WBH#6lٳf͛6&q%Dq*K0P+3u!y|Lٳǚ=_Jlaie%C$1 !"58qO7~fEO}Սu;Rۈx W]Ro5Ld>\ ~l: R2-%Ccoi櫩-$/oIu37Jn ?#?/&CRYޙb%f͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛#?Ňǚ y&[Zf;-R9m-d wVd"_O˲5宽6kW4>'>=Im*[ҭV6RuNW[ݥAmKZ;.9h u 8/6lٳf͛6lٳC95|;0@׶:en-)p$_6z v*꿜KXzu4[mV5suKNw喾>(\鳃,&@VH$ڴuٰ~|o X%L̂2 ß}S랪Wj>\M\ٳg5Oy7^۝;Vxxt2N4Sߜ-MzH<{6fu-{G[U#Q?p[oCѼ3.tUAT=NΣud#ѵ˰mҔ}2uE&㼏ɲG{:^-/A7'T퓜ٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͜ɞVռWt/GZj*.boUBhr;L|2).$pI} 5ݚS>u/<ͺqo|p4ͬ'韞ߖח"Q}![M^,]Q}PhqOz_@n,xH8Jt ЎC;8q)N4ڞ͛16OMo| )c}iZWKi-|ƺa~o?: 퍽ƫW6$%qw ?#?/KkY,mPԖ)b%t ٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͜X77`F֋IQ:qmwu}5/eӮ"L 4`=OF5X}N @KP r?̯"h^މi.6wc"ZO,vVߑ׆vٳf͛6l+E&Og T*|ydg]Lsuvu=P\ۊC$_*hzoٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6l9f=ϗ_E|uOv[3+][E'~QOy_NZ֘lٰD󗕵۝FHྛHC,-C! y[/Ȟkwb+q\ Zr^ACv_򳼄|5o#_n\Ξ>;_lFt3IZzK(>i'C<ٟ!)k#Vt7?`ۏlf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳZ&g/mfZhHg-SYQ[qӗ\cFԼ+GIyil䃅A-d"Tw7X |u-uZbms߭So)ʦz{ Ŧkl2޳ h}@i~#ߓQG#)j5D/'G#Nsf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͑kZZ)lKH#~PJnhG\)/T?#Eqx?=|B[vX_~by^};WPÐ ?SR4_fhԍXYmWHvǥ@91UִE̩x%Eu @)/T4?F,mל2-l统 [Һ1T GJ^HSk w6]VNUjpGCh/R)/TGvw!~g L#`gn ĵ49vuſIx1|7ՠTVG+SR4_e4?F,byAѮuGv4R $0]Ƶݼp6$Fk?3SR4_e4?F,byCA pщXC hs͛6lZV^چoE,w*?qmMK_ksŵW_H>b6&l/;DY!{ϫs+M!]a6:ijK*syZgl_N4}'MVK+^B%v.Û5clPT`Ahz~ZhrX"Gbt͌9 cYCŅE,m"IVK+RY05 0nlB +LQ<3hJHZtt:L-4@VՉb#B($`UmuM2M/T&9TFcYYeeog" h5!#PRz1l [uHV{+^U1E0lpTG {G@w4QA͉]wi5n#hpTЏc]YvjVՉb#B(,w; Z}]i@2[ΪJQ#/O--[{HA$E=vl6zƓy_)k;dU%IU*0lpEV[DXAAbXk5揨+=M£b 8 >@S isj*evfTbBaF 3f0L&#=؇6M{S*Hd7Hz0üTt'NԵ+,-ss) Ա8 ʾnyz5 <}b099-+m_ 7ͅ~f>}k\zmZrW@jOa9yE5-EpU] 9EF{d6#C5]^;-:y\]Lx@>`O*>lF-J9+e4`hFf:޹hZ]ƫ]cZ9fG#vKt+{-j;+GDfNF>Gv+s6A9켣wlo,q$Q*hzaoF=KZ桦EOu]J?JBPB3||b#:VlUna\( )sfcz{bڶ/ []D<d +X+`-sPt[F6 .'̑!r|hMiN'yɋ9Gc%ޕ4g,qKCs,+8@.?liJ_g4'RLYm G EUcF5vü#ך "[>+V;)c{9'9?>&Tv?(7h^dSjQiN!g%Ea=ġO$ǂWn;l@󏑇GcӠxEe,q\O_SP[kfִm`֤m-ba)ozP;"үlYy>o͟v6ެ嶒Y0KɑPv/әмg懗̺[K~MxÃęd/NLٳf͛6lٳf C=FPULٳMLٳf͛13f͛0 3f͛6lٳf͛6lٳf͛6l٨+Zo6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf{kƳf];Sc{,KU >(ƻy>VуIEX?L?P Z5y,4%Η>G)UQ|d9<[W2=M:;I'k{sƓU? n>+դSGm4tᏯ흧^[d f w [\( 6;S3f͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lbh)T>stream AdobedC        s!1AQa"q2B#R3b$r%C4Scs5D'6Tdt& EFVU(eufv7GWgw8HXhx)9IYiy*:JZjz?i-jzLۗv; _WGa75&Ep2QAe&'zoom+[d9uMYj~hΓqX\JE P)4VFREv:vyAch!Uw(讌 ApAyf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6ys+Οe$s\rA궤;WiLq Ǥ~^\y"W|pܙ xCl@ 4+=r_V]Cދ*efot/xA$BjOyG]|Kۻ4j|PCY:0njh9Aff# Pߟ5;_5O8j yn-BUmTf`TIR*?53G-qgxc`~HWҝ[:&:>Aui޵b fG|3濡 ꌳiJHqFxS&f͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͜ΟSygJ󎳪C>Iì\?f|}ɏ%yZiUam,Y!X:8(ԪЀ£lGmWIΡ%Db FTf޽2g6l/ iɡj K$x H\6Fῆs/7|Y?XKf, 0-y:lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٰ>aptqK~vhi@=HSo1;m5N:P )'/ <Ttٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6D5<ӭyW4$%>% (Iw i@^O-W2Mm:lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛"J~\AUE+KUl _:ޝcc/G[ƺ K@КҾ{c5ƮWvc4ͧEk[^6U$0 ]@G41'5bI,;{7X\\[=eeHUciS?>Rҧnt}̐ @yqa<g2\3(-OZadWvX],Vmh20%= "(mS|O1,xBXT2؂;f͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf̈́b򽾻-+k9LZF#TzSF~ EY0ڵi<ꖭ \A,X&P6u& :4m?Dmt:?Jq-j|K3ٙf'g<#+UNo#NsCZ.)[]$>]qQ[ԇΙ6s.Iuh n8w< T{P|sZT~v;dc|Ťëhiya=xJ22:2:X\1͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٰ>l6VWrXߋ{ zbM0JtVeOLP DdZ~Ҍ6lY&z Ʀ?:B9(!?;gP4\+juLٳk'w헢Y;W^E;]foVf<,u@OniN|}#}\=dޖ]v$prC6lٳf͛6lٳf͛6lٳf͛6lٳ`]VN:QdH:'%kr+_=ב^y^]Ig w $!"<&f͛6lٳf͜Tִ" 'Z_ Cq?IJCBg?KdwKNuie󎲦=?]%k xP ,:.gC_;)=~Cj8-'6 NM$7oæk"m ; ]~ z27<7}1'"Yۢfc@Næ0+iVkidhdtqUeaGU6덟A'u|[g;2hIC[_y~ mGιӳf{v^fȧ<s\maġ'Sou{wӪq?)y[A[UѼnCoi{f̿6lٳf͛6lٳf͛6lٳf͛6lٳfGWo 5oɾlٳf͛6lٳdwϾW_1yVwjaRAmsjޤrI:|Axuc>mqj:M .PVP5 6F<5k[@\]oWJiof=EmYׁI|soqڍCMygWQñ?ݲs_Z^hAtOkRY%yeБX@m{i=6s(/':0'$p)M4<_sI7I r068GEW:Nl|]t,ٰ;MitWBl4iV NYI-66(jгf͛6lٳfGWo 5oɾlٳf͛6lٳg57E7xEQ*M@s͛k:.wVkv;i2GPF2hoK>֞iK;U_ٟ'G[qo"o2!6 *6 ͛6lٳf͛6lٳdSj6'f͛6lٳd#7Dd6lٳf͛6lٲlhp<2\q߽Kac'~ޙ?,05k3Z.^m[\ Mǧ& 3jzeDb=6l؅k)Ń鍅ά )U(k3\^y䶳4rYG$0|~,f͛6lNEAb9.<~_\IJ u?)MKQRr5yGm& ˞d|ǤChKwc=xȵYvdt4du;2e6lٳf͛6lٳdSj6'f͛6lٳd#7Dd6lٳf͛6lٲq<2[ou}b c3j)O[g3? ciGԭl&D`[^Qީx_w1-7ͫ󾷯-/h.d.8l0cH! H.碃ޘco拟4y/MXX*o34E=+L.˗\]i3ͽSM;!~TypyοK0o}SJyxvη6lٳf͛6A|ZV^F;=nj>Lxj$+٪0x| `-[E.%YUa9"n EV4UDdkB(67VJ#x\͛6lٳf$SNF50ZI ,mӴa^|A☠әc.Ǩ$~-Q8$zMBӉ3ƎiyG/w/"ORVmlٳf͛6l˼ Z/uDq-Yosլ?-F=#YyMH\!|BƉm1$;gDVWPC+ /6lٳf͛6l~fj^SUCM-FUmٹ!d4mXC>^kП-u,֧DEPeHCJ,|u* 6;]cceorHHi$+R4:Ep~-W*S:lٳf͛6lٳa'G?o-^w-;;?.DݥD*##ٕ#f͛6lٳf_K FKH' OX48B;lWn4^gt]M[kJ=W5@ n$6~gẅ́aq/8zo5=3J,޸]>ܢ5HP n%0~Fy [i/1ߐyCzM7lTCC#U@?fDhvVlٳf͛6r5 V6g5;[Zmmli@P^Ma\"n)N苯hGP~O~c Ԏl:gt͜v]dҴMF75u*{kmB{N͛6lٳf͛6l$(Y\$h ;U@$g5/x-5{+XiQtpJӥ3f͛6lٳf͛6lٳf͛6l Vzfq^ :HB"c9+Z15FL$ ,hZN͛6?TOmCŴ7C2skzyizZVQ?Ay ^+_zӥG[gjЬ7q;!'/gt]:k$k VƋ钍CZ'9$Ԝtq2QZ[q,R]\ XxFt3RH;+ur < )8/6lٱ A/,KkĉnG̜! f?55Ikh lW̓nUrV=`smnȠLٳf͛6lٳf͛6lٳf͛6lٳf͐]cz_"̚~;z)+j=TBfd慾6Y5I'O(dc cr+q)&zOd`>?.5fڊM3P4CQYc1\MmvLA!4~\֢SF]O!׊F9ѳf͛!s<æXݪ麮Wf%bKx@Z>yյ۟3hNѵg`W(#D0h8$Pu15k7ȩy8;#< wˏj OmcX^('/P[]>HhZ:"YiEdfPz9~bϾx76zc BTTjΗ6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٰ.i>.,W 2ִ4 .~^y/Wr]:L:}c9+0cPIZ6l(lٳf͛6פDl '1IaO)RpFs_ɫvBէִPK멤^J^Pα6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳfͅ:7YӴkˡ.yIBZmNGzmG?,YGu s<pyf l:ᆛXz}a:]ƲΆ⠌FK.$.oR66򿤏  _'s~Y\Ϟx_NBK[[uQH&us͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٰkiw6mPOٽ'6yUT iC!6G!k{~"8U{ "V ;FG[6}&'&."P,eCĆ`5wi-y#Lѯ=Y'&y9~W.˷j5OZL-#!V Qw4YggN[U[y'S:lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٰ>Q\=ܬlawM 7J=Tx}OMIuE_C*D7+6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lSM:-nDEBO 1 N'9eo;Ǫk ҋQ%q3Wƹӳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lX4}2SC$Q$j@m41wU=ڠcE &.#8ӡ8wCXN?Pѣmonu[1 11D^M8ff4XVYdP⍸L矒yΩyjšYM*-$V0Hο\9f͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lCy#˺gj(g4mǛ/- ERdP CUuٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lFjw4:}4gehhvx${dne(ܤQ" >05m?W-=:eez2Ѓ8EcckҁuWeRz9dϞwvֶ]+3I%͚76S5PJ_Tyk>+[ jSV.e/cƇ9#EaS?1ssʢLfO/[^^jcQmii~iڭ҉- F3IQXo\\?g7.oTV3?t?mFfg5hVDf ץ0ULf*3bvO-~Zk~gS ,tY]M~%23vÿTV3?7+qULf?/[_]>dQּmci{Zf):O*~Z^_[jMhN0R0VMwÿTV3?7+q~Q)7鋟넞W}ljVT 7t#~/YQULf*3b 3yu~iwKkhMB(MVGu"[5pULf*3bvMcu~SU:ƹ{WT6tz@pULf*3b`O|v:?~N4>WcUHiC \;EaS?1ssʢkG`'e4u~iwIhQ_UF6:[ R\;EaS?1ssʢkG` OX ?+c#.nS$~K\[##6䘂ٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛ MOlM9\@"( Ul򮓯Q0j78[RiQe@82Ȫ8Ԩ {6s= m[OՓORQuզ+ GM4DOՒ'ƭNAmΙjjW҈lye5!cK3mg2W׸մ%ͺQ$!lƶ|PznyuٳPEi]:>bWWu?ѰoEc~CgÀˉ-MB;ia8FXH:Rxg6{Zᦲ~4j-xZ\ґC8έ7cl܄oD?/CƾYMsCQvMKYuHuo43e-JAUc6B?1-Kj[A>kg{kԪLy^/ ci$risՌ\CJfmzd͐_kkOWZeց2xE-lj"fu_.Y3iZskSl#aE˔=铬 γg/&Me<ZE,omp4~(ւմq0#TeyeJᴸt"<1}9;͐f7}ϯYYE$8Z pV14Ko5++;kI.e'e Se+Sd/7ů|ַay}=qȢ`_nDHޛdN?O?:t}3Mהu[IxLrJlDe_|f͛6l?.zlw'OSf;b+&,H"XaG 38ʝ6Fu2j6`nm%y1I@~*VtYt]VV6lRh.Ɨ}P)͛6lٳf͛6lٳf͛6lٳf͛6lٳ`siCJ)/.gi^ٟQs_D$נ2FFX  ]ڹyf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳngQ:KBK/MNңTv= C󗝮gxzl2sqkVHO.q8 ?6a,m!L, ZgXLIK*9ܝt9cRra >(:0G㇙GZ֭5ͫһ ҀW?** ]QZ7)F*C(Η6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳg<9!=SY򞗤ǣ\AUwuۄ_H?<3,?3,|X ՞.&LRA=6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6l7䇖5{_2AB?"tsK_î-<9 yu(`_I.;7>,l~c˩fu;ic2D*A43E<1 UᕅA1͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6D3oMo=ݥ4Nw?UVPP6BMY?'t4l iiP+$P)o4g0rط ~[qu̱[OaڶcuZҞpP@4`]$aSE~r*i>c?s=s:`(:L9g1׵%%ѮbRQ[).Uc *+) N<ĽFI}r[+Pm#:xI3; qA<2/풌ٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛)][ Аh}rO(WAŮ5ǖD;<+( 3f͐?'9yK40JIVɤv[Ye=O/Ag5/ x;4i#-K;WΖO{p+N&8Ky^.?BR4/KZco尖IO<)ǗȲuv6VSKPs45EY(kȿ]-6<覉f"G.4;lμ̽KNGin4e-A/*q R t(=oF?\(BT:|\k+Ҹ]_,eeҵe.$NhCFC-<ˮy -#S幝bҼr[@ݖ7q9 );:6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛#xusH[ SLg b1"ص+nMΩbZ[$Q_`5$$e+DAy/qoN 桨K귅}5~>@>ip {ye"TqJwlMռwO7c;$I;W D4ޙ׳f͛6%wikym-)qm:U(j#sk~Xn5Ѽx =o^Qt+V5}:RA%,OpF ͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛)ۊ3PO&9G?{W:lٳf͛9wʺǘ|Ù(ݱsٱmؓ~,St߯3wk*m_ -G"ìٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٰ40OEe ,Zi#Jǥpvlٳfv'&*M<ro*/1~y\]Ejh"j.H.uٳf͛6lȷSCTItJu&o}YƝy7Pk\izhi'M ّvhvFlٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lt^{?/E拱4ՙ]VlOFpTwȷ;ߘm+`ffn/ Auf5%OV=m VzY. ʈ6)\ٳe9*ʥ>휳ڦ~y6Ϣ̾W +2'6*Ӷ3f͛6lٳdo^Ei݁/떄%լ[߷UXuWa;^l:[uoz 1Ί#YhHUZ[}VNM1z1qU]_Ot6;-:+8j"b5RI@p[ykJD en FEk g0Flٳf'T|'3fO˞^PǪivȥL*;ղ-sS5ѺܑOWOkExE}OOhdӝwKս=OJ9y,ywOIi 7Z][jgՇ$7.Zk|r CʚV˺IjOmxzwgmYGH@yb$,lJ`yZ mtU}>J{ FJ3ysV.4V #xV>9'J;b/\gA͛6lٳf͛6@;ӧ?p]j+ =cX)QSC)4c<ѧZjTl,YY.-gV*i/('Fh:C:r>w7$5dHo 3f͛6lؔ I$PDOɿʽQ<$ݦ Dpp-"FuGg\h ȩ,.-'[{䦗cA/M>WE_^b8hri= !_:u_"_҆y;Q- !֗[<5{i4$YQ*JZ{Vм%V=̷6zToE[IұM4)=B  )LR]8z׶q# (j02[(uCT5B,(jIOKr=">hGԬ}3WoFCp7jG?2y*Tz)!-|kXFUԠJYv· O,2xBYXT2؂1f͛jwPӮoEVzWhJcWw˺i1uOKẐq'$ٳf͛6T3}\IPhE8K@%!G;sf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳfRJ$R)Y#`YH#9HmC]1ߓ.h5f^"4?4$Zzh7?Un$yf͛!?[5Mf͛6luDgcEPKar-y@/ך-G䋋&eT=ulٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳfϛ/O24vdvŽ 3Q*|0z."?1c-a-W1;"ݡ$~잌:dTMFIt{X\ƭ1d/Q6sbK[k[&ZK2YT<{:l(|=ykz͖U,8UvVDWus~pY{gE͛6D?6umFWkg{aH,ܔ0@cVH8?/*ޟAusiam)_PD n&9~.=<_m^Y mZZH2XAZڹ,/RdhFV+8֬{f焷wQ~k-9rT+߮uٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͉]ZZIkw \[L&U ###yvMW8mMڔ ~&s5CW6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳfczw+x2SڪUp_>J䗚73+$y`Uwe* 4I3bwVv[]B)IC ejkIZir1C@ D! 6;of͛6lP=ۊ3yR/8p œx^զr,ailf E?Kل!__6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛ <+aGuTa&@A,i'ONiJӐdVI&עNiwzKU{{bm+FFM,.&̫\ܧwqQ8H. 7}RH`(%W؀N'|XӼa,Zy]Y.V- p=wޤW͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6S$e T#+W9?.=ơ|%4]B"v)g6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lNѕŁC3ycBo)ykB;)gX͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛66QĴ|qlC/:S.'x#?\@3͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳdw~h YnJPzVydUvͰ$p?4?%kjΝ}MZL̖T~T`vSi5jƫVZyC4FݣOVX2}Euqkmm-ԩ J^i`VffIi Z~w5զ+d9+zutX3i?m5S6I^oX3i?m5 WMS^oX3i?m5S6I^oX3i?m5 WMSc?/f:k+m'?/f:k+3i_m5S6I^oX3i?m5S6I^oX~@Jo7ONIo7ONm+?/f:k+m'?/f:k?0zyJo7ONIo7ON? NIo7ONIo0yJ[ya_ͤuכV'LO'[yb~_ͤuכV?f:k+3i?m5S6I^oX3i?m5NIo7ONIo7?N? Cm*m5S6I^oX3i?m5S6I^ch|ͥ1^oX3i?m5S6I^oX3i?m5z.uH`}0F YPxqZf͛#uƽkc6v:֑tUܱ$&TJߕ/o4ykUQXVqp.>f?H4qehXÏ'yVG}CRծ<ìI0^" OJR4bI$x!xXeRD2BN/Οgf,E0iB/L7=[^MH^MH^MHK7o$󭟘V--t^E(TDW_&ՇNH?&ՇNH?&ՇNH?%ϛ4mr+;(-tkyhïWç$FoWç$FoWç$Fj\&Ceemo=BV]B"PM^rpћћф凗/k.[w5hza+ɿaӿ7+ɿaӿ7+ɿaӿ |g_LNtiV䶷);GJ/Jy/Im N$&_&ՇNH?&ՇNH?'wu}.OӥKwY'Ih^rL{͡iǩ6y7:w"A4fy7:w"A4a7+ycQѬ,tvpJ:hNtL{w&_&ՇNH?&ՇNH?)o取u+5cj6[G}%2-֟<3QHcMOEBiOJ+ɿaӿ7+ɿaӿ omW˺kXXOiZBZ&6HU4 yNKGir5S֕^MH^MHT{eam%ݼ-ZC S\C˟V|i7:eu^Ii)Z3!1S?&ՇNH?&ՇNH?N#E=OFA"AU(XycC򶕢i:ƝmZBR`Wç$FoWç$FZ3j؋Ha+<*%华=l{%!vNw oXtDh oXtDh̾Kr:iх>YDn!o} iT(&JL͛6lٱ9!T;CsMJٰ+jZ+5Rt21qy ͛ɫiq1i^@dɤA;XTSr ͛ݢYP )y$"TM@M+6j^g֗uYXL(dpMTvRjv fē_gG$,J9.@,݆ ͛ u_3yoG(mZNpL1E80YYC)H#pA͛,4I/5 "wXPM'rni#0d` 5eo/le;kXW:((5ە)sc)$TbD(9QRe-ŻN*CA0P ^b\[񤲢<%fP(=Mv?Ki_Er~U=NWzSfKq%,fV͂sVILAm-uԤC*XNю"2Y\AS4vv TW=6kX"{G`Gn( &͛6lٳg%o9q 70Gus 9^랯ƛε6r3]~]?zf 0\):k A(GҤӪ͜t]i`d֊܅W(ulyg|?^XMlWK#yG N>ĀSe͛8憕X5fS}彤VV+ȡ$L YAN sf=Gfծm~{8q;3#%Pı@ ׉Qީyz.-O! ;׋06A?4t#Q>6m}7ieoq5W/oj?}w 2Qn›855 (@fmtYj.ްHzx&5*(ltLZmE PtVl~m Kj-{ =A,n247%RcÒok Nz|:+Hq5(`q$Ѩ`!d Pd6rs:ϑ任RnOg$P`Vbr=͂#A[#A hmƑ*ʋNYg-3j7vfY9zٵjYsmCr%,s@qeu tPgP*MsE1+qctvc%DBSZji6s?-CZn&<0EfPK8@L{ yw^zw]/Yk0K%6c;>ҙ(yzY:sf͛6l٨<=f͕kZ ͛5kMsf͛6l٨+Zn:ٳf f͛6lٳ6l(w͛6j ٳPxfilوAQ߾^lW5kMW6lW6lٳf͛6lٳf͛6lٳf͛6lٳf͛6Fw<1v6M".cnP 8SMOA&g( k۝9.ad_O״6}>Gg{6tG7q-O4nLah(bT꺞s\iz6Ki42mugr`rQQjj"H+Dg)Xd j2KOuocq=6xm3+U@E^Gj9;yP4KDCԴcmi#Ie軌͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6E?1,~fXԴ (؆ݜpY54jZlՃM!bPϓsizfinZYư[( *c򷗼bf,D^,=8*_P+[^ -ĺr8|#n n)Z|v[Mq 9)~1$0 J8UU loˉz +ڹ?,_>6 a$I ڡgS͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6Fk l4OYkK#Z-MvV 95p'R?@kZXDwx_fjn>Zh[k(?,A.E|Ӽ~e0#UAGz7|aC!mҁYX-O2;qm6ws^—(\A (v ayNѬ`ƒ[[ :Rsf͜E͏?:zF?B+vAnNpw+^[sͷ/{y{Sf,vnwٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛66AY}Ρ{('fĥݍ<W9΁{嫝+O!GԤ[igYx,[Ps][wnk,2 H2A_;G,:[u' OAwwkq`׫ZV&n*n˼AܙBA;>ptKߚ4gV(% gZdi'寙3ZEu;-x9զj7aaq{$r̖ѴARƵfcM^^u8--"i* yT)jM͛9ΌE΃6SHtaPA؂sY-?+{8X hƭ4 *dN/ @֗v]L0ttaUeabf͛6lٳf͛6lٳf͛6lٳf]9Xծ턺li<^3/@-yoCZ%-бPy1Ͼf͛6lٳf͛6%-2[8$i=VѬXlq=qȺǡKӯiz]JySR⑤N̑N*"QA((xjSyVfmmHYA3'?]ԭond6wɖٛ[JZxV+^u8'w-Xå>=/NӬ!YFA UQAܟw8!*3HPITs_=j k Ϛ][E'[k0o"J|ydKOӵXk-!Ԣq"] f/I+ZM%fʬXP 45O[u] /3/.jzz KB5=?U:;2:0e#͛6lٳf͛6lٳf͛6lٳf͜$ߚf&O>Ccf͛6lٳf͛ g5;(.EV!i#e?5،i_7ϡo1JߢV(ğS'5Դ{.k'խAEoMG ͛6STf XHQJa\ߖڕ֥˝:Jƒ [yoܼF>,Yf͛6lٳjz6BX7NYUv5{=? ]g:6kZ]]Gyݠ#Ue?ٳf͛6lٳfͅksڤ&{9YY$ W㉑##AҬc[ EY睤gp6t|ٳf͛6l?M`bd/?V;6lٳf͛6lٰXZ&_Ki7V)PE'~,45o-E6g&Oc&E P:5zzg[kM:չ[[P1<(U<:ٳe;R u4+U0<q](B[ʡʼZtٳf͛6lٳk^_ּy]^UoUۼٗ3.Fo+ucr* M̬*\2͛6lٳf͛6la*\f͛6lٳfo_3'v!ٳf͛6lٳfͅiF"o-d1f>ʟVBz/͕ Pj3ZeVSNCaamcL6$r5n1UřEX'a$GuNl9*ǠY B]vSG&Zҧ¹Ϳ-u{?>M&|IkP@:Vlٳf͛6lٲ+^<=iO- x+xѺI[z6J|m̺D:?k-U$D4xQȍ+nf͛6lٳf͈_YZ!{Eu@KDo?9+-_]\r1k'7"?FA+7yJV{RRJk$8Sc9~4qD龈H_ls~jyϘv ,TWONU?4{p lR1t)#KhNrsY,٭@\JÄj>^`D-*)Qk{1)}y[Q:}V|k,+/?4.ߘf6UF̤7#?d1|4+ǰ_|Q'}d17DAb!ߛY+<˩Cu_k./u+ˍĉ@zl.KϜV;/1c+[}u[[hfKiI 0ttaPPAlٳf͛6lٳ{\OKt={Y:ז,-DWDfxݓҊ *]9:g9|}K ]ƕ-yٴ0QphMzGDX w?n%~qrBEH\oq'DeqAQ͂4#ڧ5mjZחYr_RjWWC\m? tž_-Ga<>f7ll[.H<6ܺ|\rqD\苫/U^_oJ/滆ylqAl\D$p*̂ڴ{mu~aUƗ|H,u Oqڙsf͛6lٳf͛ g򦳤kQ$4oNTP~Wh?8mͽFt"ǧjE6D^Uto=E]yFcQzu1OʢE=1j.Mf=>q_.MԞ_FK4DX>5U- ȷ䳻Yh'\2m6lٳf͛9I5LKq80 Aא5+\˩\M3K{aͻ5Mg) zd^w/-#7E.KE _C44D#%Oᒌٳf͛6lٲ8B(t=UA!uieMݴW+ʊZr*U(lՕ;SVTW acd(żb;r഍B eii,m$lARխH#q\Sj9.aZ?Wӡ+׶tٳf͛6lٳf͐4y/PYy="d煮nhTu5* WlyGIl+?ޫsͦZiO%;b)#$9!>|˾2 (:n$ac[S@$Y[_1ƆW][yĺoմ1Y_園,ږ&:/V4\I")Ҽ}"$J,#(OFk6lٲ'E\T8͛6lٳf͜$ߚf&O>Cc;F`j1&Lf͛6lٳag fJFҎ~;陳f͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͘*g7-t =v_+{P[ɮ5eҌ4a[/>M+~mͣYGa OP[àe0>nd@ث l_o2sa[{q }S~UypDwaY[6([ &V1:q,~bյ'hx%DIT"x]͛6lj:o\G}勤4;E]}j5`Bq~2K+2nIMRmOVdH#eE 5ڧsW7v7G=w0̡xQն*GZ21y1IlSC_^1odˮuLٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳe;*g (=kTѵ?_>v׺{ %cH-(tٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳe;*3}{g04=_~{4ԆH%R&ߎ3f͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͔$ 曮~byPgii(- 8J}͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٲ+um#Q:.?S҈MN8y=V/KKHʬͥM#@K|ߜJH>SMG_9Y_lTO3S?nH@|Nє`Ap>[ϖt/M$d odeA@[lXb42fd[i)Vd(J֢63A Ѵ=?HH4hm"B AKR.;6vfΧdT{id%y+eo o IXQIË́r򭗚>{,[%$4 pr (Z f̈́i򵟘.ӵ MN#RQ,Ef̈́muy[@GXdbva7|iC'QT sߗz{lQjUtMFi]KxЎ4[v 1"6lٳf͛6yB-ǖkn.p"C@8q6G-Ov0^"Zqo$V2B+4V8 +7`J6l^|е-zm 0l/-KKF(cf|fͅ_]O\K)j+ąSr fMi `mOQ4۽JZYC%ÀXq)w4*/$=feMқ{+ y HX09"GH ,Ÿ/AGL2ZYMiq#[f "@oSf|ϠkCu[F+5FNf͛6lٳg5^U^:PѿJsuq}ON˶tٲksjKy_RKktFGkZ)2| |*iܜ͜GȺn4=>Vn# ҺIm*/Sۢzmzl!4΀`QQ>{м 0e=ŞݜOKzQZ 0z_ך*wZOly)q%@>*{yv֟wVN-->b1S9q铵>0^.zE%ƢmL "I m'rNMs@HOtW~w[Ek褑΄=7#ѵ7HS_]ͤWjB#/|]e'qZ\d 75=ߘ'Gw S4߅°ue_R 6޹7ѼɣyNu8gXGR~)7`ܺɆlٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳfci:m,1OJ7P20s~O1dyW\HNy'}-*wN4&C\iC[Kikmo"~]C:RCI ]&U$V[r㵍ڃ9f~F:"j}=j(%_ m(UskSyCImj-Yiq%#P%ixEV\>͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf͛6lٳf1ĉlc:w30`>J=)LG8ezl2H8`#`Vw<\,xy|oS}sSS@=>,]EF#i4b  dޓրdDs M > endobj 17 0 obj <>/ProcSet[/PDF/Text]/ExtGState<>>> endobj 18 0 obj <>stream /GS1 gs BT /F5 1 Tf 8.9663 0 0 8.9663 59.7543 725.7825 Tm 0 0 0 1 k 0 Tc 0 Tw [(acupuncture)-393.7(points,)-395.1(either)-387.3(by)-388.2(manipulation)-393(or)-389.2(by)-388.2(applying)]TJ 0 -1.2203 TD [(electric)-278.5(pulses)-274.3(or)-275.4(other)-279.1(appliances.)-274.8(The)-278.2(acupuncture)-273.5(protocol)]TJ 0 -1.2266 TD [(was)-438.7(selected)-437.3(based)-431.8(on)-436.1(the)-433.7(ve-phase)-439.5(acupuncture)-444.2(method)]TJ 0 -1.2203 TD [(using)-355.4(ve)-345.1(inductive)-350.3(points)-354.3(in)-348.4(TKM,)-349(which)-352.7(is)-346.3(different)-353.3(from)]TJ T* [(the)-395.8(Traditional)-389.7(Chinese)-391(Medicine)-390.7(\(TCM\).)-391.5(In)-391.2(TKM,)-386.9(the)-395.8(acu-)]TJ 0 -1.2266 TD [(puncture)-380.9(works)-377.6(by)-375.6(applying)-375.6(acupuncture)-381(to)-376.3(the)-376.8(12)-372.1(meridi-)]TJ 0 -1.2203 TD [(ans)-503.7(and)-505.4(5)-505.3(inductive)-502.1(points.)]TJ 6.7246 0 0 5.9768 174.3307 663.9872 Tm [(27,34)-9.4(,35)]TJ 8.9663 0 0 8.9663 202.4503 660.0187 Tm [(Each)-504.7(inductive)-502.1(point)-511(is)]TJ -15.9148 -1.2203 TD [(assigned)-579.1(to)-578.6(Wood,)-579.6(Fire,)-574.2(Earth,)-579.1(Metal,)-574.2(Water)-581.3(of)-572.3(the)-579.1(ve)]TJ 0 -1.2266 TD [(phases)-512.6(with)-508.5(the)-509.6(characteristics)-511.7(of)-509.1(each)-507.9(elements,)-508.4(whereas)]TJ 0 -1.2203 TD [(eight)-378.4(principles)-378.3(in)-373.6(TCM)-375(includes)-382(Interior)-374(and)-379(Exterior,)-376.6(Hot)]TJ T* [(and)-341(Cold,)-341.2(Full)-335.3(and)-341(Empty,)]TJ /F7 1 Tf 12.336 0 TD (Yin)Tj /F5 1 Tf 1.8273 0 TD (and)Tj /F7 1 Tf 2.017 0 TD (Yang)Tj /F5 1 Tf 2.1561 0 TD (.)Tj 6.7246 0 0 5.9768 226.4314 620.1636 Tm (36)Tj 8.9663 0 0 8.9663 236.1826 616.1951 Tm [(These)-342.6(inductive)]TJ -19.6769 -1.2203 TD [(points)-284.7(represent)-292.2(the)-282(ow)-285.6(of)]TJ /F7 1 Tf 12.4308 0 TD (Qi)Tj /F5 1 Tf 1.3215 0 TD [(inside)-286.6(the)-282(12)-283.6(meridians)-284.3(using)]TJ -13.7523 -1.2266 TD [(the)-522.2(ow)-525.9(of)-515.4(Water)-524.4(as)-519.3(metaphor.)]TJ 6.7246 0 0 5.9768 193.4362 598.2802 Tm (30)Tj 8.9663 0 0 8.9663 204.8314 594.2549 Tm [(Therefore,)-525.8(acupuncture)]TJ -16.1803 -1.2203 TD [(applied)-341(to)-332(an)-338(appropriate)-333.6(point)-340.3(of)-332(specic)-336.5(element)-339.8(can)-337.3(alle-)]TJ T* [(viate)-408.8(the)-402.1(symptoms,)-408(even)-402.3(though)-407.8(the)-408.4(acupuncture)-406.3(point)-409.9(is)]TJ 0 -1.2266 TD [(not)-335.4(near)-338.6(the)-332.5(body)-337.1(part)-330.8(causing)-335.3(symptoms.)]TJ 1.1128 -1.2203 TD [(Hot)-338.3(ashes)-337.2(are)-335.2(considered)-339.3(to)-338.4(be)-333.1(a)-334.6(classical)-339.6(sign)-335.1(of)-338.4(meno-)]TJ -1.1128 -1.2203 TD [(pausal)-404.9(symptoms)-398.8(and)-404.2(can)-394.2(be)-402.7(measured)-401.6(via)-402.1(self-report.)-400.2(Al-)]TJ 0 -1.2266 TD [(though)-287.7(self-reports)-284.8(of)-281.5(hot)-284.8(ashes)-286.6(are)-278.3(generally)-284.9(considered)-282.4(to)]TJ 0 -1.2203 TD [(be)-244.6(acceptable)-241.1(for)-244.2(assessment,)-242.9(women)-245.5(with)-243(hot)-240.6(ashes)-242.4(tend)-240.7(to)]TJ T* [(under-report)-274(hot)-272.2(ashes,)-264.3(resulting)-271.5(in)-266.2(high)-267.6(specicity)-275.3(but)-265.5(low)]TJ T* [(sensitivity)-528.4(of)-515.4(subjective)-521.7(measurement.)]TJ 6.7246 0 0 5.9768 215.9999 499.6345 Tm (37)Tj 8.9663 0 0 8.9663 227.3952 495.666 Tm [(There)-519(are)-518.6(several)]TJ -18.6968 -1.2266 TD [(studies)-402.9(to)-395.3(compare)-393.1(subjective)-395.2(and)-397.9(objective)-395.3(method)-399.1(for)-396(as-)]TJ 0 -1.2203 TD [(sessing)-438.8(hot)-430.3(ashes.)]TJ 6.7246 0 0 5.9768 137.3669 477.6943 Tm (3739)Tj 8.9663 0 0 8.9663 158.0598 473.7259 Tm [(Carpenter)-429.7(et)-436.6(al.)]TJ 6.7246 0 0 5.9768 221.6125 477.6943 Tm (37)Tj 8.9663 0 0 8.9663 232.2141 473.7259 Tm [(and)-429.5(Otte)-433.8(et)-430.3(al.)]TJ 6.7246 0 0 5.9768 292.1385 477.6943 Tm (38)Tj 8.9663 0 0 8.9663 59.7543 462.7841 Tm [(assessed)-507.1(hot)-506.1(ash)-506.7(frequency)-507(using)-507.2(self-report)-511.1(and)-505.4(sternal)]TJ 0 -1.2266 TD [(skin)-581.7(conductance)-580.7(monitoring,)-581.9(and)-581.3(the)-579.1(ndings)-578.5(indicated)]TJ 0 -1.2203 TD [(dissimilarities)-532.1(between)-534.4(subjective)-534.3(and)-524.4(objective)-534.4(measures.)]TJ T* [(Kim)-389.6(et)-386.1(al.)]TJ 6.7246 0 0 5.9768 99.8362 433.8707 Tm (39)Tj 8.9663 0 0 8.9663 109.9842 429.9023 Tm [(assessed)-393.3(hot)-386(ashes)-387.8(by)-381.9(using)-387.1(Mexameter,)-387.5(Skin)]TJ -5.6021 -1.2266 TD [(Thermometer,)-527.3(Corneometer,)-523.3(and)-524.4(Laser)-516.6(Doppler)-523.2(Perfusion)]TJ 0 -1.2203 TD [(Imager)-484.8(objectively,)-488.4(and)-486.4(results)-489.1(indicated)-483.5(weak)-486(correlation)]TJ T* [(between)-439.6(subjective)-433.2(and)-429.5(objective)-433.3(measurements)-439.2(of)-433.2(hot)-430.3(a-)]TJ 0 -1.2266 TD [(shes.)-280.7(Although)-280(previous)-277.2(studies)-276.4(show)-274.7(no)-278(objective)-281.5(measures)]TJ 0 -1.2203 TD [(of)-452.2(changes)-447.5(in)-449.5(hot)-449.2(ashes,)]TJ 6.7246 0 0 5.9768 164.5795 379.0487 Tm [(37)-9.1(39)]TJ 8.9663 0 0 8.9663 185.4425 375.0802 Tm [(the)-452.7(authors)-445.8(tried)-450.2(to)-452.2(include)]TJ -14.0179 -1.2203 TD [(objective)-376.4(measure)-373.3(to)-370(explain)-373.8(the)-376.8(phenomena)-371.6(of)-370(hot)-373.4(ashes.)]TJ T* [(On)-360.5(the)-357.8(basis)-364.2(of)-357.3(the)-357.8(ndings)-363.5(that)-357.9(the)-357.8(subjective)-363.6(sensation)-363.4(of)]TJ 0 -1.2266 TD [(Heat)-562.6(is)-561.3(the)-566.5(predominant)-565.7(feature)-565(of)-559.7(a)-562.2(hot)-563(ash,)-560.2(infrared)]TJ 0 -1.2203 TD [(thermography)-581.3(was)-571.5(used.)-571.2(Thermography)-577.5(ndings)-572.1(from)-576.9(a)]TJ T* [(small)-492.3(group)-491.1(of)-496.4(patients)-490.5(have)-496.7(provided)-489.2(objective)-496.5(evidence)]TJ 0 -1.2266 TD [(that)-427.5(menopausal)-421.2(ushing)-425.1(is)-415.8(associated)-427.9(with)-420(an)-420.2(increase)-424.8(in)]TJ 0 -1.2203 TD [(skin)-366.7(temperature.)]TJ 6.7246 0 0 5.9768 129.8834 302.3432 Tm (40)Tj 8.9663 0 0 8.9663 139.8614 298.3748 Tm [(The)-366.7(current)-366.2(study)-364.6(measured)-363.7(facial)-359.9(tem-)]TJ -8.9343 -1.2203 TD [(perature)-509.7(during)-509.6(hot)-506.1(ash)-506.7(episode)-511.3(and)-505.4(analyzed)-512.3(the)-503.3(tem-)]TJ 0 -1.2266 TD [(perature)-642.5(differences)-644.1(between)-635.6(high)-640.7(and)-638.2(low)-633.9(temperature)]TJ 0 -1.2203 TD [(areas)-310.8(to)-313.1(compare)-310.9(the)-313.6(change)-313.4(in)-310.4(skin)-309.8(temperature)-318(before)-311.7(and)]TJ T* [(after)-538.5(acupuncture)-539.1(treatment)-539.8(across)-536(individuals.)-541.5(However,)]TJ T* [(the)-522.2(relationship)-516.6(between)-521.8(differences)-517.7(in)-519.1(facial)-511.7(temperature)]TJ 0 -1.2266 TD [(and)-435.9(hot)-430.3(ashes)-432.1(was)-432.4(dissimilar)-428.5(at)-436.3(each)-432(measurement)-431.5(point)]TJ 0 -1.2203 TD [(from)-444.1(baseline)-445.4(to)-439.5(the)-446.4(end)-442.6(of)-439.5(the)-446.4(study,)-443.4(which)-441.2(is)-441.1(consistent)]TJ T* [(with)-337.8(the)-332.5(results)-337.4(of)-338.4(previous)-334.1(studies.)]TJ 6.7246 0 0 5.9768 203.1306 214.696 Tm (3739)Tj 8.9663 0 0 8.9663 69.7323 199.729 Tm [(Acupuncture)-256.4(is)-245.1(a)-252.4(relatively)-250.2(safe)-247.8(treatment)-255.3(modality.)]TJ 6.7246 0 0 5.9768 273.3732 203.7543 Tm (30,41)Tj 8.9663 0 0 8.9663 290.7779 199.729 Tm (In)Tj -25.7659 -1.2203 TD [(previous)-359.4(studies,)]TJ 6.7246 0 0 5.9768 127.4456 192.7559 Tm (1820)Tj 8.9663 0 0 8.9663 147.4582 188.7874 Tm [(no)-353.9(reported)-350.2(adverse)-359.1(events)-353.5(were)-349.9(seri-)]TJ -9.7815 -1.2203 TD [(ous)-308.9(enough)-312.4(to)-306.7(warrant)-309.4(concern.)-308.8(Several)-312.6(studies)-308.1(have)-307(shown)]TJ 0 -1.2266 TD [(additional)-332.1(benets)-322.2(of)-325.7(acupuncture,)-333.3(including)-328.9(improvements)]TJ 0 -1.2203 TD [(in)-474.8(emotional)-468.7(and)-467.5(physical)-471.6(well-being,)]TJ 6.7246 0 0 5.9768 214.8094 159.874 Tm (16,19,22)Tj 8.9663 0 0 8.9663 242.5889 155.9055 Tm [(and)-467.5(increased)]TJ -20.3914 -1.2203 TD [(sex)-389.1(drive)-393.6(in)-386.3(some)-387.2(women.)]TJ 6.7246 0 0 5.9768 166.8472 148.9323 Tm (19)Tj 8.9663 0 0 8.9663 177.0519 144.9638 Tm [(Reported)-391.7(adverse)-390.8(events)-391.4(were)]TJ -13.0821 -1.2266 TD [(slight)-288.5(bleeding)-287.7(or)-288(bruising)-288.2(at)-290.8(the)-288.3(needle)-287.8(site.)]TJ 6.7246 0 0 5.9768 235.1621 137.9905 Tm (18)Tj 8.9663 0 0 8.9663 244.4598 133.9653 Tm [(In)-283.7(the)-288.3(present)]TJ -20.6 -1.2203 TD [(study,)-373.9(there)-377.4(were)-375.2(no)-372.9(serious)-377.6(adverse)-371.8(effects,)-377.8(which)-371.6(is)-377.9(com-)]TJ T* [(parable)-337.7(with)-331.5(the)-338.9(ndings)-331.9(of)-338.4(previous)-334.1(studies.)]TJ 1.1128 -1.2203 TD [(The)-309.8(present)-310.5(study)-307.7(had)-303.1(several)-309.1(limitations.)-313.4(First,)-304.2(the)-307.3(study)]TJ -1.1128 -1.2266 TD [(consisted)-394.3(of)-382.6(a)-385.2(small)-384.8(sample)-388.9(and)-385.3(was)-388.1(conducted)-385.5(at)-385.7(a)-385.2(single)]TJ 0 -1.2203 TD [(acupuncture)-305.1(clinic.)-300(The)-297.1(participants)-299(were)-299.3(treated)-301.1(by)-293.4(a)-296.7(single)]TJ T* [(acupuncturist)-848(\(Kwon\))-846.2(who)-842.4(was)-843.4(also)-841.8(the)-844.7(investigator.)]TJ 0 -1.2267 TD [(Therefore,)-500.5(the)-496.9(relatively)-496.8(small,)-495.2(selective)-501.8(sample)-496.4(limits)-496.8(the)]TJ 28.0042 74.5598 TD [(ability)-259.7(to)-262.5(apply)-263.1(the)-256.7(results)-267.8(to)-262.5(the)-256.7(general)-264.3(population.)-263.2(Second,)]TJ 0 -1.2203 TD [(the)-503.3(design)-502.4(of)-502.8(the)-509.6(study)-503.7(is)-504.4(not)-499.8(optimal.)-504.8(The)-505.8(study)-503.7(was)-502(a)]TJ 0 -1.2266 TD [(single-arm,)-567.3(observational)-566.3(study)-567(without)-563.7(a)-562.2(control)-569.3(group.)]TJ 0 -1.2203 TD [(Without)-466.3(a)-467.4(placebo)-472.3(or)-465(proper)-468.4(control)-474.5(group,)-468.8(the)-465.3(benecial)]TJ T* [(effects)-248.4(of)-249.8(acupuncture)-254.6(can)-248.8(be)-244.6(overestimated.)-253(A)-248(large,)-244.9(double-)]TJ 0 -1.2266 TD [(blind,)-514(randomized,)-515.3(controlled)-518.9(trial)-513.6(is)-517(required)-519.3(to)-515.4(provide)]TJ 0 -1.2203 TD [(reliable)-672.6(evidence.)-682.8(Third,)-674.1(the)-680.3(follow-up)-675.5(period)-681.5(after)-677.6(the)]TJ T* [(treatment)-577.8(may)-570.6(not)-575.7(have)-578.9(been)-576.7(of)-572.3(sufcient)-575.5(duration.)-580.4(Al-)]TJ 0 -1.2266 TD [(though)-420.5(the)-414.7(effects)-419.1(of)-420.6(acupuncture)-419(were)-419.4(maintained)-418.5(at)-417.3(a)-416.8(4)0(-)]TJ 0 -1.2203 TD [(week)-246.1(follow-up)-251.8(in)-247.2(this)-249(study,)-247.4(long-term)-253.5(follow-up)-251.8(results)-248.9(are)]TJ T* [(required)-399.2(to)-401.6(clarify)-403.5(the)-402.1(efcacy)-404.2(of)-401.6(acupuncture,)-409.2(because)-404(the)]TJ T* [(duration)-394.1(of)-388.9(the)-395.8(intervention)-395.2(was)-394.5(shorter)-394.9(than)-392.4(those)-393.5(of)-388.9(pre-)]TJ 0 -1.2266 TD [(vious)-344.8(studies.)]TJ 6.7246 0 0 5.9768 365.4991 598.2802 Tm (1820,22)Tj 8.9663 0 0 8.9663 393.8456 594.2549 Tm [(Finally,)-347.7(a)-347.3(validated)-348.3(measure)-348(of)-351(hot)-348.1(a-)]TJ -9.2567 -1.2203 TD [(shes)-391.6(was)-394.5(not)-398.7(included)-396.4(in)-392.6(this)-394.4(study.)-399.2(It)-394.6(would)-391.7(be)-396.3(helpful)-399.2(if)]TJ T* [(objective)-660.9(measurements)-666.8(of)-667.1(changes)-662.5(in)-664.5(hot)-664.2(ashes)-659.7(were)]TJ 0 -1.2266 TD [(available,)-409.1(as)-405.5(facial)-410.5(temperature)-412.8(measured)-414.2(by)-407.2(infrared)-415.9(ther-)]TJ 0 -1.2203 TD [(mography)-336.6(failed)-332.4(to)-332(show)-337.9(reliable)-337.5(results)-331.1(in)-335.7(this)-337.5(study.)]TJ 1.1128 -1.2203 TD [(Despite)-652.8(these)-662.5(limitations,)-654.8(to)-660.8(the)-655(best)-657.4(of)-654.5(the)-655(authors)]TJ -1.1128 -1.2266 TD [(knowledge,)-316.7(this)-318.5(is)-314.7(the)-313.6(rst)-315.3(study)-314.1(to)-319.4(show)-312.6(the)-319.9(feasibility)-315.5(and)]TJ 0 -1.2203 TD [(safety)-524.6(of)-528(acupuncture)-532.8(for)-528.7(the)-528.6(treatment)-533.5(of)-521.7(hot)-531.4(ashes)-526.9(in)]TJ T* [(Korean)-344.2(patients)-345.1(with)-337.8(breast)-347.7(cancer)-343.5(who)-336.6(are)-341.5(undergoing)-349.3(an-)]TJ T* [(tiestrogen)-320.4(therapy.)-322.5(The)-316.1(results)-324.7(of)-319.4(this)-318.5(study)-320.4(showed)-321.8(a)-315.7(mean)]TJ 0 -1.2266 TD [(reduction)-280(of)]TJ /F6 1 Tf 5.6211 0 TD (>)Tj /F5 1 Tf .7208 0 TD [(60%)-278.9(in)-272.5(hot)-284.8(ashes,)-276.9(which)-276.8(is)-276.7(comparable)-280.4(to)-281.4(the)]TJ -6.3419 -1.2203 TD [(results)-539.7(of)-534.4(previous)-536.5(studies.)]TJ 6.7246 0 0 5.9768 423.3826 477.6943 Tm (13,16,17)Tj 8.9663 0 0 8.9663 451.729 473.7259 Tm [(Furthermore,)-539.6(this)-539.8(study)]TJ -15.7124 -1.2203 TD [(was)-615.8(performed)-619.7(with)-622.3(a)-612.8(standardized)-623.8(algorithm)-616.6(of)-616.6(TKM,)]TJ 0 -1.2266 TD [(which)-498.1(allows)-499.2(for)-497.1(replication)-504.8(in)-500.1(future)-503.8(biomedical)-497.6(studies,)]TJ 0 -1.2203 TD [(and)-239.8(suggests)-242.1(that)-244.1(TKM)-238.6(may)-241.8(be)-238.3(a)-239.8(viable)-245.6(treatment)-242.6(for)-244.2(women)]TJ T* [(with)-356.8(chemotherapy-induced)-368(menopause-related)-368.6(hot)-360.7(ashes.)]TJ 0 -1.2266 TD [(This)-371.6(studys)-380.5(results)-375.3(provide)-378.7(important)-376.5(preliminary)-378.5(data)-375.5(in-)]TJ 0 -1.2203 TD [(dicating)-289(that)-288.4(acupuncture)-298.8(is)-289.4(a)-284(good)-291.2(alternative)-296.2(treatment)-293.2(for)]TJ T* [(hot)-335.4(ashes)-330.9(among)-336.4(patients)-338.7(with)-331.5(breast)-341.4(cancer)-330.9(in)-335.7(Korea.)]TJ /F3 1 Tf 0 -2.4217 TD (Conclusions)Tj /F5 1 Tf 1.1128 -1.8336 TD [(The)-448.9(present)-456(results)-457.5(showed)-454.6(the)-452.7(feasibility)-454.6(and)-454.8(safety)-455(of)]TJ -1.1128 -1.2266 TD [(acupuncture)-400(for)-402.3(the)-395.8(treatment)-407(of)-395.3(hot)-398.7(ashes)-400.5(in)-398.9(Korean)-401.1(pa-)]TJ 0 -1.2203 TD [(tients)-628.7(with)-628.7(breast)-632.3(cancer)-628(receiving)-635(antiestrogen)-633.1(therapy.)]TJ T* [(These)-348.9(ndings)-344.5(suggest)-348.3(that)-351.6(acupuncture)-349.4(is)-346.3(a)-347.3(useful)-349.4(alterna-)]TJ T* [(tive)-270.2(treatment)-280.6(for)-269.5(alleviation)-273.3(of)-275.1(facial)-271.4(ashes)-274(in)-272.5(patients)-275.5(with)]TJ 0 -1.2266 TD [(breast)-423.6(cancer)-432(who)-425.1(are)-423.7(undergoing)-431.5(antiestrogen)-430.8(therapy.)-423.6(A)]TJ 0 -1.2203 TD [(randomized,)-629.1(controlled,)-629.3(prospective)-631(study)-630.2(with)-622.3(a)-625.5(larger)]TJ T* [(sample)-306.7(size)-307.8(is)-308.3(required)-304.4(to)-313.1(clarify)-302.3(the)-313.6(efcacy)-303(of)-313.1(acupuncture)]TJ 0 -1.2266 TD [(for)-332.7(such)-334.1(patients)-338.7(in)-335.7(Korea.)]TJ /F3 1 Tf 0 -2.8327 TD (Acknowledgements)Tj /F5 1 Tf 1.1128 -1.8336 TD [(This)-415.9(study)-415.2(was)-413.4(supported)-416.9(by)-413.5(a)-416.8(grant)-419.5(of)-414.2(the)-414.7(Ministry)-420.8(of)]TJ -1.1128 -1.2203 TD [(Health)-329.3(and)-328.4(Welfare,)-328.4(Republic)-327.4(of)-325.7(Korea)-328.2(\(Project)-332.4(No:)-328.1(20-11-0-)]TJ T* (090-091-3000-3033-320\).)Tj /F3 1 Tf 0 -2.447 TD [(Disclosure)-336.7(Statement)]TJ /F5 1 Tf 1.1128 -1.8336 TD [(The)-360.4(authors)-369.9(declare)-366.2(that)-364.2(no)-366.6(competing)-373.1(nancial)-362.9(interests)]TJ -1.1128 -1.2203 TD (exist.)Tj /F3 1 Tf 0 -2.447 TD (References)Tj /F5 1 Tf 8.4682 0 0 8.4682 315.0424 120.1323 Tm [(1.)-501.9(Korea)-494.4(Central)-499.7(Cancer)-498.3(Registry.)-493.1(Annual)-501.3(Report)-492.9(of)-496.1(Cancer)]TJ 1.2519 -1.2385 TD [(Statistics)-474.4(in)-459.2(Korea)-467.6(in)-465.9(2008.)-461.4(Seoul:)-466.8(Ministry)-471.7(of)-462.6(Health)-469.4(and)]TJ 0 -1.2318 TD [(Welfare,)-336.2(2010:25.)]TJ -1.2519 -1.2385 TD [(2.)-501.9(Kohler)-315.5(B,)-310.9(Ward)-309.4(E,)-304.2(McCarthy)-313.5(BJ,)-310.2(et)-314.6(al.)-308(Annual)-313.8(Report)-312.1(to)-308.6(the)]TJ 1.2519 -1.2318 TD [(nation)-358.6(on)-359.9(the)-351.9(status)-363.3(of)-355.5(cancer,)-358.7(19752007,)-351.5(featuring)-363.3(tumors)]TJ 0 -1.2385 TD [(of)-422.4(the)-418.8(brain)-421.4(and)-419.5(other)-423.4(nervous)-419.6(system.)-423.3(J)-421.1(Natl)-418.2(Cancer)-418(Inst)]TJ 0 -1.2318 TD (2011;103:714736.)Tj /F3 1 Tf 8.9663 0 0 8.9663 59.7543 749.7069 Tm [(ACUPUNCTURE)-340.1(AND)-337.2(HOT)-334(FLASHES)-339.4(IN)-328.8(BREAST)-338.7(CANCER)-340.8(PATIENTS)-19735.3(695)]TJ ET endstream endobj 19 0 obj <> endobj 20 0 obj <>/ProcSet[/PDF/Text]/ExtGState<>>> endobj 21 0 obj <>stream /GS1 gs BT /F5 1 Tf 8.4682 0 0 8.4682 66.274 725.7825 Tm 0 0 0 1 k 0 Tc 0 Tw [(3.)-501.9(Kronenberg)-377.2(F.)-369.6(Hot)-377(ashes:)-375.8(Phenomenology,)-381.3(quality)-373.5(of)-375.5(life,)]TJ 1.2519 -1.2318 TD -.0371 Tc [(and)-303.4(s)-2.7(e)-4.3(a)-5.7(rch)-301.9(f)-3(o)-4.9(r)-301.5(tr)-6.9(ea)-5.7(tme)-4.3(n)-7.4(t)-297.5(o)-4.9(p)-6.5(t)-3(io)-4.9(ns.)-302.6(E)-8.9(xp)-301(Ge)-4.3(ro)-4.9(nto)-4.9(l)-305.1(19)-5.7(94)-5.7(;29)-5.7(:)-1.3(31)-5.7(9)-5.7(33)-5.7(6.)]TJ -1.2519 -1.2385 TD 0 Tc [(4.)-501.9(Carpenter)-874.5(JS,)-876.3(Andrykowski)-877.8(MA,)-874.9(Cordova)-872.1(M,)-875(et)-877(al.)]TJ 1.2519 -1.2318 TD [(Hot)-437.3(ashes)-438.4(in)-432.4(post)-437.7(menopausal)-445.3(women)-440(treated)-439.1(for)-432.4(breast)]TJ 0 -1.2385 TD [(carcinoma:)-644.8(Prevalence,)-653(severity,)-654.3(correlates,)-648.5(management,)]TJ 0 -1.2318 TD [(and)-332.4(relation)-338.8(to)-335.4(quality)-333.4(of)-335.4(life.)-332.8(Cancer)-337.7(1998;82:16821691)-7(.)]TJ -1.2519 -1.2385 TD [(5.)-501.9(Holmberg)-284(L,)-284.1(Andersson)-290.5(H.)-280.3(HABITS)-290.2(\(hormonal)-291.5(replacement)]TJ 1.2519 -1.2318 TD [(therapyis)-251.4(it)-253.9(safe?\),)-250.8(A)-254.3(randomized)-253.5(comparison)-255(trial)-252.8(stopped.)]TJ 0 -1.2385 TD [(Lancet)-337.3(2004;363:453455.)]TJ -1.2519 -1.2318 TD [(6.)-501.9(Sassarini)-427.1(J,)-432.2(Lumsden)-433.9(MA.)-433(Hot)-430.6(ushes:)-430.1(Are)-432.3(there)-429.4(effective)]TJ 1.2519 -1.2385 TD [(alternatives)-339.1(to)-335.4(estrogen?)-337.9(Menopause)-341.5(Int)-332.9(2010;16:8188.)]TJ -1.2519 -1.2318 TD [(7.)-501.9(Molassiotis)-510.9(A,)-506.4(Fernandez-Ortega)-517.9(P,)-509.3(Pud)-506.3(D,)-506.4(et)-508.8(al.)-508.8(Use)-508.4(of)]TJ 1.2519 -1.2385 TD [(complementary)-321.2(and)-312.4(alternative)-319.9(medicine)-318.8(in)-318.6(cancer)-320.8(patients:)]TJ 0 -1.2318 TD [(A)-327.9(European)-343.3(survey.)-335.6(Ann)-335.5(Oncol)-333.7(2005;16:65566)-7.4(3.)]TJ -1.2519 -1.2385 TD [(8.)-501.9(Richardson)-837.1(MA,)-834.7(Sanders)-839.8(T,)-833.1(Palmer)-834.6(JL,)-839.1(et)-830.1(al.)-836.8(Com-)]TJ 1.2519 -1.2318 TD [(plementary/alternative)-551.2(medicine)-553.1(use)-544.8(in)-546.2(a)-544.4(comprehensive)]TJ 0 -1.2385 TD [(cancer)-253.8(center)-260.2(and)-258.8(the)-258.1(implications)-257(for)-258.3(oncology.)-258.7(J)-260.4(Clin)-253.5(Oncol)]TJ 0 -1.2318 TD (2000;18:25052514.)Tj -1.2519 -1.2385 TD [(9.)-501.9(Daley)-247.5(A,)-252(MacArthur)-254(C,)-247.1(McManus)-254.2(R,)-248.9(et)-254.4(al.)-247.7(Factors)-254.7(associated)]TJ 1.2519 -1.2385 TD [(with)-348.6(the)-358.6(use)-350.7(of)-355.5(complementary)-354.7(medicine)-358.9(and)-352.5(non-pharma-)]TJ 0 -1.2318 TD [(cological)-460.5(interventions)-464.2(in)-459.2(a)-457.4(symptomatic)-458.6(menopausal)-465.4(wo-)]TJ 0 -1.2385 TD [(men.)-332.2(Climacteric)-340.7(2006;9:336346.)]TJ -1.754 -1.2318 TD -.0188 Tc [(1)-18.8(0)-18.8(.)-522.8(Kronenberg)-363.9(F,)-357.9(Fugh-)-4.8(B)2.8(erman)-357.3(A)-5.3(.)-357.9(C)-.4(omple)-6(m)-.7(ent)-4.8(a)-.8(ry)-363.9(and)-358.8(a)-.8(lt)-4.8(erna-)]TJ 1.754 -1.2385 TD -.0193 Tc [(tive)-488.6(medi)-6.1(cine)-488.6(for)-484.5(m)-1.2(enopausal)-481.4(s)-5(ympt)-5.3(oms:)-485.6(A)-487.8(r)4.2(e)-6.5(v).4(iew)-485.1(o)-.5(f)-487.3(r)-2.5(an-)]TJ 0 -1.2318 TD -.0183 Tc [(domized,)-330.7(co)-18.3(n)16.8(t)-4.3(r)5.2(o)-18.3(l)13.7(l)1.6(ed)-331.5(tr)5.2(ia)6.4(ls.)-330.7(A)-4.8(nn)-336.7(Intern)-336.7(Med)-331.5(2002;137:80581)6.4(3.)]TJ -1.754 -1.2385 TD 0 Tc [(11.)-504(Avis)-501.6(NE,)-506.5(Legault)-509.4(C,)-501.5(Coeytaux)-505.8(RR,)-506.8(et)-508.8(al.)-502.1(A)-502(rando)-9(mized,)]TJ 1.754 -1.2318 TD [(controlled)-415(pilot)-418.9(study)-418.5(of)-415.7(acupuncture)-418.5(treatment)-425.6(for)-412.3(meno-)]TJ 0 -1.2385 TD [(pausal)-330.5(hot)-339.1(ashes.)-335.6(Menopause)-341.5(2008;15:10701078.)]TJ -1.754 -1.2318 TD [(12.)-504(Vincent)-265.3(A,)-265.4(Barton)-269.4(DL,)-270.6(Mandrekar)-265.4(JN,)-273(et)-261.1(al.)-267.8(Acupuncture)-275.7(for)]TJ 1.754 -1.2385 TD [(hot)-419.5(ashes:)-422.7(A)-421.7(randomized,)-425.3(sham-controlled)-428.1(clinical)-424.7(study.)]TJ 0 -1.2318 TD [(Menopause)-334.8(2007;14:4552.)]TJ -1.754 -1.2385 TD -.0187 Tc [(1)-18.7(3)-18.7(.)-522.7(Wyon)-243.4(Y,)-244(Wijm)6.1(a)-248.4(K)3(,)-244(N)-.1(edstrand)-238.2(E,)-237.3(Hamma)6(r)-242.9(M)-5.6(.)-237.3(A)-246.2(comparison)-243.4(of)]TJ 1.754 -1.2318 TD -.0178 Tc [(a)6.9(c)-2.6(u)6.1(pun)5.2(ctur)5.7(e)-326.4(a)6.9(nd)-317.6(oral)-319.2(estr)5.7(adio)]TJ 12.854 0 TD [(l)-319.3(t)-3.9(r)5.6(e)1.6(atment)-318.5(of)-318.5(v)-4.9(a)6.8(so)7.6(motor)-322.5(s)3.1(ymp)6(-)]TJ -12.854 -1.2385 TD -.0186 Tc [(tom)6.2(s)-252(in)-250(postmenop)5.3(a)-.6(usal)-246.4(wo)6.9(men.)-250.6(C)6.5(limacter)4.9(i)1.3(c)-251.1(2)-.6(0)6.1(04;7:153)6.1(164)6.1(.)]TJ -1.754 -1.2318 TD 0 Tc [(14.)-504(Tukmachi)-399.6(E.)-397.9(Treatment)-404.7(of)-402.3(hot)-406.1(ushes)-398.9(in)-405.6(breast)-403.1(cancer)-401.1(pa-)]TJ 1.754 -1.2385 TD [(tients)-337.1(with)-335.2(acupuncture.)-342.6(Acupunct)-335.9(Med)-334.2(2000;18:2227.)]TJ -1.754 -1.2318 TD [(15.)-504(Porzio)-305.6(G,)-308.9(Trapasso)-309.6(CT,)-305.9(Martelli)-314.2(S,)-307.9(et)-307.9(al.)-301.3(Acupunctur)-14(e)-301.9(i)0(n)-311.9(the)]TJ 1.754 -1.2385 TD [(treatment)-392.1(of)-388.9(vasomotor)-391.7(symptoms)-390.9(in)-392.2(postmenopausal)-394.3(wo-)]TJ 0 -1.2318 TD [(men)-334.5(taking)-334.1(Tamoxifen.)-339.1(Tumori)-336.2(2002;88:128130.)]TJ -1.754 -1.2385 TD [(16.)-504(De)-442.4(Valois)-449.7(BA,)-444.7(Young)-443.5(TE,)-450(Robinson)-444.9(N,)-447.7(et)-441.8(al.)-448.6(Using)-448.4(tradi-)]TJ 1.754 -1.2318 TD [(tional)-334.9(acupuncture)-338.2(for)-338.7(breast)-336.2(cancer-related)-345(hot)-332.4(ashes)-337.9(and)]TJ 0 -1.2385 TD [(night)-312(sweats.)-316.5(J)-314(Altern)-315.1(Complement)-322.3(Med)-314.1(2010;16:10471057.)]TJ -1.754 -1.2318 TD [(17.)-504(Hervik)-384.5(J,)-378.7(Mja)]TJ 7.391 .0067 TD ()Tj .4352 -.0067 TD [(land)-386.2(P.)-382.2(Acupuncture)-389.5(for)-385.5(the)-385.3(treatment)-392.1(of)-382.2(hot)]TJ -6.0722 -1.2385 TD [(ashes)-425(in)-419(breast)-423.2(cancer)-427.9(patients,)-426.8(a)-423.9(randomized,)-425.3(controlled)]TJ 0 -1.2318 TD [(trial.)-330.9(Breast)-337.8(Cancer)-337.7(Res)-337.9(Treat)-332(2009;116:311316.)]TJ -1.754 -1.2385 TD -.0197 Tc [(1)-19.7(8)-19.7(.)-523.7(Deng)-398.3(G,)-399(Vickers)-400.4(A).5(,)-399(Y)-3.1(eung)-398.3(S,)-392.3(Cassil)-6.5(e)-.2(th)-398.4(B.)-399(Randomiz)5(ed,)-392.3(c)-4.5(on-)]TJ 1.754 -1.2318 TD -.0183 Tc [(tr)5.2(olled)-351.6(t)2.4(rial)-346.5(of)-352.4(acup)5.6(uncture)-347(f)2.4(or)-349.6(th)4.7(e)-353.7(t)2.4(r)5.2(e)-5.5(a)6.4(t)2.4(ment)-352.4(o)7.2(f)-352.4(hot)-345.7()-3.4(a)6.4(s)-4(h)4.7(e)1.1(s)-352.1(i)1.6(n)]TJ 0 -1.2385 TD [(b)4.7(r)-1.6(ea)6.3(st)-245.4(ca)6.3(ncer)-249.3(patients.)-250.4(J)-245.4(Clin)-249.8(Oncol)-246.2(200)6.3(7;2)6.3(5)-.4(:5584)6.3(55)6.3(90.)]TJ -1.754 -1.2318 TD -.02 Tc [(1)-20(9)-20(.)-524(Walker)-291.1(EM,)-285.5(R)-3.4(odriguez)-283.2(AI,)-285.5(B)1.6(all)-288(R)-3.4(M,)-285.5(et)-287.1(al.)-285.5(A).2(cupunct)-6(u)3.9(re)-288.4(vers)-5.7(us)]TJ 1.754 -1.2385 TD -.0187 Tc [(venlafaxine)-434.4(f)2(or)-437.1(the)-434.4(m)-.6(anag)4.4(e)-5.9(m)6.1(ent)-433.1(o).1(f)-439.8(v)1(asom)6.1(otor)-430.4(sy)4.4(mptom)6.1(s)-439.5(in)]TJ 0 -1.2318 TD -.02 Tc [(patients)-353.8(with)-351.8(hormone)-348.7(r)3.5(e)-7.2(c)1.9(eptor-)]TJ 13.8649 0 TD -.0209 Tc [(pos)-6.6(i)-1(tive)-349.6(b)-4.5(r)2.6(east)-355(canc)-5.7(er:)-353.3(A)-348.8(r)-4.1(a)-2.9(n-)]TJ -13.8649 -1.2385 TD -.0189 Tc [(dom)5.9(i)-5.7(z)5.8(e).6(d)-251.7(c)3(ontrolled)-245.1(t)-4.9(r)4.6(i)1(al.)-250.9(J)-245.9(Clin)-250.3(Oncol)-246.7(201)5.8(0;28:634)5.8(64)5.8(0.)]TJ -1.754 -1.2385 TD 0 Tc [(20.)-504(Frisk)-291.1(J,)-284.9(Carlhall)-294.7(S,)-294.5(Kallstrom)-293.7(AC,)-287.1(et)-294.6(al.)-287.9(Long-term)-293.1(follow-up)]TJ 1.754 -1.2318 TD [(of)-576.4(acupuncture)-579.2(and)-580.1(hormone)-578.4(therapy)-584.7(on)-574.1(hot)-580.1(ushes)-579.7(in)]TJ 0 -1.2385 TD [(women)-634.2(with)-636.4(breast)-637.5(cancer:)-639.8(A)-635.9(prospective,)-635.7(rando)-9(mized,)]TJ 0 -1.2318 TD [(controlled)-334.7(multicenter)-345.2(trial.)-330.9(Climacteric)-340.7(2008;11:166174.)]TJ -1.754 -1.2385 TD -.018 Tc [(2)-18(1)-18(.)-522(Da)6.7(vies)-171.1(FM.)-176.4(T)3.6(he)-172.6(effec)3.9(t)-178(of)-178(ac)3.9(upu)5.9(n)-1.7(c)3.9(t)-4(u)5.9(r)-1.2(e)-179.3(t)2.7(r)5.5(e)1.4(atment)-178(on)-175.7(the)-172.6(i)1.9(nc)3.9(iden)5(ce)]TJ 1.754 -1.2318 TD -.0198 Tc [(a)4.9(n)-3.5(d)-379.9(s)-5.5(everit)-5.8(y)-378.3(o)-1(f)-387.4(h)3.2(ot)-387.4(ushes)-380.4(experienced)-386.5(b)3.3(y)-385(w)3.1(omen)-385.1(followi)-6.6(ng)]TJ 0 -1.2385 TD -.0193 Tc [(treatment)-406.9(f)1.4(or)-410.9(brea)5.4(s)-5(t)-406.9(cancer:)-405.3(A)]TJ 13.4766 0 TD -.0199 Tc [(comparison)-411.9(of)-407.5(traditional)-408.4(a)-1.9(nd)]TJ -13.4766 -1.2318 TD -.0183 Tc [(m)6.5(i)1.6(nima)6.4(l)-252.8(a)6.4(cup)5.6(u)-1(ncture.)-243.6(E)-3.4(u)5.6(r)-249.2(J)-252(C).1(a)6.4(n)-2(cer)-249.2(200)6.4(1;3)6.4(7)-.3(:S438)6.4(S43)6.4(8.)]TJ -1.754 -1.2385 TD 0 Tc [(22.)-504(Ne)18(d)14.9(s)0(t)15(r)0(a)21.4(n)0(d)-470.9(E)0(,)-464.9(W)0(i)15.7(j)14.8(ma)-472.8(K,)-464.7(Wy)18.9(on)-473.7(Y,)-463.1(Ha)16.5(mm)22.7(ar)-474(M)13.1(.)-479.7(Va)19.6(so)19.7(mo)16.8(to)19.5(r)]TJ 1.754 -1.2318 TD [(s)14.3(y)0(m)14.4(p)0(t)24.6(o)0(m)16.8(s)-233.4(d)14.9(e)0(c)14.6(r)0(e)16.2(a)0(s)18.9(e)-228.3(i)13.2(n)-231.4(wo)15(me)17.4(n)-224.7(w)0(i)16.1(t)0(h)-224(b)0(r)19.8(e)12.8(as)18.9(t)-233.7(c)0(a)19.8(n)0(c)18.2(e)12.8(r)-230.9(r)0(a)14.7(n)0(d)24.5(o)0(m)16.8(i)0(z)17.8(e)12.8(d)]TJ 0 -1.2385 TD [(t)14(o)-376.2(tr)17.4(e)12.8(a)0(t)18.6(m)0(e)17.4(n)0(t)-364.6(w)0(i)16.1(t)0(h)-364.6(a)0(p)21.8(p)0(l)17.1(i)0(e)19.3(d)-373.4(re)16.1(l)13.2(a)0(x)19.2(a)0(t)18.6(i)0(o)18.6(n)-378.7(or)-359.4(el)12.6(e)12.8(c)0(t)15.9(r)0(o)22.2(-)0(a)18.6(c)0(u)19.1(p)0(u)14.4(n)0(c)18.2(t)14(ur)13.9(e)12.8(:)]TJ 0 -1.2318 TD [(A)-321.2(p)0(r)20.6(e)0(l)19.3(i)0(m)17.9(i)0(n)16.1(a)0(r)21.4(y)-325(st)21.7(ud)18.7(y.)-316(Cl)18.3(i)13.2(m)0(a)16(c)0(t)22.6(e)0(r)16.1(i)0(c)-313(2)0(0)15.9(0)0(5)22.6(;)0(8)20.3(:)0(2)20.3(4)0(3)15.9()0(2)22.6(5)0(0)22.6(.)]TJ 27.8905 77.8202 TD [(23.)-504(Liljegren)-424.6(A,)-426.1(Gunnarsson)-430.5(P,)-422.3(Landgren)-429.4(BM,)-425(et)-428.5(al.)-421.8(Reducing)]TJ 1.754 -1.2318 TD [(vasomotor)-572.4(symptoms)-565(with)-569.5(acupuncture)-572.5(in)-566.3(breast)-563.8(cancer)]TJ 0 -1.2385 TD [(patients)-549.6(treated)-552.9(with)-549.4(adjuvant)-556.7(tamoxifen:)-547.5(A)-548.9(randomized)]TJ 0 -1.2318 TD [(controlled)-341.4(trial.)-330.9(Breast)-337.8(Cancer)-337.7(Res)-337.9(Treat)-332(2012;135:791798.)]TJ -1.754 -1.2385 TD [(24.)-504(Johnstone)-494.3(PA,)-495.9(Polston)-496.5(GR,)-486.4(Niemtzow)-499.6(RC,)-491.6(Martin)-491(PJ.)-488.6(In-)]TJ 1.754 -1.2318 TD [(tegration)-542.5(of)-536.2(acupunctu)-12.9(re)-532.8(into)-540.1(the)-546(oncology)-542.2(clinic.)-540.6(Palliat)]TJ 0 -1.2385 TD [(Med)-334.2(2002;16:235239.)]TJ -1.754 -1.2318 TD [(25.)-504(Miller)-473.4(HG,)-471(Li)-467.4(RM.)-476.8(Measuring)-471.1(hot)-473(ashes:)-476.2(Summary)-473.4(of)-469.3(a)]TJ 1.754 -1.2385 TD [(National)-539.3(Institutes)-547.6(of)-536.2(Health)-536.4(workshop.)-545.7(Mayo)-536.2(Clin)-534.7(Proc)]TJ 0 -1.2318 TD (2004;79:777771.)Tj -1.754 -1.2385 TD [(26.)-504(Kim)-342(DI,)-347.5(Roh)-343.3(JJ,)-344.5(Choi)-348.3(MS,)-341.6(et)-348.1(al.)-341.4(A)-348(clinical)-344.4(trial)-346.6(to)-342.1(assess)-347.2(the)]TJ 1.754 -1.2318 TD [(efcacy)-455.9(of)-462.6(acupuncture)-458.7(on)-460.3(hot)-459.6(ashes)-458.4(in)-459.2(postmenopausal)]TJ 0 -1.2385 TD [(women.)-337.3(Korean)-337.5(J)-334.1(Oriental)-339.9(Med)-334.2(2007;28:7485.)]TJ -1.754 -1.2318 TD [(27.)-504(Association)-305.6(of)-301.9(Korean)-304(Oriental)-306.4(Medicine.)-308(Oriental)-306.4(Medicine)]TJ 1.754 -1.2385 TD -.0188 Tc [(of)-232.4(Kor)4.7(e).6(a.)-237.4(Seou)5.1(l:)-237.4(Association)-236.8(o)0(f)-239.1(K)2.9(orea)5.9(n)-236.8(O)-1(rienta)5.9(l)-239.9(M)1(edicine,)-237.4(19)5.9(98.)]TJ -1.754 -1.2318 TD 0 Tc [(28.)-504(Deadman)-578.1(P,)-583(Baker)-577.3(K,)-578.5(Al-khafaji)-585(M.)-580.4(A)-575.6(Manual)-580.3(of)-583.1(Acu-)]TJ 1.754 -1.2385 TD [(puncture:)-526.9(Journal)-521.6(of)-522.8(Chinese)-525.2(Medicine)-524.6(Publications,)-526.8(Ann)]TJ 0 -1.2318 TD [(Arbor,)-337.2(MI:)-334.5(Cushing)-336.3(Mallory,)-336.8(2001.)]TJ -1.754 -1.2385 TD [(29.)-504(Ahn)-335.5(YK.)-334.3(Meridianology)-340.4(Series.)-338.5(Seoul:)-332.9(Seongbosa,)-343.4(1886.)]TJ T* [(30.)-504(Kaptchuk)-452.9(TJ.)-450.8(Acupuncture:)-454.2(Theory,)-450.7(efcacy,)-453.6(and)-452.9(practice.)]TJ 1.754 -1.2318 TD [(Ann)-335.5(Intern)-340.6(Med)-334.2(2002;136:374383.)]TJ -1.754 -1.2385 TD [(31.)-504(Richardson)-254.7(A.)-252(The)-250.6(health)-250.8(diary:)-253.2(An)-251.4(examination)-255.2(of)-248.3(its)-253(use)-250.3(as)]TJ 1.754 -1.2318 TD [(a)-330.2(data)-336.8(collection)-337.9(method.)-338(J)-334.1(Adv)-340.2(Nurs)-334.7(1994;19:782791.)]TJ -1.754 -1.2385 TD [(32.)-504(Ezzo)-452.6(J,)-452.3(Berman)-458.9(B,)-451.5(Hadhazy)-455.6(VA,)-451.2(et)-455.2(al.)-455.2(Is)-449.4(acupuncture)-458.7(ef-)]TJ 1.754 -1.2318 TD [(fective)-420.5(for)-419(the)-418.8(treatment)-418.9(of)-422.4(chronic)-417(pain?)-415.4(A)-421.7(systematic)-418.7(re-)]TJ 0 -1.2385 TD [(view.)-337.5(Pain)-330.2(2000;86:21722)-7.4(5.)]TJ -1.754 -1.2318 TD [(33.)-504(De-Craen)-326(AJ,)-318.3(Moerman)-321.3(DE,)-324.2(Heisterkamp)-323.3(SH,)-322.7(et)-321.3(al.)-321.4(Placebo)]TJ 1.754 -1.2385 TD [(effect)-245.2(in)-238.3(the)-244.8(treatment)-244.8(of)-235(duodenal)-248.9(ulcer.)-237.1(Br)-242.8(J)-240.4(Clin)-240.1(Pharmacol)]TJ 0 -1.2318 TD (1999;48:853860.)Tj -1.754 -1.2385 TD [(34.)-504(Lee)-455.1(BY,)-461.7(Lariccia)-458(PJ,)-455.1(Newberg)-459.1(AB.)-458.1(Acupuncture)-463.2(in)-459.2(theory)]TJ 1.754 -1.2318 TD [(and)-278.9(practice)-279.2(part)-282.1(I:)-280.6(Theoretical)-282.6(basis)-278.6(and)-278.9(physiologic)-282.1(effects.)]TJ 0 -1.2385 TD [(Hosp)-339.4(Physician)-335.1(2004;40:1118.)]TJ -1.754 -1.2318 TD [(35.)-504(Napadow)-239.8(V,)-243.8(Ahn)-241.7(A,)-238.6(Longhurst)-249.9(J,)-238.1(et)-241(al.)-241(The)-243.9(status)-242.8(and)-238.7(future)]TJ 8.4682 0 0 8.4682 327.9117 380.5794 Tm [(of)-402.3(acupuncture)-405.1(mechanism)-406.7(research.)-403.7(J)-401(Altern)-402.1(Complement)]TJ T* [(Med)-334.2(2008;14:861869.)]TJ -1.754 -1.2385 TD [(36.)-504(Macioca)-450.8(G.)-449.5(The)-451.5(Practice)-453.3(of)-449.2(Chinese)-451.5(Medicine.)-455.3(New)-447.8(York:)]TJ 1.754 -1.2318 TD [(Churchill)-335.4(Livingstone,)-343.2(1994.)]TJ -1.754 -1.2385 TD [(37.)-504(Carpenter)-372.4(JS,)-374.2(Monahan)-371.9(PO,)-371.1(Azzouz)-371.9(F.)-369.6(Accuracy)-367.8(of)-375.5(subjec-)]TJ 1.754 -1.2318 TD [(tive)-295.1(hot)-292.3(ush)-292.1(reports)-297.7(compared)-290.1(with)-295(continuous)-300.4(sterna)-296.1(skin)]TJ 0 -1.2385 TD [(co)20.6(nd)17.8(uc)19.1(ta)18.6(nc)18.2(e)-268.4(m)0(o)16.8(n)0(i)16.1(t)14(or)15.5(i)13.2(n)0(g)19.4(.)-272.2(Ob)20.8(st)15(e)12.8(t)-267.1(Gy)13.2(ne)22.4(co)20.6(l)-274.7(2)0(0)22.6(0)0(4)22.6(;)0(1)20.3(0)0(4)15.9(:)0(1)20.3(3)0(2)22.6(2)0()15.9(1)0(3)22.6(2)0(6)15.9(.)]TJ -1.754 -1.2318 TD [(38.)-504(Otte)-470.3(JL,)-464.2(Flockhart)-470.7(D,)-466.2(Storniolo)-474.8(AM,)-466.5(et)-461.9(al.)-468.6(Comparison)-472.7(of)]TJ 1.754 -1.2385 TD [(subjective)-257.9(and)-252.1(objective)-250.6(hot)-252.1(ash)-257.9(measures)-250.7(over)-253.3(time)-256.6(among)]TJ 0 -1.2318 TD [(breast)-429.9(cancer)-421.2(survivors)-431.6(initiating)-427.8(aromatase)-433.8(inhibitor)-424(ther-)]TJ 0 -1.2385 TD [(apy.)-334.4(Menopause)-341.5(2009;16:653629.)]TJ -1.754 -1.2318 TD [(39.)-504(Kim)-261.6(HJ,)-266.3(Leem)-269.6(KH,)-265.3(Kim)-261.6(MH.)-267.2(Correlation)-264.7(between)-273.6(subjective)]TJ 1.754 -1.2385 TD [(and)-365.9(objective)-377.8(measurement)-371.2(of)-368.8(climacteric)-377.4(womens)-369.9(hot)-372.6(a-)]TJ 0 -1.2318 TD [(shes.)-335(J)-334.1(Korean)-337.5(Acad)-333.5(Nurs)-341.4(2010;40:765774.)]TJ -1.754 -1.2385 TD [(40.)-504(Sturdee)-415.9(DW,)-410.2(Reece)-418.6(BL.)-409.9(Thermography)-417.2(of)-415.7(menopausal)-411.8(hot)]TJ 1.754 -1.2318 TD [(ushes.)-336.4(Maturitas)-336.6(1979;1:201205)-7.4(.)]TJ -1.754 -1.2385 TD [(41.)-504(Birch)-291.8(S,)-287.8(Hesselink)-296.6(JK,)-290(Jonkman)-297.1(FAM,)-289.4(et)-294.6(al.)-287.9(Clinical)-294.3(research)]TJ 1.754 -1.2318 TD [(on)-400(acupuncture.)-409.5(Part)-402.6(1.)-394.8(What)-404.4(have)-401.9(reviews)-403(of)-402.3(the)-405.4(efcacy)]TJ 0 -1.2385 TD [(and)-359.2(safety)-359(of)-362.2(acupuncture)-365(told)-360.9(us)-356.7(so)-361.9(far?)-357.7(J)-354.2(Alter)-10.1(n)-358.6(Comple-)]TJ T* [(ment)-333.8(Med)-334.2(2004;10:46848)-7.4(0.)]TJ 8.9663 0 0 8.9663 441.5243 161.7448 Tm [(Address)-339.4(correspondence)-340.1(to:)]TJ /F7 1 Tf .43 -1.2203 TD [(Sung)-328.9(Hwan)-336.7(Park,)-334(MD,)-338.2(PhD)]TJ 2.447 -1.2266 TD [(Department)-337.9(of)-330(Surgery)]TJ 1.4669 -1.2203 TD [(College)-337(of)-336.3(Medicine)]TJ -4.0087 -1.2203 TD [(Catholic)-334(University)-340(of)-336.3(Daegu)]TJ -3.9202 -1.2266 TD [(\(705718\))-339(3056-6,)-329.7(Daemyoung-4-dong)]TJ 9.3453 -1.2203 TD [(Nam-gu,)-338.2(Daegu)]TJ -.6133 -1.2203 TD [(Republic)-337.3(of)-330(Korea)]TJ -4.0656 -2.0549 TD (E-mail:)Tj /F5 1 Tf 3.2626 0 TD (shwpark@cu.ac.kr)Tj /F3 1 Tf -46.6694 76.1784 TD (696)Tj 47.6052 0 TD [(JEONG)-333.7(ET)-338.7(AL.)]TJ ET endstream endobj 22 0 obj [/Indexed/DeviceRGB 255 23 0 R] endobj 23 0 obj <>stream 8;X]O>EqN@%''O_@%e@?J;%+8(9e>X=MR6S?i^YgA3=].HDXF.R$lIL@"pJ+EP(%0 b]6ajmNZn*!='OQZeQ^Y*,=]?C.B+\Ulg9dhD*"iC[;*=3`oP1[!S^)?1)IZ4dup` E1r!/,*0[*9.aFIR2&b-C#soRZ7Dl%MLY\.?d>Mn 6%Q2oYfNRF$$+ON<+]RUJmC0InDZ4OTs0S!saG>GGKUlQ*Q?45:CI&4J'_2j$XKrcYp0n+Xl_nU*O( l[$6Nn+Z_Nq0]s7hs]`XX1nZ8&94a\~> endstream endobj 24 0 obj <> endobj 25 0 obj <> endobj 26 0 obj <>stream hޤU P^֨`~j#VDĨexjXA` h 4F F0h[Fド]Tiܙ{ΜssݫB1:4 $4|G@bVmL̗=?X0 v:n7IS(*&CrҪ 7iu:ǶΙ&$uRɘ[c% z6C8URS Fɠ3 YܺXHNJFI+e5ZC_)'3L:)MI7H<֘oLNLuƩAPO( tA!a ,Bp!Vao`/8W\E"[qn]WJ{ero+ڟEhԀcqwHqp]a}fsnŅqh7i?Yd=$f"+a5d1ɪf cɃ #>kf?1J31IE%gdueТaoZIğg0S,U˧_qMwla};{&?$n>XKeaYt#, #f~Ga)\D%0g(buwv~*aX%7t/o~`Ӆ{;W 1"Dk]2_Nr8Auh _F$u:t$c6-p{0^trB ;ik%)3&0Lhjwh/Kؕ灃bwo1{#9_Ed WMd#MA8[4xKةHUڞc|n0 ynN{76(v=FXŔٔC}H,e1xeo[ -myMd-IߐULnZ_!?;q(M4/z'5m e F^%LS)`oAy^sȒT U_l]wTԒ{+Sx&2Jcu;WSg/RV6k6h3Ur 87oDg= f9`|yJKpn j?WDG`:6~22xGL,~ˇ΁b70`~BkھG^|"[TКnT_Of.KCJqt {X|H aU^BGhq)֦L̓d~SL1°ol:]5 KfGƬNE |!}=G/q s#7cNCaJk=7+Saf"mhdϲ!d)r~kt{ʽ%an"+bsi )&M֛L!S eM?=3X/[u&lfL?~@H싃 ̏0 l#zangp"അ9Ҡ(̜s*jBF1cb"!x{h#eaM|XVtXhH!1k wu E5\ɗeȁ3╚?f\ߏJ6n*. KCG=W.%qxbhktf[U-16‘m\l8$xA;sMdOfCyegM¹\B4:q#e{JK"JŦUN[H-9RA_Ɣm]co-#sFWMmhq:.,yu|z9ǃT)n~ 5CYՋ!WBnm~(k3^!?s?|sTQ I2}w~-4[/0y9T endstream endobj 27 0 obj <>stream 8;Z\7CO1XV%.l7QbPfaBf.!mO6:cVB]<)R8JuiR>OGjcr0a$-de76;F7TGr@7IK\j 9\W[#Mg'W>bi>qh4o'mqa*tDk)9QRO8DGVN[tY_em)&qGFV]VTM!K%b4OTf\n,.AD :V36OTB(9McC'MO6C"=4EU]sL&+$"NAEos80aq9K=@auu/\^GaTjoJb^V$Fl`2[i( c]gt'L,1o$O)1=AFF_u$S+)+*U/:%F1os`a.6\3+c0DM&A)S>cC/mLpr+5_EiUSg3 SZVB_Y3[6`3bH<46@DX8TG[Y>j80<[m2nPmfV/n)hppVBg:*ka=koKXr>H4Z9 +8c@)UV@1_99Bta)?@<1cKP~> endstream endobj 28 0 obj <>stream 8;Z\7;0E$b#kThLj8N]M3c1Xp+J?nMXF2bg1YJ^hEPt-T5PDkm^7[,-lE($R`VS(, d0C?b%:)'!`O+pc-E6`oGAss8FD_`DA_o%Yg"p#E,0a@Y"deSna6FN*IZ&C5gGN66 no\C!8C6:7*+(0O^A&&+US;*p\&pZ!n+s3YAbqS[KoK)hN3RoNGT4Y(UlF%'.?eqE O4CbTVdF[^I+dltpbM]ZDiQ1afk[0LN\cWt=h0=ZGDul[mH[7?[f=C/C;O;\8_UD[e:\g)mW&U!@FPrKUp=*Dr^emg1rkUL*ZZ[ _iUEX\muL#L9B?&F6?D4Wr7RD,1R_9)'_.U)-)!b0?TZle!HsnRo72.9 /@gu;YBN]rfm,Z4X3pn9:G"]C$oc&A&e&.2Z+8+ZqRZU/>QL$IrN -Uqp-j5]J)7)6Au\o#n:NR-MZLr!Diorq_$5He@qcS:-WJu(9Q%a=M!;phG*:+dXc ch9L%\;[O&~> endstream endobj 29 0 obj <>stream 8;Z\7;3Iau%-0,20DFEhgaDjBUU8[Ljj=Kn@A);#68dk SBX,$:`lKna@4nJ4Q#T@>l2M5UgA.503&U^^RirU;5A**oOV%coK#rM'l/)?rUlmS'sH=i eG.,hA%-Z1oIn"D^IDOT!J60:+8$Xej=_*[+g8U.85Fs2g;hC!^I[4*lU=0qDsMOi *H0J8,G2Y+_&6QRL0r#?kDJ)"`HXDp^Q2[f'-WW\@L8:Y,H<).OM9M[Jf&n\o6iE" q#2hqX/WgTjf]-g4cA.q7po:4I:AQ]-,FAidia-;4mPS@,rB+C%c^gR$gjt/2W0$d H;UH):1QesJB+`%O26D%0d1H+HXIj]%[7h`qjo/LpX\SNjK?_l7*A7#3Xpo8*2*LM o[<\L/5Oh*ogaa%Z#+6mj#j0VjR9)4qoMsUVTn.Z]_^=\>^#"X;M-,.l3U)sOIB#Xb8!"m4ANGQj<']m'r4C+o!-@9S.drj*oU4,lfK E7J9WKJ/idGnUA<7-kB>T.D"#_Nd6+.V.]qCp(#?G1EhKRopkOXa0-:oBK>V1/*Y+ e.S/Y&/tB$?H#Qt:=fk:mL5IH7Z7mU#+N^IC"FFWhfiO4e\ptMiq_'jh_U^D]rIE! X]@BAFY"S<']78QUAc&rRa$u^9h\M#f@m_QF6PdYMuOTC"p"Da7Q1~> endstream endobj 30 0 obj <>stream 8;Z\7=dF[o%-q?sbPfbMlV(GJ_3*dqbfn+,IC,4boEdFq&<7f_+j0qNVArIKeZZWd]_H,>WE2L3W6%8_1??6s5hMYC?Ki a[aqumU?EGNMrmC6ts3,d378]U\k# j%OfLh+)8;iAoeJoLQ!Y8=e1KMXfCVYLPA^3S`o7:.e=4 endstream endobj 31 0 obj <>stream 8;Z\7>IK/<#g?cU@mAY-qf+i:kGejN733jXml=.(V6pm_!sM*jE!A"e\7bqom8.G: 1VeN,"-lsYb;09:gq"<=]'.#IY]+d[*A%.-fru6PPqar7PuC2u/(,ip$<*Fq@X-kG o?A0J"hP+u,uqX$.N^G$"M\`M!0R\G,uqYOfBhgE]dPX%&Zk2MP\4hJ?Cgk IQ5*gBc/l"86VZ7l>p72m endstream endobj 32 0 obj <>stream 8;Z\7?$_/H%,AbqQM[:cY1'PP5S=]]@/F>85(?sK*/4b"D[Zcr7_D"!C]3s0XJ8'' o?XE9O16ib=nmuRDf(rXU#g'iY&Pn,]"Z[ZWp!*/hOmM7RAJr$MD^pU7V7a0)19L_ JF];V@mj[o3WH]]6Xuf0:Tn]uc#17KLTCo2*fh%4]1F`XF^Gn'Kt\HOLUd8JhP8H,]7-3P:n>%b&QT&:iQ7,b'jQ?S:U3Jbfl+_)gonao endstream endobj 33 0 obj <>stream 8;Z\7;3p5b%-'&>q>P$sFgb[LFstI+qjRNN3%o+M"<:jnMYj$ZA(KO^W12I"5OQcZ efKT2S8Hj$a"c=r[*=n,qe1iTjM >/'@eMg_pZAhtIZDq0Vp?=8L6/Ga=5%\#71qGh\Jrc-Q,[t=%nYCR*ZMkL[R`ejMI N0XKJD%1m:DbW4!go&f:(XSS6pP2OMcc?!o7csM/k@cB8niQd+[/"0^d&stm6(g7; ,*AIO2aN<i`bT*,i$lcrTV\2h ?nhQB1:dhDqD$R>pjG>$[*T#d3kWW4S(ZXj]TBmi`5WCOW>OsfpPif[TGO]"XPZ9j NQ`-hpt^9%6kj8i4$,N`)*60aDS?UJOhEmQjC7UI2SN^4Eo>oVPjZW=@'km,7Om1f f1TXunJV=c*2\2S(peF38JN\#b'*F.MYVt[,@eB&ehuig#q8)s/gGk.Y=^oc"T"q) NZ!39W^_B%/6*i/12.`-ML2V/qQ&\J.V5U65Y:LS(`4Du*Ee`!W\IWWY0G%UUu1f0 4Md!GU3:Fo/$P0:=l\8$WHBSf3n>)u.,c;\Nr^nJq'PNOm?@/W['[$Xq0UMc3n[UE TZK*+<)pgT9-%&%75<<3fpF'V`;Wuj<8Ot,GfH(#qNqk-YNU0-BrKmg!*)gJK9cl= 2H)LX1Cp`JXP3ncXX:L#I&nl];Q2>fZhDKomb?+S'.$7'1+de3]-"?0Ttsk*\7Muu >U#VMM_Vj?#RLXHN"!n+]]qHbf71c`0Sfoe7+_`G,Z\6 <.ibZ4_Gnp\"XnLH7rSZU0SA&r)?/D3qq?PnKk%`'g&J+.[8Z%V%"@oOXag+9\J)+ ^XZLac/MAE&=QbaN%5BO@,8o@CWA!XUmGPA\rUB&WK4ZD[nZ=8fX.u9>Gt!Du BW*g1aAJap4uSoE@kcbohH48DjXZ=>?eYX%sTmHl1qN3OX]Nq'GLj6/j"Ia?2% qg\"j!*I#(EW~> endstream endobj 34 0 obj <> endobj 35 0 obj <> endobj 36 0 obj <> endobj 37 0 obj <>stream 2013-07-31T17:02:44+05:30 Arbortext Advanced Print Publisher 9.0.114/W 2013-07-31T17:02:44+05:30 Acrobat Distiller 8.1.0 (Windows) application/pdf untitled uuid:fcdb2927-5d9a-4672-8094-d0271a08cf81 uuid:cfbaced3-e9d2-4494-8af4-e95178b96880 endstream endobj 38 0 obj <> endobj xref 0 39 0000000000 65535 f 0000042954 00000 n 0000043094 00000 n 0000043217 00000 n 0000056116 00000 n 0000056256 00000 n 0000056429 00000 n 0000066348 00000 n 0000145109 00000 n 0000145250 00000 n 0000145384 00000 n 0000159069 00000 n 0000159212 00000 n 0000159387 00000 n 0000167595 00000 n 0000183325 00000 n 0000226315 00000 n 0000226458 00000 n 0000226572 00000 n 0000243104 00000 n 0000243247 00000 n 0000243351 00000 n 0000260759 00000 n 0000260807 00000 n 0000261321 00000 n 0000261611 00000 n 0000262191 00000 n 0000264281 00000 n 0000264976 00000 n 0000265724 00000 n 0000266647 00000 n 0000267450 00000 n 0000268217 00000 n 0000269033 00000 n 0000270444 00000 n 0000270480 00000 n 0000270505 00000 n 0000270597 00000 n 0000274136 00000 n trailer <> startxref 116 %%EOF